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ABSTRACT 
 Background: The United States is experiencing a primary care physician 
shortage that will grow in the next decade as demand for primary care services is 
projected to increase.  The growth in physician, Nurse Practitioner, and Physician 
Assistant supply alone will not be adequate to meet the demand for primary care services 
by 2020.  Creating pharmacist-inclusive collaborative care teams for outpatient clinical 
care can help alleviate this health care delivery shortage.  
Methods:  A qualitative mixed-methods case study was conducted in Tucson, 
Arizona to determine the supports and structures behind the Pharmacy-Based Diabetes 
Management Program (PBDMP) at El Rio Community Health Center.  Using key 
informant interviews from El Rio, other outpatient clinical pharmacy programs (OCPPs), 
and the Tucson Accountable Care Organization, coupled with Lean Management 
brainstorming group sessions, the study elicited information about how the experience of 
El Rio with the PBDMP can inform nationwide development and implementation 
guidelines for other OCPPs. 
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Results: The PBDMP at El Rio provides a blueprint for other programs interested 
in creating an OCPP.  Key contributing factors to program success within El Rio and the 
other OCPPs interviewed included a focus on six key practices.  Challenges inhibiting 
success were pharmacist provider status and reimbursement of clinical services provided.   
Translation: Three public health practice products were developed as a 
framework to provide future OCPPs interested in implementing a pharmacist-inclusive 
practice model: 1) implementation guidelines, 2) a self-assessment outpatient clinical 
pharmacy program worksheet for clinics looking to create or expand an OCPP, and 3) a 
student management decision case study. 
Conclusion: This study demonstrates the value of considering all potential 
members of a care team for diabetes care management.  The decision by a clinic to create 
an OCPP should be based on team-based approaches to patient-centered chronic disease 
care management.  Clinics looking to participate in a CDTM model OCPP need to 
identify if organizational transformation is needed for program buy-in and consider 
relational coordination between clinical roles as a major component of the coordinated 
work needed for a successful OCPP.   
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CHAPTER ONE 
Background and Significance 
Introduction 
 Unfolding the layers of a program’s development and implementation reveals the 
structures and supports in place leading to a program’s successes and sustainability.  
These structures can prove beneficial for organizations looking to adopt a similar 
program.  This dissertation seeks to identify and analyze the successes and barriers to the 
establishment of a pharmacist-inclusive outpatient clinical pharmacy program from the El 
Rio Community Health Center in Tucson, Arizona.  The information collected can assist 
interested outpatient clinics in their development and implementation of their own 
collaborative pharmacy program.   
This dissertation provides products that can inform future clinics to self-assess 
their barriers to collaborative practice models for pharmacist-inclusive primary care 
teams. Clinics interested in implementing and developing an outpatient clinical pharmacy 
program can apply the implementation guidelines and outpatient clinical pharmacy 
program worksheet generated from this research.  A management case study applies the 
case facts from the El Rio Community Health Center (El Rio) for management education 
on decision-making for collaborative care teams.  Ultimately, findings that emerge from 
this research can address the impending national primary care shortage in the coming 
decades by providing support and guidance for the inclusion of pharmacists in direct 
patient care. 
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The following eight chapters outline the background, setting, methods, findings, 
and discussion of the case study of the Pharmacy-Based Diabetes Management Program 
at El Rio.  While El Rio is a good candidate for an in-depth case study, there are many 
options for a clinic to implement a pharmacist-inclusive care team to treat and manage 
chronic disease.   
Problem Statement 
 In the mid-1960s, Physician Assistant (PA) and Nurse Practitioner (NP) education 
programs were established in part to address the primary care physician shortage 
identified at that time in the United States.(1)  However, the demand for primary 
healthcare services continues to outpace the available supply of primary care 
providers.(2)  Currently, it is estimated that over 56 million Americans lack adequate 
access to primary health care because of shortages of primary care physicians and allied 
health professionals in their communities.(3)  Moreover, nearly half of all Americans—
and over three-fourths of adults aged 65 and older—live with at least one chronic 
condition that requires prescription medication therapy.(4)  There are serious 
shortcomings within our current healthcare system related to the provision and delivery 
of affordable, safe, and effective medication management in primary care services.(5)  
According to the American College of Clinical Pharmacology (ACCP), in 2000 the costs 
of drug-related illness and death in outpatient clinical care settings alone were estimated 
at more than $177 billion.(5)  More recently, the persistent and critical unmet medication 
use support needs have been directly addressed through efforts led by the Institute for 
Safe Medication Practices (ISMP) among others.(5)   
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 Many options exist for potentially addressing the healthcare system’s current and 
future shortcomings in terms of access to primary care services.  The need for expanded 
access to primary care may force the United States to look more broadly within the 
healthcare system to identify opportunities to expand capacity to provide quality primary 
and preventative care services, including the development of inter-professional teams to 
provide the highest quality of care to all patients.(5)(6)(7)(8)(9)  In sum, with the 
expansion of health insurance and an aging U.S. population, more Americans than ever 
before will lack adequate primary care services in the future.  This population will 
necessitate medication-based chronic disease care management in cooperation with all 
members of a primary care team including physicians, RNs, NPs, PAs and potentially the 
inclusion of pharmacists.(3) 
Purpose Statement 
The purpose of this study is to assess the viability and transferability of the 
Collaborative Drug Therapy Management (CDTM) program through a case study 
examination of the Pharmacy-Based Diabetes Management Program (PBDMP) at El Rio 
in Tucson, Arizona.  The findings will be translated into immediately applicable public 
health practice products including implementation guidelines to create an outpatient 
clinical pharmacy program (OCPP), a self-assessment worksheet for clinics to evaluate 
their preparedness for an OCPP, and a management case study for educational purposes.  
The creation of intervention guidelines and a self-assessment outpatient clinical 
pharmacy program worksheet will assist willing and able clinics to engage pharmacists at 
the top of their educational level and involve them in outpatient primary care.  The 
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management case study will outline the decision making processes taken by El Rio as an 
example case for future study in the development and implementation of OCPPs. 
 
Research Questions 
Central Question 
How can the experience with the CDTM Pharmacy-Based Diabetes Management 
Program at El Rio inform nationwide development and implementation guidelines for 
other outpatient clinical pharmacy programs? 
Sub-Questions 
1. What led to the creation and implementation of the CDTM program at El Rio? 
2. What were the major factors enabling or hindering the program’s progress? 
3. How transferable are these findings from El Rio to other settings? 
4. How can theoretical constructs of the PRECEDE portion of the PRECEDE-
PROCEED model and organizational transformation model be applied to the 
research to understand implementation actions taken or not taken? 
Translation Question 
How can the findings from this case study be translated into public health practice 
products to support successful implementation and maintenance of outpatient clinical 
pharmacy programs? 
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Background and Significance 
Primary Care Shortage 
According to the 2007 Institute of Medicine (IOM) report on Future of Health 
Care Workforce for Older Americans, primary care is the foundation and backbone of the 
U.S. healthcare system.(10)(5)  The IOM defined primary care as: “the provision of 
integrated, accessible health care services by clinicians who are accountable for 
addressing a large majority of personal health care needs, developing a sustained 
partnership with patients, and practicing in the context of family and community.”(11)  
Primary care often serves as the point of entry to the health care system for patients who 
require medical care and attention.  According to the ACCP, in addition to the diagnosis 
and treatment of acute and chronic illness, primary care practice encompasses activities 
such as health promotion, disease prevention, health maintenance, counseling and patient 
education.(5)  
 At the national level, both the supply and demand for primary care providers will 
grow over the next decade, due largely to aging and population growth.(12)(13)  The U.S. 
population is increasing by one percent each year, with an aging baby boomer generation 
set to double the number of Americans 65 years and older by 2025.(10)  Over 10,000 
people of the baby boomer generation are qualifying for Medicare every day, further 
increasing the need for primary care services.(14)  To a much lesser extent, the expanded 
insurance coverage implemented under the Patient Protection and Affordable Care Act 
(ACA) of 2010, includes a number of investments that strengthen the primary care 
workforce due to a projected increase in demand for primary care services. Given the 
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projected population growth trends, the shortage of primary care providers is even more 
critical and is projected to exceed 44,000 by 2025.(15)(16)   
Primary Care Physician Shortage 
The United States is likely to experience a shortage of physicians within the next 
decade which will also grow over the next decade.(16)(12)  By 2025, a shortage of 
124,000 physicians is projected in the United States.(16)  Figure 1 describes this trend in 
supply and demand of physicians.  According to the Association of American Medical 
Colleges (AAMC)’s Center for Workforce Studies, there will be a shortage of 45,000 
primary care physicians in the next decade.(14) Physicians practicing in primary care 
comprise one-third of the U.S. physician workforce yet are responsible for more than half 
of all patient visits.(5)     
Although the supply of physicians is anticipated to increase modestly between 
now and 2025, the demand for physicians in primary care is estimated to increase even 
more sharply.(16)  The number of primary care physicians is projected to increase from 
205,000 FTEs in 2010 to 220,800 in 2020, an eight percent increase.(12)  However, the 
total demand for primary care physicians is projected to grow by 28,700, from 212,500 
FTEs in 2010 to 241,200 FTEs in 2020, a 14-percent increase.(12)  During the past 
decade, the number of generalist physician graduates fell by 22 percent and the number 
of newly graduated U.S. medical students who chose primary care as a career has 
declined by 50 percent since 1997.(5)  The AAMC estimates that by 2020 the U.S. will 
face a serious shortage of both primary care and specialist physicians to care for an aging 
and growing population.   
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Figure 1.  Baseline Physician FTE Supply and Demand Projections, 2006-2025 (16) 
 
Source: Dill M. The Complexities of Physician Supply and Demand: Projections Through 2025. Assoc 
Am Med Coll Cent Work Stud. 2008 
 
Nurse Practitioner and Physician Assistant Shortage 
While physicians are considered the cornerstone of the primary health care system 
in the U.S., there is a wide array of allied primary care health care professionals in the 
workforce.(5)  While many consider nurse practitioners and physician assistants primary 
care physician-extenders due to their limited licensure, they can have large impacts and a 
broad scope of practice. Over the past two decades the supply of PAs and NPs has grown 
faster than the supply of physicians.(16)  
According to the U.S. Department of Health and Human Services, Health 
Resources and Services Administration (HRSA), the supply of primary care NPs is 
projected to increase by 30 percent, from 55,400 in 2010 to 72,100 in 2020.(12)  The 
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supply of primary care PAs is projected to increase by 58 percent, from 27,700 to 43,900 
over the same period.(12)  This 17 percent combined increase in supply in 2020, could 
help mitigate the projected shortage of physicians if NPs and PAs continue to be 
effectively integrated into the primary care delivery system.(12)  The efficient use of NPs 
and PAs will require patient and health system acceptance and the continued 
dissemination of more effective models of workforce deployment.(12)(16) 
Future Shortages and Pharmacist-Inclusive Practice 
Given the projected growth in the NP and PA primary care workforce, as well as 
ongoing efforts to effectively integrate these providers into the primary care delivery 
system, the physician shortage could be somewhat alleviated.  Models that include 
patient-centered medical homes (PCMH)s and emphasize team-based care, have the 
potential to help address the projected shortage of primary care physicians.(12)(17)  
However, the growth in primary care physician, NP and PA supply alone will not be 
adequate to meet the demand projected for primary care services in 2020.(12)(18)  
Other members of a team-based model for primary health care delivery can 
include clinical pharmacists in pharmacist-inclusive health care delivery models.  
Pharmacists represent the third largest health professional group in the U.S.(19)  
Although some pharmacists work in non-patient care settings (e.g. teaching, research, and 
administration), most work in a variety of patient care settings.(19)   
In 2011, according to the Bureau of Labor Statistics, there were 272,320 working 
pharmacists and an estimated 343,550 pharmacy technicians in the U.S. 
workforce.(20)(19)  This corresponds to a national average of 87 pharmacists and 108 
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pharmacy technicians per 100,000 population.(19)  Table 1 shows the projected need for 
pharmacists from 2001 as compared to 2020.(20)  The increase in pharmacist demand for 
secondary and tertiary services follows the increased need for medication therapy 
management and medication dispensing for chronic disease management.  The Bureau of 
Labor Statistics estimates that the total number of pharmacists in the U.S. is expected to 
increase by 95,680 (35 percent) from 2020 to 2030.(19)   
Table 1. Projected Need for Pharmacists(20) 
Service Type No. Pharmacists 
Employed in 2001 
No. Pharmacists 
Needed in 2020 
Order Fulfillment 136,400 100,000 
Primary Services 30,000 165,000 
Secondary and Tertiary Services 18,000 130,000 
Indirect and other 12,300 22,000 
Total 196,700 417,000 
Source: Johnson TJ. Pharmacist work force in 2020: implications of requiring residency 
training for practice. Am J Health Syst Pharm [Internet]. 2008 Jan 15 [cited 2014 Nov 
26];65(2):166–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18192265 
 
As of 2010, 62 percent of pharmacists worked in retail pharmacies that were 
either independently owned or part of a larger chain store.(21)  About 23 percent worked 
in hospitals, while others worked in clinics, mail-order pharmacies, or the Federal 
government.(21)  In 2013, the Aggregate Demand Index (ADI)—a monthly survey of 
unmet demand for pharmacists initiated in 1999 by the Pharmacy Manpower Project—
showed a roughly balanced supply and demand of pharmacists across the 
country.(22)(19)  Figure 2 shows the trend of the Pharmacist ADI mainly reaching a 
balance (in the range of 2.5 to 3.5) between 2009-2011.(22)  To reach a balanced supply 
and demand of pharmacists in the U.S., a data point needs to fall within the 2.5 to 3.5 
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range in Figure 2. While the demand for pharmacists has decreased relative to supply in 
recent years, pharmacists still remain in high demand. 
Figure 2.  ADI Supply and Demand for Pharmacists, 1999-2011 (22)
 
Source: ADI [Internet]. Pharmacy Manpower Project, “Aggregate Demand Index” National 
Pharmacist Demand. 2013 [cited 2014 Jun 23]. Available from: 
http://www.pharmacymanpower.com/index.jsp 
 
The 2013 American Association of Health-System Pharmacists’ annual survey found 
that pharmacists perceived a 33 percent shortage in clinical-specialty roles available for 
potential pharmacist job placement.(23)  The survey concluded that a slightly higher 
number of pharmacists are seeking clinical non-medication dispensing roles from 2012 to 
2013.(23) 
Pharmacists, coupled with NPs and PAs among other allied health professionals, 
can help address the future need for integrated team-based approaches to primary care 
services.  Solutions on how to address primary care shortages will require creative ways 
of looking at the healthcare system that are inclusive of all licensed primary care 
providers and focus on providing the highest quality of care to all patients.(5) 
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The rate of Doctors of Pharmacy (PharmD) training is expected to increase by over 
12,000 by 2025.(13)  Figure 3 represents the historical number of pharmacists from 1965 
and projected number of pharmacists in 2025.  National trends suggest that the supply of 
pharmacists is growing faster than previously projected primarily as a result of the recent 
rapid growth of pharmacy education programs and expansion of enrollment at existing 
schools across the country.(19) 
Figure 3.  Number of First-time Pharmacy Degrees Conferred, Historical and Projected 
1965-2025 (13)
Source: Services H, Resources H. The Adequacy of Pharmacist Supply : 2004 to 2030. 
2008;(December) 
While the number and rate of pharmacists graduating annually is projected to 
grow through 2025, the number of clinical pharmacists is more difficult to estimate.  
Table 2 describes the practice site of pharmacists as of 2006.  Mindy Smith, the 
Executive Director for the American Pharmacist Association (APhA) estimates that 
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nationally there are 8,500 clinical pharmacists practicing in outpatient settings with direct 
patient care.(24)  Practice sites only represent part of the full picture for pharmacists and 
their employment.  According to the ACCP, there are no data on residency-trained 
pharmacists practicing in other areas, such as managed care and community 
pharmacy.(20)   
Chronic Disease and Medication Use 
In 2005, 133 million Americans—almost one out of every two adults—were 
diagnosed with a least one chronic illness.(4)  Moreover, nearly half of all Americans and 
over three-fourths of adults aged 65 and older, live with at least one chronic condition 
that requires medication therapy overseen by a medical professional.(4)  As a result, 75 
percent of our nation’s $2 trillion in annual health expenditures are attributable to 
management of problems associated with chronic diseases.(4)  While chronic diseases are 
common and costly, many are also preventable though strategies such as healthy eating, 
being physically active, and using medications safely and appropriately.(25)   
 Medications play a significant role in the management and prevention of chronic 
diseases in primary care, and are taken by a greater proportion of the population than ever 
before.(18)(5)  Predictably, medication use among older adults is high—accounting for 
more than a third of all prescriptions.(5)  In addition, 28 percent of patients aged 65 and 
older take five or more medications treating chronic conditions each month.(10)  Two out 
of every three patients who visit a doctor leave with at least one prescription for 
medication, leading to a record volume of nearly 3.4 billion prescriptions dispensed in 
2005.(26)  This is an increase of prescriptions dispensed by nearly 60 percent since 1995.   
  
13
 According to the American Association of Colleges of Pharmacy (AACP), “there 
are serious shortcomings within our current healthcare system related to the provision of 
safe and effective medication management and primary care.”(5)  In the past decade, the 
persistent and critical unmet need to address medication use was highlighted through 
efforts by the Institute for Safe Medication Practices (ISMP) and the IOM.(26)  These 
primacy care medication management needs are expected to rise for patients of all ages 
over the coming decades.(18)(5)  
 According to research published by the California Board of Pharmacy, half of 
prescriptions taken each year in the United States are used improperly, and 96 percent of 
patients nationwide fail to ask questions about how to use their medications.(27)  When 
patients do not take medication that has been prescribed, unnecessary disease 
progression, disease complications, reduced functional abilities, a lower quality of life, 
and even death can result.(28)(26)  At least 1.5 million preventable adverse drug events 
occur in the United States each year; these costly and sometimes fatal incidents include 
cases of drug mix-ups and unintentional overdoses.(28) 
 The increasing complexity of patients, comorbidities, and their treatment 
regimens in primary care requires access to providers who can manage patient’s 
medication therapy, identify adverse events, and manage drug-related problems.(5)  
Factors such as increased outpatient surgery, shorter hospital stays and decreased 
recovery time have contributed to patients accessing the primary care system with more 
serious health care needs that require more immediate treatment resources and more 
complicated medication therapy.(5)(26)  This demand for more intensive primary care, 
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combined with the role that medications play in quality prevention and primary care 
treatment, has created an increased demand for accessible healthcare professionals who 
can fill the needed primary emergent and longitudinal care roles.  Doctors of Pharmacy 
(PharmD)s are trained and qualified to help fill these documented gaps in care around 
medication management in the primary care setting through both drug dispensing and 
patient care.(5)  Table 2 describes the accreditations and possible educational paths for 
pharmacy-related fields and pharmacists. 
Table 2. Pharmacy-Related Educational Paths 
Terminal Degree Education U.S. Practice Purview  
Bachelor of 
Pharmacy 
(BPharm) 
-Pre-Pharmacy undergraduate 
program 
-60-90 semester credit hours 
-completion of a four-year program; 
120-130 credit semester hours 
-does not qualify a recipient to sit 
for licensing exams to practice 
-pharmaceutical research 
-usually obtained as a prerequisite to 
apply to pharmacy school 
-BPharm degrees are phasing out of 
popularity in the U.S. (now superseded by 
the PharmD degree) 
 
Master of 
Pharmacy 
(MPharm) 
-1-2 year post-graduate program 
-does not qualify a recipient to sit 
for licensing exams to practice 
-pharmaceutical research 
 
Doctor of 
Philosophy 
(PhD) 
-2-5 (average) years of post-
graduate education 
-does not qualify a recipient to sit 
for licensing exams to practice 
-research intensive degree usually 
focusing on pharmaceutical 
sciences 
-pharmaceutical research 
-academic jobs; teaching and research 
Doctor of 
Pharmacy 
(PharmD)  
(in some states 
referred to as a 
Registered 
Pharmacist 
(RPh)) 
-3-4 years of doctoral training 
-“educationally prepared for 
practice and should satisfy 
educational requirements for 
licensure.”(29) 
 
-After passing the licensure exam, 
pharmacists may then be designated 
“Pharmacist” or “Registered Pharmacist” 
(RPh) and practice (30) 
-Pharmacists can practice in a multitude 
of industries: research, teaching, clinical 
practice, industry, manufacturing, and 
judicial jobs 
Clinical 
Residency 
Programs  
(for PGY1/ 
PGY2, PharmDs) 
-residencies are 1-2 years in length 
and are necessary to practice 
clinical pharmacy 
-Most pharmacists participate 
during the first year after graduation 
-During residency, pharmacists practice as 
a pharmacist, complete a resident project, 
and see clinical patients 
-There are 15 recognized specialties for 
clinical residencies (e.g. immunology, 
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with a PharmD degree 
 
transplantation, cardiology, 
pharmacotherapy) 
Pharmacist 
Fellowship 
Programs 
-fellowships train PharmDs and 
RPhs for careers in academic 
research, laboratories, clinical, and 
industry settings 
-fellowships range from 1-4 years  
-fellowships exist in over 50 areas of 
study ranging from direct patient care 
(e.g. transplantation), to academic 
laboratory sciences and pharmacy/drug-
specific topics (e.g. 
pharmacokinetics)(31) 
 
Clinical Pharmacy/Pharmacology: Nationwide 
The requirements to become a pharmacist in the United States include: 1) 
graduating from a Doctor of Pharmacy program at an Accreditation Council for 
Pharmacy Education (ACPE) accredited school, 2) conducting 1800 hours of internship 
under a licensed pharmacist, and 3) passing the North American Pharmacist Licensure 
Examination (NAPLEX) and a Multi-state Pharmacy Jurisprudence Exam (MPJE).  
While residencies are optional, they are necessary to practice clinical pharmacy.(29) 
Clinical pharmacy is “a professional discipline that combines basic pharmacology 
and clinical medicine.”(1)  In 1965, most pharmacy graduates were entering a 
professional practice that had changed very little over the previous 50 years.(1)(32)  This 
practice focused almost exclusively on the preparation and distribution of drug products.   
The clinical pharmacy movement began at the University of Michigan in the early 
1960s.  Much of the pioneering work about the nascent field of clinical pharmacy was 
completed by David Burkholder, Paul Parker, and Charles Walton at the University of 
Kentucky in the latter part of the 1960s.(1)  In the late 1960s, pharmacy students at the 
University of Kentucky created an institute to study pharmacists in the decision-making 
process of patient care.  The institute encouraged the clinical pharmacy movement to 
  
16
differentiate itself from the standard pharmacy education based only on drug information.  
The institute eventually led to the creation of a unique and separate entity and degree 
program, a Doctor of Pharmacy (PharmD).  By the late 1960s, many other schools 
followed the University of Kentucky’s lead and developed PharmD programs for training 
clinical pharmacists.(1)(32)  The most important reason for the rapid growth of this 
almost entirely new profession probably was “the great dissatisfaction of pharmacists 
with old practice norms.”(1)  Pharmacists began to specialize in areas of medication use 
or disease pathways and were looking for ways to address a specific patient population 
through clinical practice.   
Doctors of Pharmacy: Educational Path 
In 2004, the American Association of Colleges of Pharmacy revised and released 
the Center for the Advancement of Pharmaceutical Education (CAPE) new educational 
outcomes which outlined target areas toward which the evolving pharmacy curriculum 
should be aimed at U.S. Schools of Pharmacy.  These CAPE outcomes have since been 
incorporated into the accreditation standards for the Doctor of Pharmacy Degree.  These 
educational outcomes include (5): 
• “Provide pharmaceutical care in cooperation with patients, prescribers, and 
other members of an inter-professional health care team based upon sound 
therapeutic principles and evidence-based data, taking into account relevant 
legal, ethical, social, economic, and professional issues, emerging 
technologies, and evolving pharmaceutical, biomedical, socio-behavioral, and 
clinical sciences that may impact therapeutic outcomes.” 
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• “Manage and use resources of the health care system, in cooperation with 
patients, prescribers, other health care providers, and administrative and 
supportive personnel, to promote health; to provide access, and coordinate 
safe, accurate, and time-sensitive medication distribution and to improve 
therapeutic outcomes of medication use.” 
• “Promote health improvement, wellness, and disease prevention in 
cooperation with patients, communities, at-risk populations, and other 
members of an inter-professional team of health care providers.” (33)  
Pharmacists in the U.S. are trained at the doctoral level and are educated in the 
following areas: pathophysiology, pharmacology, therapeutic, clinical problem solving, 
medication use, and laboratory monitoring.(5)(33)  They are trained to become patient 
educators, patient coaches, with the most extensive knowledge and training in medication 
use, medication management, and problem-solving with any member of the healthcare 
team.(5)  Furthermore, pharmacist experiential training is composed of significant 
practice experiences rooted in primary and ambulatory care, community health, different 
health care settings (rural and urban health challenges), and long-term care.(5)(34)  
According to the ACPE’s Accreditation Standards, PharmDs are trained and 
qualified to (5)(35):  
• “Manage complex drug therapy and make recommendations for initiation, 
modification and termination of therapy 
• Obtain medical histories 
• Perform health screening and prevention assessments and evaluations 
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• Perform and interpret diagnostic and laboratory studies 
• Counsel and teach health and nutrition 
• Screen and refer patients to specialists and other health care providers 
• Provide education to allow patients to make decisions about their own 
health 
• Pharmacists are increasingly being integrated into these primary care 
teams, in family practice settings, ambulatory care clinics and community-
based locations.”(2) 
There are many commonalities when the educational competencies of NPs, PAs, 
and PharmDs are compared.  The educational path for PharmDs focuses more on 
therapeutics and medication pharmacology while NP and PA programs place more 
emphasis on patient diagnostic skills.(32)  These overlaps—and slight but important 
differences in educational competencies—create a solid foundation for building 
integrated, team-oriented and collaborative approaches to patient care.(5)(32) 
Clinical Pharmacy Residencies 
After accreditation with a PharmD degree, a pharmacist can pursue a residency 
consisting of one or two years.  The purpose of a postgraduate year one (PGY1) or 
postgraduate year two (PGY2) pharmacy residency is to prepare pharmacists for practice.  
Residency training is designed to provide residents experience working with a wide range 
of patients and in three types of residency settings—1) Pharmacy Practice (based in a 
hospital setting, 2) Community Pharmacy (based in a community pharmacy), and 3) 
Managed Care Pharmacy (based in managed care organizations such as health plans or 
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pharmacy benefit management companies.(36) 
Residency training offers pharmacists advantages in the job market by making 
their training more highly specialized in a specific market, helps them network to expand 
their professional acquaintances, and further plan their careers.  During residency most 
residents gain a clearer picture of what type of practice best suits them and the specific 
field where they want to work in the future.  Currently, the American Society of Health-
System Pharmacists (ASHP) recognizes fifteen specialized areas of practice. 
Historically, pharmacy residencies date back to the early 1930s where the primary 
purpose of the residency was to train pharmacists in hospital pharmacy management.  In 
1948, the ASHP developed standards for pharmacy residencies in hospitals.  During the 
early 1970s, residencies in clinical practice grew at a rapid rate, leading to the 
establishment of accreditation standards for clinical pharmacy and specialized residency 
training programs to ensure a quality training experience.(36)  As of 2012, there were a 
total of 1,443 accredited programs participating in the resident matching program and a 
total of 2,594 residents were placed in these programs.(37)  The supply of pharmacists 
and pharmacist demand for residency programs is growing significantly faster than was 
previously projected.(13)    
ASHP is the sole accrediting body for pharmacy residencies in the United States.  
In 2007, approximately 1,600 PGY1 residency positions were available, and over 1,300 
residency candidates obtained positions through the ASHP Resident Matching 
Program.(38)  Table 3 describes pharmacist employment by sector in 2006.  If all 1,600 
PGY1 positions were ultimately filled, then 16 percent of the approximately 10,000 
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pharmacy graduates in 2007 entered residency training.(20)  Outpatient clinical pharmacy 
requires residency training and disease-specific certifications.  
Table 3. Pharmacist Employment in 2006 (20) 
Practice Site No. Pharmacists Employed 
Community 155,010 
Health Systems 63,190 
Public Administration 7,450 
Other 14,270 
Total 239,920 
Source: Johnson TJ. Pharmacist work force in 2020: implications of 
requiring residency training for practice. Am J Health Syst Pharm 
[Internet]. 2008 Jan 15 [cited 2014 Nov 26];65(2):166–70. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/18192265 
 
There is a clear disconnect between the number of residency positions available 
and the number of residency-trained pharmacists likely to be needed in the future.  
Currently, most residency training programs are conducted in a health-system setting.  
Many pharmacists are entering residency training as a prerequisite for direct-care 
practice.  While the majority of these residency-trained pharmacists will enter inpatient 
hospital clinical care, others are looking for outpatient clinical practice.  Some describe 
this disconnect as a ‘chicken and egg’ problem—what comes first?  Are there enough 
residency-trained pharmacists interested in outpatient clinical pharmacy to take a job in 
the community, or are there enough outpatient clinical care centers looking to hire 
outpatient clinical pharmacists?   
This uncertainty carries through to the residency training programs—are there 
enough pharmacists looking for outpatient clinical pharmacy training for these roles upon 
graduation?  Are potential pharmacy students looking for community–based jobs when 
they apply to pharmacy school?  According to Mindy Smith at the APhA, the lack of 
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clinical pharmacy positions offered to PharmDs after residency is due directly to patient 
demand for medication disease state management clinical services.(24)  Smith posits that 
patients are not referred to pharmacists for disease state management since pharmacists 
cannot bill for the claim of services rendered due to a lack of pharmacist provider status.  
This lack of patient supply leads to a decrease in demand for potentially beneficial 
clinical pharmacy services and therefore a lack of programs or jobs for pharmacists 
looking to provide clinical services.  While there are no direct answers to these questions 
or ways to confirm or deny claims about clinical pharmacy supply or demands, chronic 
disease care management can most likely benefit from pharmacist-inclusive practice. 
Pharmacist Compensation 
In contrast to NPs and PAs, pharmacists do not have provider status as recognized 
by Title XVIII of the Social Security Administration (SSA).  Consequently, pharmacists 
are not considered ‘providers’ according to the SSA and therefore cannot bill the 
government or private insurance plans for patient services rendered since they cannot 
submit a claim for clinical services provided.  Without provider status, pharmacists do 
not have reimbursement eligibility under Medicare Part B.  Funding received from a third 
party grant or award can be spent to reimburse pharmacist services, pay a pharmacist’s 
salary, among other options.  However, pharmacists are credentialed to submit claims 
through three mechanisms in Medicare—Part A, B and D.  In Medicare Part B, 
pharmacists can bill for “Incident-to” billing for services rendered after a referral from 
another health care provider.(39)(40)  The services provided through “Incident to” billing 
are defined as services or supplies furnished as an integral, although incidental, part of 
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the pharmacist’s professional services.(41)  For example, a pharmacist can bill through 
Medicare Part B if a physician sends a patient with high blood pressure to a pharmacist 
for medication follow-up education.  If the clinic is accredited as a Diabetes Self-
Management Training (DSMT) or Diabetes Self-Management Education (DSME) site, 
then a pharmacist can bill Medicare Part B for diabetes education or training by a 
pharmacist. 
Medicare Part A has a facility-fee claim that a pharmacist can submit to Medicare 
for the use of the clinical or pharmacy location for patient education or management.  
Medicare Part A claims are usually submitted by a drug dispensing pharmacist within a 
pharmacy when the patient education itself occurs after a drug is dispensed and 
counseling services are provided.  Medicare Part D is also associated with drug 
dispensation specifically for Medication Therapy Management (MTM).  A pharmacist 
can bill for MTM services in a drug dispensing pharmacy or a clinical outpatient practice. 
The reimbursements through Medicare Part A, B and D are not solely sustainable 
for a clinic to employ a full-time clinical pharmacist since the reimbursements for the 
services provided from Medicare are lower than the services themselves cost to the clinic.  
Moreover, pharmacist reimbursements through these mechanisms are not sufficient to 
sustain an individual pharmacist’s salary based on the percent of the reimbursement that 
comes back to the pharmacy.  Since pharmacists are not considered clinical services 
providers in terms of insurance compensation and cannot support their full salary from 
these claims, many pharmacists receive an annual salary from the clinic or outpatient 
facility. 
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Pharmacist’s Role in Helping Solving the Primary Care Crisis 
The public health problems caused by the expanding gap between the supply of 
primary care providers and the demand generated through unmet patient needs are 
formidable and will not be solved by a re-constituting or adapting a single 
profession.(5)(33)  Since the issues are complex and will be compounded in the future 
with an aging population, collaborative efforts to identify solutions and provide high 
quality, team-delivered primary care are necessary.  In assessing the functions and areas 
of deficiency in primary care practice, and thinking critically about untapped resources, 
pharmacists, among other clinicians, emerge as a potential resource to increase access to 
primary care and address one of the most challenging aspects of patient care—
appropriate medication management. (5)(26) 
Many pharmacists will be motivated to seek proficiency in the skills required to 
become a primary care provider, others may not choose to practice pharmacy clinically.  
Moreover, the health care system could not afford a global shift away from the role that 
many pharmacists play in the provision and delivery of medications.(43)   However, 
some pharmacists will look to expand their care role, and their current educational 
background provides a strong foundation from which to build competence in physical 
assessment and diagnostic skills that will complement their expertise in managing 
complex medication therapies for their patients.(5)(44)(8)(6)  
As of 2012, there were approximately 286,000 pharmacists and 353,000 
pharmacy technicians practicing in the United States.(45)  The average age for a 
pharmacist was 45 and 53.7 percent of pharmacists were women.(21)  The national mean 
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annual earnings for a pharmacist were $116,670, with the lowest 10 percent earning on 
average $89,000 while the highest 10 percent earned $145,000.(21)  Table 4 provides an 
overview of trends for of trends for pharmacist training and employment wages. 
Table 4. Pharmacist Trends, 2012 
Pharmacist Training and 
Prevalence  
Employment Overview Wages 
-Since 2003, the number of 
pharmacists in the U.S. 
increased by 23 percent in 10 
years.(21) 
-As of 2010, 62 percent of pharmacists 
worked in retail pharmacies, 23 percent 
in hospitals, while others worked in 
clinics, mail-order pharmacies, 
wholesalers, some health care agencies 
or government.(45) 
-Pharmacists experienced 
a 16 percent increase in 
real wages since 
2003.(21) 
-The U.S. Bureau of Labor 
Statistics projects faster than 
average growth for both 
pharmacist and pharmacy 
technicians from 2010-
2020.(45) 
-As of 2010, 73 percent of pharmacy 
technician and aide jobs were in retail 
pharmacies.(46) 
-In 2012, median annual 
earnings for pharmacy 
technicians were $29,320, 
representing just a 3 
percent increase in real 
wages since 2003.(45) 
-In April 2013, the Aggregate 
Demand Index calculated by 
the Pharmacy Manpower 
Project was 3.21; indicating a 
roughly balanced supply and 
demand of pharmacists across 
the country.(22) 
-As of 2010, about 21 percent of 
pharmacists worked part-time.(45) 
-In 2012, reported 
earnings for pharmacists 
varied by industry, type of 
employment, and region. 
-While reports once suggested 
demand for pharmacists would 
outpace the supply in the 
coming decade, trend data 
show that it has not been the 
case for the previous ten 
years.(22)(47) 
-In 2012, Gallup Poll measured public 
perceptions of professional ethics and 
honesty.  Respondents placed 
pharmacists second only to nurses—75 
percent of respondents ranked 
pharmacists as “very high” 
professional ethical standards.(48) 
-In 2012, health and 
personal care stores 
reported the highest 
concentration of 
pharmacist employment, 
while the highest average 
annual wages were in 
pharmaceutical and 
medicine manufacturing. 
(21) 
-As of 2012, there were 61,275 
students enrolled in 124 
accredited programs.(49) 
-In 2012, the pharmacist workforce 
was 6.8 percent African American, 
18.5 percent Asian, and 5.1 percent 
Hispanic or Latino.(50) 
 
Source: AFL-CIO. Fact Sheet 2013: PHARMACISTS AND PHARMACY TECHNICIANS FACTS 
AND FIGURES. Dep Prof Employees [Internet]. 2013;1–7. Available from: 
http://dpeaflcio.org/wp-content/uploads/Pharmacists-and-Pharmacy-Technicians-2013.pdf (21) 
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Chapter One Summary 
 In summary, Chapter 1 outlined the research questions, propositions, and 
translation of this research.  Chapter 1 also outlined the future of pharmacist-inclusive 
practice for primary care in the United States.  The projected primary care shortage of 
physicians, Nurse Practitioners, Physician Assistants and other allied health professionals 
leaves a potential gap for pharmacists to fill for medication management of chronic 
disease.  To understand how pharmacists can address this gap, Chapter 1 defined 
pharmacy education, residency and training in the United States.   
To understand the Collaborative Drug Therapy Management program at El Rio, 
background knowledge about pharmacists and current supply and demand trends is 
paramount.  The projected increase in future U.S. demand for primary care services and 
the potential benefit pharmacist integration into clinical outpatient care services, leaves a 
gap for pharmacist inclusion that could be addressed with CDTM models and theory.  
Chapter 2 describes the study setting and case study analysis employed by this research. 
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CHAPTER TWO 
Literature Review 
Introduction 
 Chapter 1 described the state of the pharmaceutical profession and the potential 
role pharmacist-inclusive practice can have in helping to address upcoming physician 
shortages.  Chapter 2 describes the specific pharmacist-inclusive practices used for 
collaborative practice in patient care settings.  The rationale behind this study, theoretical 
models and the gaps in current research are discussed in Chapter 2.  The specific aims 
and models used to analyze the case study of El Rio are further developed as well. 
 
Collaborative Practice 
The IOM has called for “a new health system for the 21st century for primary 
health care teams to play a central role in the care of patients.”(33)  The leap in the 
complexity of patient care prevents physicians, NPs, or PAs from managing a patient’s 
treatment plan alone.(51)  Studies have demonstrated that in settings where physicians 
and non-physician professionals work together as teams, patients have improved health 
outcomes and lower hospital 30-day re-admission rates.(52)(53)(54)(6)(55)(56)(57)(25)  
According to the IOM, “all health professionals should be educated to deliver patient-
centered care as members of an interdisciplinary team, emphasizing evidence-based 
practice quality improvement approaches and informatics.”(10)(5)  Each health care 
professional on the healthcare team brings a core set of skills and training to provide 
primary care services that directly impact quality care for patients and contain costs of 
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treatment.  The highest quality healthcare is provided when all members of the healthcare 
team improve communication and collaboration between each other while treating a 
patient.   
The imperative of cost containment in health care leads provider organizations to 
favor hiring lower paid clinicians over physicians.(52)  Moreover, the demand for quality 
patient care encourages primary care settings to add caregivers with skills that physicians 
may not possess.(5)  PAs and NPs are formally recognized primary care providers with 
national provider status as defined by the Social Security Administration.  These 
professionals have significantly expanded the primary care capacity, access, and 
availability in the U.S. over the past 40 years.(5)  Although some are state-regulated—
PAs practice in collaboration with and under physician supervision—many exercise 
autonomy in clinical decision making.(53)  Nurse Practitioners also practice through 
collaborative practice agreements or under some level of physician supervision in most 
states.(5)(34) While healthcare settings differ in patient volume and complexity of care, 
in 22 percent of states in the U.S., NPs have authority to practice independent of 
physician involvement.(58)   
States determine the laws regarding licensing of pharmacists.  All states require, 
at minimum, both graduating from an accredited first professional degree program from a 
pharmacy college and passing of the North American Pharmacy Licensing 
Examination.(21)  After licensure, pharmacists can work in many settings ranging from 
drug dispensing, administration, to outpatient clinical pharmacy. 
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Collaborative Practice Agreements (CPAs) 
According to the Centers for Disease Control and Prevention (CDC), “a CPA is a 
formal agreement in which a licensed provider makes a diagnosis, supervises patient care, 
and refers patients to a pharmacist under a protocol that allows the pharmacist to perform 
specific patient care functions.”(59)  CPAs can be arranged between any type of licensed 
health care provider in both inpatient and outpatient settings. CPAs define certain patient 
care functions that each care provider on a team can provide autonomously under specific 
situations and conditions.(60)  While CPA’s provide one option for increased 
collaboration, they are one of many tools used by hospital and clinical administrators to 
address a patient-centered team-based approach to care.  The CDC collaborative practice 
framework is outlined in Figure 4. 
CPAs are most common for NPs and PAs due to their direct involvement with 
patient care.  In 21 states NPs must practice under a CPA with a physician.(58)  The 
requisite level of specificity for a NP’s clinical purview varies by state.  Nationwide, 
CPAs and other types of binding contracts are in place for PAs as they must work under 
the auspices of a physician. 
Research has shown that pharmacists can directly improve a patient’s health and 
the health care delivery system only if they are a part of the patient’s health care 
team.(17)  As illustrated in Figure 4, one way to meet this goal of including a pharmacist 
on a care team is through pharmacist-inclusive CPAs between pharmacists and other 
health care providers.(59)  Patient care services provided by a pharmacist-inclusive team 
can reduce fragmentation of care, lower health care costs, and improve health 
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outcomes.(59)  A 2010 study found that patient health improves significantly when 
pharmacists work with doctors and other providers to manage patient care under 
CPAs.(61)   
 
Figure 4. Framework for Successful Collaborative Practice Agreements.(59)
Adapted from: Centers for Disease Control and Prevention. Collaborative Practice Agreements 
and Pharmacists’ Patient Care Services: A Resource for Pharmacists.  Atlanta, GA: US Dept. of 
Health and Human Services, Centers for Disease Control and Prevention; 2013. (59) 
 
Collaborative Drug Therapy Management (CDTM) 
Many types of employment and practice agreements exist between NPs, MDs, 
and PAs, however, a Collaborative Drug Therapy Management (CDTM) Collaborative 
Practice Agreement is specific to pharmacists.  The CDTM contract identifies and 
clarifies a pharmacist’s clinical practice role when pharmacists are working with other 
clinicians in a collaborative manner.  These pharmacist-specific CPAs are the foundation 
Align Incentives
Patients, providers, and payers 
receive appropriate incntives while 
collabrorating to advance patients' 
health.
For patients: A product, service, 
experience, or added value that 
motivates the patient to take 
actions that will improve health.
For health care providers: 
Appropriate compensation for 
products and services provided.
For payers: Minimizing total 
health care expenditures while 
providing high-quality, necessary 
services.
Improve Outcomess
As pharmacists, patients, and 
others on the team work together, 
patient health outcomes improve.
Tracking progress and reporting 
outcomes ensures all members of 
the health care team involved in 
the patient's care are aware of the 
impact of the collaborative efforts.
Control Costs
The aligned incentive for the 
health care system is similar to 
that for each payer: control 
overall health care costs.
Improved health status 
unltimately decreases health 
care costs.(22) 
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of pharmacist-inclusive CDTM models that have been shown to reduce fragmentation of 
care, lower health care costs, and improve a patient’s health outcomes.(34)(62) 
According to the AACP, “CDTM is a team approach to healthcare delivery that 
seeks to maximize the expertise of the pharmacist and the physician in order to achieve 
optimal outcomes through appropriate medication use and enhanced patient-care 
services.”(5)  The Academy for Managed Care Pharmacy (AMCP) describes CDTM 
models as a formal partnership between a pharmacist and physician or group of 
pharmacists and physicians to allow the pharmacist(s) to manage a patient’s drug therapy 
autonomously.(63)  The CDTM designation is used primarily because it is descriptive of 
the usual scope of practice between the physician and the pharmacist; e.g. drug therapy 
management.(63)  
CDTM is most commonly provided under mutually agreed upon practice 
protocols and guidelines in both clinical inpatient and outpatient settings.  The AACP 
defines CDTM activities that include, but are not limited to, the following pharmacist 
activities: 
• “Initiating, modifying, and monitoring a patient’s drug therapy 
• Ordering a performing laboratory and related tests 
• Assessing patient response to therapy 
• Counseling and educating patients about their medications 
• Administering medications”(2) 
Pharmacists have varying degrees of prescriptive authority depending on state 
law.  Because CDTM allows pharmacists to provide services that are typically outside 
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traditional pharmacy practice laws, authorization in each individual state is required to 
establish the laws governing the CDTM scope of practice for pharmacists.(63)  A 
significant barrier to the ability to deliver this quality primary care is embedded in 
pharmacist practice laws and regulations.(5)  In forty-seven states, the District of 
Columbia, the territory of Guam, the Department of Veterans Affairs, and the Indian 
Health Service, pharmacists are authorized to enter into collaborative drug therapy 
management (CDTM) agreements with physicians in clinical settings.(64)(40)  In forty-
six states and the territory of Guam, laws and regulations permitting pharmacists to 
authorize either a limited or broad scope of drug therapy management have been 
adopted.(34)(59).  As of December 2013, only Tennessee, South Carolina, Michigan, and 
Alabama did not have a law or identified legal authority condoning or eliminating clinical 
pharmacy practice.(34)  Figure 5 identifies state authorizations regarding drug therapy 
management by pharmacists.  In many cases, CDTM acceptance and integration into 
current care models is more of a barrier than the legal obstacles approving pharmacist-
inclusive team-based care models in outpatient care settings.   
Due to their regular direct contact with patients, pharmacists are the most 
accessible and frequently visited members of the healthcare team.(5)  Community 
pharmacists are among the most widely accessible healthcare professionals, and can be 
utilized not only as the traditional prescription medication dispensers, but also as disease 
state managers providing patient education, counseling, and monitoring of drug 
therapy.(26)  Many pharmacists have established practices in primary and ambulatory 
care settings, working in teams to provide medication therapy management and (usually 
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disease-specific) chronic and preventative care to patients in disease specific 
models.(5)(65)(66) 
Figure 5.  Map of States with Laws Explicitly Authorizing Pharmacist Collaborative 
Practice Agreements, 2012 (59)
 
Services UD of H and H. Collaborative Practice Agreements and Pharmacists’ Patient Care 
Services: A Resource for Pharmacists. US Dept Heal Hum Serv Centers Dis Control Prev 2013. 
2013. 
 
CDTM models make drug therapy earlier, more efficient and convenient for the 
patient, pharmacist and physician.  With a CDTM model in place, the health care team is 
able to expand the ability of health care professionals able to provide optimal care to their 
patients.(63)  A CDTM model extends access to health education, health screening, 
vaccine administration, among other services for community health where physician 
access is limited.(67)   
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An example of a successful CDTM model is when a physician and pharmacist 
both see the same patient with diabetes.  The visits are different—the clinician diagnosed 
the patient, and the pharmacist completed the follow-up tests and initial medication 
dosing.  At a later check-up when the pharmacist observed that the patient’s insulin dose 
needed to be increased or decreased by one small unit of measure, the pharmacist could 
prescribe and fill the new medication dosing.  When a CDTM model is in place, a 
pharmacist does not need to run medication changes by the physician.  Instead of having 
‘double work’ by having the physician check the dosing change before approving and 
filling it, the pharmacist can change the medication dosing, write the prescription and 
note the change in the patient’s chart without physician approval.  Not only do CDTM 
models save patients time, they are cost effective for clinics as practitioners are not 
repeating work.  
A successful example of how changes in scope of practice for pharmacists can 
impact the care of patients is the provision of immunizations.  As of 2010, more than 
40,000 pharmacists have received formal training and recognition as providers of a wide 
range of immunization services.  This broad adoption of immunization training and 
services has resulted in millions of patients receiving pharmacist-delivered 
immunizations each year.(5)  Due to this increase in vaccination coverage, the AACP 
believes that, “state-based scope of practice laws and regulations must be revisited and 
updated to allow CDTM and immunizations in all U.S. states and territories.”(5) 
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Pharmacist’s Role in Diabetes Care 
One of the many chronic diseases that can be clinically and cost-effectively 
managed by pharmacists in collaborative practice is diabetes.(25)(65)  Diabetes mellitus 
is one of the most prevalent chronic diseases in the United States and is also a leading 
cause of morbidity and mortality.(68)  Diabetes is a group of metabolic diseases in which 
a person has abnormally elevated levels of blood sugar.  Diabetes is the seventh leading 
cause of death in the United States and can cause serious health complications including 
heart disease, blindness, kidney failure, and a potential for lower-extremity 
amputations.(69)  The symptoms of diabetes include: frequent urination, unexplained 
weight loss and extreme hunger among other symptoms.(70) There are two main types of 
diabetes—type 1 and type 2.   
Diabetes type 1 (T1DM), historically referred to as juvenile diabetes or insulin-
dependent diabetes mellitus (IDDM).  T1DM accounts for five to ten percent of all 
diagnosed diabetes cases.  Autoimmune, genetic and environmental risk factors are 
involved in the development of this type of diabetes.  Treatment includes frequent insulin 
injections.(71)   
Diabetes type 2 (T2DM), historically referred to as non-insulin dependent 
diabetes mellitus (NIDDM) or adult onset diabetes.  T2DM accounts for 90 to 95 percent 
of all diagnosed cases of diabetes.  Risk factors for type 2 diabetes include older age, 
obesity, physical inactivity, and ethnicity.(72)  African Americans, Hispanic and Latino 
Americans, American Indians, and some Asian Americans are at particularly high risk for 
T2DM.  Treatment typically includes diet control, home blood sugar testing and in some 
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cases oral insulin medications or insulin injections.(71) 
According to the American Diabetes Association (ADA), the total estimated total 
cost of diagnosed diabetes in 2012 was $245 billion—a 41 percent increase from the 
previous estimate of $174 billion in 2007.(73)  Of the $249 billion total costs, an 
estimated $175 billion were direct medical costs and an estimated $69 billion in reduced 
productivity.(73)  The ADA estimates that care for people with diagnosed diabetes 
accounts for more than one in five health care dollars in the U.S., and more than half of 
that expenditure is directly attributable to diabetes.(73)  While total diabetes-related costs 
are estimated to accurately represent the cost of diabetes, the burden of diabetes is 
imposed on all sectors of society through higher insurance premiums paid by employers 
and employees and reduced earnings from productivity losses.(68)  In response to the 
growing health burden of diabetes, the public health community is working to prevent 
diabetes; cure diabetes; and take better care of people with diabetes to prevent 
devastating complications.(70)  
El Rio: Historical and Current Context 
El Rio Community Health Center was founded in the late 1960’s by neighborhood 
activists and the University of Arizona.  The clinic founders wanted to bring accessible 
and affordable health care to Tucsonans who were “being overlooked by traditional 
health care systems.”(74)  El Rio now consists of seventeen clinical sites and serves over 
79,000 patients—almost 900 patients per day.(74)(75)  Over 70 percent of the patient 
population self-identify as Hispanic or Mexican-American.(76)  El Rio provides 
accessible and affordable health care primarily to underserved populations in the greater 
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Tucson area and southern Arizona. Of the patients served at El Rio, 76 percent report 
living at or below the federal poverty level.(74)   
 As one of the largest non-profit community health centers in the United States, El 
Rio has become a national model for pharmacy-based outpatient health care delivery.(76)  
As many patients who receive care at El Rio are pre-diabetic or have diabetes, the 
Pharmacy-Based Diabetes Management Program (PBDMP) began in 2001 and has 
served over 4,000 patients.(75)  The program includes direct service and interventions for 
patients through disease state management including prescribing medications and in-
depth educational consults empowering patients to proactively manage their health.  This 
ongoing direct consultation integrates treatment of three related diseases: diabetes, 
hypercholesterolemia and hypertension.  The program has been found to be cost effective 
and clinically effective in treating diabetes (T1DM and T2DM) and preventing hospital 
admissions.(76)(65) 
 In 2009, a team of researchers from the University of Arizona and El Rio 
developed and implemented an internal case study analysis of the El Rio patients who 
had participated in the PBDMP.  The methodology included the identification of a few 
key indicators, development of an abstraction tool, and then data collection from the 
program’s data base.  The first deliverable of the project was to evaluate the program’s 
effectiveness in terms of affecting utilization of emergency departments (ED) for diabetes 
and other indicated outcomes.(76)  After the first phase of data was collected and 
analyzed, the second variable examined by the team was cost effectiveness data of the 
PBDMP in contrast to the diabetes-related ED visits. 
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 The study team found that the El Rio measures were generally superior by a 
relatively large amount for tests and exams related to diabetes as compared to the ED.  
The trend data showed substantial improvements from 2000-2009 in El Rio performance 
of the diabetes tests and exams over time.  This trend was accompanied by a shift from 
lower rates than the control group to higher rates, around 2003, and the maintenance of 
that superiority in all subsequent years between 2000 and 2009.  While data related to 
total charges are a notoriously poor proxy for total costs, the analysis showed average 
total charges were substantially lower for El Rio.  The team showed that there was 
substantial evidence to support a conclusion that the El Rio PBDMP is effective in 
improving the care and, within stated constraints, succeeds in reducing the health care 
costs of the patients that it treats. 
Research Gaps 
Patients with a broad range of diseases and conditions can be managed by 
pharmacists in conjunction with primary care clinicians.  Many of these conditions are 
comorbid and thus require complicated medication therapy and sometimes may require 
other clinical interventions.(5)  To effectively care for these complex patients and “take 
responsibility for achieving intended therapeutic outcomes through medication 
management,” pharmacists rely on a strong clinical and pharmacological knowledge and 
experience base.(5)   
Numerous scientific publications have conclusively demonstrated dramatic 
reductions in morbidity and mortality that pharmacists practicing in primary care can 
have on patient populations afflicted with chronic diseases such as asthma(77), 
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diabetes(6)(7), Hepatitis C(57), hyperlipidemia(6), hypertension(25), chronic kidney 
disease(66), and HIV(78), among others.(6,25,55–57,78,79)  Many articles examine the 
perspective of family physicians and NPs with the inclusion of a pharmacist in their 
collaborative practice.  Although operational and practice integration challenges are 
usually recognized, the clinical benefits of working collaboratively with a pharmacist 
include: “access to colleagues with reliable drug information, fresh perspectives, and 
increased security in medication prescribing”.(80)  Many of these articles focus on the 
clinical outcomes or cost-effectiveness of pharmacist-inclusive collaborative care while 
overlooking exactly how the model for pharmacist integration was initially formed.  As it 
is difficult to rationalize clinical time spent describing best practices of a program or 
intervention, many clinics have not published what worked and why it worked for their 
specific patient population and the subsequent potential for larger dissemination and 
transferability to other clinical sites. 
 
Study Purpose 
The purpose of this dissertation is to study the process, successes, and challenges 
associated with the implementation of pharmacist-inclusive collaborative care models in 
outpatient clinical settings.  The study will investigate the CDTM Pharmacy-Based 
Diabetes Management Program at the El Rio Community Health Center in Tucson, 
Arizona.  An in-depth examination of the experience with CDTM implementation will be 
analyzed using the PRECEDE-PROCEED model (a cost-benefit evaluation framework) 
and the organizational transformation model (describing a model for moving 
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organizations from short-term, isolated performance improvements to sustain and 
organization-wide improvements in patient care) in order to identify factors influencing 
the improvement initiatives leading to organizational transformation in El Rio’s CDTM 
Pharmacy-Based Diabetes Management Program.(81)  Study findings will be used to 
create intervention guidelines for CDTM in public health practice by: a) developing 
practical outpatient clinical collaborative practice agreements for pharmacist-inclusive 
practices b) proposing mechanisms for more successful CDTM implementation, both in 
Arizona and in other locations considering similar CDTM models. 
 
Specific Aims 
The objectives of this dissertation are to address the current gap in knowledge of 
the ways in which CDTM models are implemented and adopted; to identify perceived 
and documented successes and challenges related to full implementation of the CDTM 
model at El Rio Community Health Center; and to develop practical tools for 
implementation, adoption, and monitoring for other outpatient clinical settings 
considering the development and implementation of a similar model.  Study objectives 
are summarized in the following specific aims and sub-aims. 
 
Specific Aim 1:  To identify the ways in which the CDTM model became a: 1) clinically 
effective, 2) cost-effective, and 3) sustainable model at the El Rio Community Health 
Center. 
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Sub-aim 1a. Identify key aspects of the clinical management processes (through 
lean management brainstorming exercises and key informant interviews) that 
served as structure and support for the CDTM model at El Rio.  
 
Sub-aim 1b: Apply the PRECEDE portion of the PRECEDE-PROCEED model 
and organizational transformation model to an analysis of the El Rio CDTM 
model implementation in order to identify the foundational aspects of the socio-
ecological model that supported the program’s inception.   
 
Specific Aim 2: To translate findings from the implementation assessment into public 
health practice products that support successful implementation and maintenance of 
CDTM models throughout Arizona and nationwide. 
 
Sub-aim 2a: To study the contextual information and literature to inform both the
 analysis of Arizona’s experience and the development of CTDM implementation
 guidelines and resources.   
 
Sub-aim 2b: Create CDTM model implementation guidelines for clinics and 
hospitals looking to implement a CDTM model in their health care setting. 
 
Sub-aim 2c. Build a decision support tool—in the form of an embedded Google 
Forms document or worksheet—that will allow clinics to assess their capacity for 
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implementation of a CDTM model.   
 
Sub-aim 2d: Develop and disseminate a management case study about the
 Pharmacy Based Diabetes Management Program at the El Rio Community Health
 Center.  The management case study will focus on key administrative decisions
 made during program implementation used by the El Rio administration and other
 stakeholders. 
 
Conceptual Frameworks 
 
PRECEDE-PROCEED Model 
According to Andrea Gielen et al., “the Precede-Proceed model can be thought of 
as a road map and behavior change theories as the specific directions to a destination.” 
(82)  The road map presents all the possible avenues a health program can take, whereas 
the theory suggests certain avenues to follow.  Gielen et al. argue that “the Precede-
Proceed model does not predict or explain the relationship among factors thought to be 
associated with an outcome of interest, rather, its main purpose is to provide a structure 
for applying theories and concepts systematically for planning and evaluating health 
behavior change programs.”(82)   
 The model is an example of a behavioral logic model, in that it links the causal 
assessment and the intervention planning and evaluation into one overarching planning 
framework from the beginning to the end of the intervention.  Developed in the 1970s by 
Lawrence Green and colleagues, the acronym (PRECEDE) stands for: Predisposing, 
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Reinforcing, and Enabling Constructs in Educational/Environmental Diagnosis and 
Evaluation.  Green described the framework, “PRECEDE is based on the premise that, 
just as medical diagnoses precedes a treatment plan, so should educational diagnosis 
precede an intervention plan.”(82)  In 1991, PROCEED (Policy, Regulatory, and 
Organizational Constructs in Educational and Environmental Development) was added to 
the framework recognizing the importance of environmental factors as determinants of 
health. 
 There are eight phases of the PRECEDE-PROCEED model including: 1) Social 
Assessment, 2) Epidemiological, Behavioral, and Environmental Assessment, 3) 
Educational and Ecological Assessment, 4) Administrative and Policy Assessment and 
Intervention Alignment, 5) Implementation, 6) Process Evaluation, 7) Impact Evaluation, 
and 8) Outcome Evaluation.  This study will utilize all eight phases as a roadmap, 
focusing on the first four phases of the PRECEDE framework.  Figure 6 presents the 
PRECEDE-PROCEED model and describes determinants of each phase.  
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Figure 6.  PRECEDE-PROCEED Planning Model 
 
Source: Phillips JL, Rolley JX, Davidson PM. Developing Targeted Health Service Interventions 
Using the PRECEDE-PROCEED Model: Two Australian Case Studies. Nurs Res Pract 
[Internet]. 2012 Jan [cited 2014 Jan 28];2012:279431. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3407641&tool=pmcentrez&renderty
pe=abstract.(83) 
 
While the PRECEDE-PROCEED framework typically addresses behavior change 
models applied to the public, this study applies the framework to a clinical model of 
practice in the context of the El Rio Pharmacy-Based Diabetes Management Program 
(PBDMP).  The first four steps of the PRECEDE-PROCEED model, specifically the 
PRECEDE segment of the model, will provide a framework to outline the key 
administrative, ecological, environmental and social aspects of El Rio throughout the 
CDTM model.  Steps five through eight of the PRECEDE-PROCEED model address the 
program’s implementation and process evaluation through an outcome evaluation phase.  
  
44
The PROCEED portion of the model covers the Administration, Educational and 
Ecological assessment, epidemiological and social assessment of the program design. The 
PROCEED segment of the model is important for the implementation, process 
evaluation, and outcome evaluation of a program.    
The PRECEDE portion of the model is more applicable give the scope of the 
research questions.  The PRECEDE portion of the model focuses on the structure of the 
environment and assessment leading up to an implementation.  These key factors are 
exceedingly important to define and address to assist in the creation of the backbone of 
the PBDMP in order to ultimately create implementation guidelines on how the program 
was created.  The research questions for this research focus on how these factors assisted 
with the structure and development of the program and not on the specific process or 
outcome evaluation of the program as a whole.  Figure 7 describes the PRECEDE 
segment of the model as it applies to the research in more depth.    
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Figure 7.  PRECEDE Model for CDTM Implementation Guidelines 
 
Adapted from: Phillips JL, Rolley JX, Davidson PM. Developing Targeted Health Service Interventions Using the PRECEDE-PROCEED 
Model: Two Australian Case Studies. Nurs Res Pract [Internet]. 2012 Jan [cited 2014 Jan 28];2012:279431. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3407641&tool=pmcentrez&rendertype=abstract.(83) 
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c 
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The PRECEDE segment of the PRECEDE-PROCEED model will provide the 
socio-ecological framework to understand the backdrop and foundation where the 
PBDMP was created.  The individual and environmental factors that influence the model 
will be defined and studied to gain and more complete picture of El Rio and Tucson as 
the program was founded.  The factors that create the PRECEDE segment of the model 
are especially important to understand the organizational and management decisions as 
the program was created.  This research is the first of its kind to apply the PRECEDE-
PROCEED framework to an organization’s behavior as a change model instead of an 
individual, study group, or community.   
 
Organizational Transformation Model 
Organizational Transformation Model offers a conceptual model for moving 
organizations from short-term, isolated performance improvements to sustained, reliable, 
organization-wide, and evidence-based improvements in patient care.(81)  The model is 
based on the IOM’s 2001 report Crossing the Quality Chasm: A New Health System for 
the 21st Century, arguing for a fundamental redesign of the U.S. healthcare system.(81)  
While many health care organizations have embraced the report’s goals, few have 
succeeded in making the substantial transformations within their organizations needed to 
achieve those aims.(81)(84)  Since transformation occurs over time with iterative changes 
being sustained and spread across the organization, organizational transformation takes 
leadership, dedication, and sustained support to succeed.(81) 
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 The model outlines five interactive elements critical to successful transformation 
of patient care: 1) Impetus to transform, 2) Leadership commitment to quality, 3) 
Improvement initiatives that actively engage staff in meaningful problem solving, 4) 
Alignment to achieve consistency of organization and goals with resource allocation and 
actions at all levels of the organization, and 5) Integration to bridge the traditional intra-
organizational boundaries among individual components.(81)  These elements drive 
change within an organization by affecting the components of the health care 
organization in which they operate including the: 1) Mission, 2) Culture, 3) Operational 
Functions and 4) Infrastructure.(81)  These five elements interact within the organization 
to create change.  The organizational transformation model identifies factors critical to 
successful redesign, transformation, and patient care. To achieve transformation through 
the OTM, the five drivers for change not only need to interact with each other, but also 
drive change through the organization’s mission, culture, infrastructure and 
operations.(81)   
 The five critical elements of the model do not operate in isolation.  Rather, the 
components of transformation occur in and through the context of complex dynamic 
health care organizations.(81)  Figure 8 describes this model.  When improvement 
initiatives are aligned with the organization’s priorities and linked to the organization’s 
administration, senior managers are more likely to provide the needed infrastructure to 
encourage the transformation.  To achieve transformation, the five elements not only 
interact with each other, but also drive change through the organization’s mission, 
culture, infrastructure and operations.  While elements such as communication and 
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relational coordination are associated with aspects of successful transformation, the five 
critical elements of transformation are the most important for sustainability of 
change.(81) 
 Transformation occurs when these five factors interact with each other over time 
and drive change through the larger organization. As described in Figure 9, the 
transformation to a CDTM model to address chronic disease care management at El Rio 
was innovative for the five factors integral for a successful intervention.  Applying the 
five factors to the timeline and organizational change at El Rio will be helpful to 
understand how the changes occurred and the most important aspects of the model 
intervention.  Looking at the complementary programs and systems in place at El Rio 
will also assist the study to highlight the most important factors necessary to be in place 
for intervention success.  
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Figure 8. Organizational Transformation Model (81)
  
Source: Lukas CV, Holmes SK, Cohen AB, Restuccia J, Cramer IE, Shwartz M, et al. 
Transformational change in health care systems: an organizational model. Health Care Manage 
Rev [Internet]. 2007;32(4):309–20. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/18075440  
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Figure 9. Organizational Transformation Model, El Rio(81)
 
Adapted from: Lukas CV, Holmes SK, Cohen AB, Restuccia J, Cramer IE, Shwartz M, et al. 
Transformational change in health care systems: an organizational model. Health Care Manage 
Rev [Internet]. 2007;32(4):309–20. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/18075440  
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Lean Management 
According to Raymond Floyd, a developer of lean culture in the process 
industries, “lean manufacturing, lean management, lean enterprise, or lean production, 
often simply, ‘lean’ is a production practice that considers the expenditure of resources 
for any goal other than the creation of value for the end customer to be wasteful, and thus 
a target for elimination.”(85)  Lean works from the perspective of the customer who 
consumes a product or service.  “Value” is defined as any action or process that a 
customer would be willing to pay for in return for that service or product.(85) 
Lean enterprise emerged from post-World War II Japanese automobile industry as 
a fundamentally more efficient system than mass production.(86)  Lean thinking is the 
dynamic, knowledge-driven, and consumer-focused process through which all people in a 
defined enterprise continuously eliminate waste and create value.(86)  In healthcare, lean 
is about shortening the time between the patient entering and leaving a care facility by 
eliminating all non-value added time, motion, and steps.(87)  The value of lean is in the 
substance of improved performance that makes the lean form of operation more effective 
than traditional manufacturing practice.(85) 
The assessment of staff support services and processes can be codified and 
measured using lean thinking by creating a process map of current or future workflow.  
Individuals or groups can map a system for a current state and extrapolate how the 
system currently functions or should function by identifying process steps integral to the 
program.  The process steps are defined and placed in chronological order on the maps.  
Through this exercise, standardization of processes can be calculated or examined. By 
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decreasing variation and streamlining steps, ‘waste’ is eliminated and a process becomes 
more efficient.   
Process maps will be used in this research as a tool to develop quantifiable visual 
representations of the PBDMP.  The process maps help understand the efficiencies and 
inefficiencies in the PBDMP process.  Process steps will be identified in the lean 
brainstorming groups and compared to each other to best understand the current state of 
the PBDMP at El Rio.  
Lean Management Project Examples 
Examples of the successful implementation of lean management to improve 
efficiency in clinical settings are relevant to understanding the potential benefit of 
applying lean thinking to the case study of El Rio.(88)  Lean management and quality 
improvement techniques have been widely incorporated into multiple levels of health 
care systems to decrease variation and waste while increasing efficiency.(88)  In 2013, at 
Virginia Mason Medical Center in Seattle, Washington, a series of lean interventions 
combined with direct observations were followed by a decrease in the number of 
medication administration errors from 10.3 errors/100 doses at baseline to 2.8 errors at 
final follow-up.(89)  The study found that lean improvements coupled with direct 
observation can contribute to substantial decreases in errors in nursing medication 
administration and an increase in quality improvement.(89)   
A collaborative quality improvement project was conducted from June 2011-
January 2012 by the Veterans Health Administration to determine whether care to 
prevent postoperative respiratory failure could be improved through a Virtual 
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Breakthrough Series (a quality improvement technique).(90)  The study showed that the 
project helped teams implement process changes that led to a reduction in Intensive Care 
Unit (ICU) readmissions for respiratory failure.  This type of quality improvement model 
shows promise for knowledge sharing between multiple medical departments.(90)  The 
Pharmacy-Based Diabetes Management Program at El Rio requires multiple medical 
departments to cooperate and align well to share patient data and create a sustainable 
treatment plan.  Lessons learned from collaborative quality improvement projects can be 
applied to these patient care models at El Rio.    
In 2008, the Greater New York Hospital Association launched a program for 
ICUs to complete Plan-Do-Study-Act (PDSA) cycles to decrease central line-associated 
blood stream infections.(62)  A total of 36 hospitals participated in the quality 
improvement project for 33 months which showed a statistically significant decrease in 
infections by 58 percent during the intervention period as compared with the mean 
baseline rate. While lean management principles have been used effectively in 
manufacturing companies for decades, the lean principles can be—indeed, already are 
being—successfully applied to the delivery and provision of health care services.(91)  El 
Rio completed PDSA cycles while studying the cost-effectiveness of the Pharmacy-
Based Diabetes Management Program, however mapping the process of the program 
itself through PDSA cycles may be worthwhile for program staff. 
This research applies lean management concepts to better understand the wastes, 
efficiencies, and inefficiencies during the implementation of the Pharmacy-Based 
Diabetes Management Program at El Rio.  Using lean process maps, participants in the 
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study outlined processes before and after the El Rio CDTM intervention.  Efficiencies 
and wastes were identified from this process and then extrapolated into intervention 
guideline recommendations for clinics nationwide.  
Conceptual Frameworks and Clinical Pharmacy 
The frameworks and theories utilized in this dissertation, the PRECEDE-
PROCEED Model, Organizational Transformation model, and lean management have the 
potential to illustrate aspects of the CDTM model never previously addressed.  These 
theories and frameworks help understand the areas of CDTM which are the most 
generalizable to multiple settings looking to create a CDTM-type model.  The clinical 
and cost effectiveness of CDTM has been studied, but examining the structure and 
supports leading to a successful application of CDTM has not been addressed in current 
literature.(64)(65)    
The PRECEDE-PROCEED model will provide a roadmap to understand the 
underlying behavior changes in management practices from the leadership at El Rio.  The 
model will help analyze the social, ecological, policy and environmental rationale for 
adopting the CDTM model.  The PRECEDE section of the PRECEDE-PROCEED model 
will be specifically applied to the key informant interviews and group sessions as to how 
the CDTM model was implemented. 
The organizational transformation model will elucidate the relational dynamics of 
transforming work between departments participating in the CDTM model at El Rio.  The 
theory will provide mechanisms to articulate and quantify these clinical relationships and 
understand how the burden of work is distributed between employees for program 
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coordination.  The organizational transformation between employees is vital and will be 
extrapolated from the lean management brainstorming activity group sessions.  
 
Chapter Two Summary 
The genesis of this research stemmed from desire to examine an example of a 
pharmacist-inclusive chronic disease care management outpatient program.  To study the 
El Rio Community Health Center’s Pharmacy-Based Diabetes Management Program, the 
PRECEDE portion of the PRECEDE-PROCEED socio-ecological model, Organizational 
Transformation Model and lean management will be applied.  Through a case study 
analysis focusing on the structures and supports in place fomenting the program’s 
development, intervention guidelines, a self-assessment Outpatient Clinical Pharmacy 
Program Worksheet, and a management case study will be created.  
The increasing numbers of people seeking primary care services, coupled with a 
physician primary care shortage will require solutions that require creative ways to look 
at the health care system and potential healthcare providers.  An inter-professional team 
provides optimal performance of providers, patient outcomes and cost-effectiveness.  The 
research presented in the following chapters provides the methodology and data to 
support the utility and applicability of a pharmacist-inclusive team for chronic care 
disease management.  Since the theoretical application of behavior change models to a 
CDTM model has not been addressed in current literature, the methodology described in 
Chapter 3 details how this analysis was conducted.     
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CHAPTER THREE 
Research and Design Methods 
Introduction 
This chapter will describe the research design and methods employed in the case 
study of the El Rio Pharmacy Based Diabetes Management Program (PBDMP).  A case 
study analysis was chosen for the research in order to take advantage of the strengths of 
the case study method: to define topics broadly and not narrowly, to confer contextual 
conditions and not just the phenomenon of study, and to rely on multiple and not singular 
sources of evidence.(92)  A case study methodology is applicable for this research since 
the phenomenon under study—the PBDMP—is not readily distinguishable from its 
context.  The case identification and boundaries are defined and set in context given the 
rationale and study propositions.  The depth of case studies makes generalizability for 
other settings more difficult.  Due to this difficulty in generalizability, Chapter 5 
discusses the importance of transferability for other outpatient clinical pharmacy settings.  
 Multiple sources of information were gathered for this research including key 
informant interviews, using tools such as root cause analysis diagrams, in the form of 
fishbone diagrams and process maps, using the lean management approach of identifying 
value.  These data will inform the ecology of the clinic and community leading up to the 
program’s development and through program implementation.  Data will be analyzed 
through NVivo coding of key informant interviews, close examination of the process map 
diagrams and comparison among the root cause analyses. 
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Data Collection Summary 
Building on the findings from the literature review in Chapter 2, the data 
collection activities for this research included a series of six key informant interviews and 
three lean management group brainstorming sessions.  Three different types of data were 
collected over the course of this study: results of key informant interviews, and process 
maps and root cause diagrams developed from the brainstorming sessions.  Table 5 
outlines the method of data collection and key findings from the three data sets. 
Table 5. Method of Data Collection and Key Findings 
Method of 
Data 
Collection 
Data Collection Subjects Key Finding Link to Specific Aim or 
Research Question 
Key 
Informant 
Interviews 
Completed interviews with: 
1. Program Director, El Rio 
2. Administrator, El Rio 
3. Program Director, MHC 
4. Program Director, UNC 
5. Interviewee 1, ACO 
6. Interviewee 2, 
ACO 
• Successful CDTM 
model programs 
focused on teamwork 
as a key element to 
their program and 
model success.   
• Supports Specific Aim 1, 
helping to identify ways 
in which a CDTM model 
became 1) clinically 
effective, 2) cost-
effective, and 3) 
sustainable. 
Process 
Maps 
Completed lean 
brainstorming activity with: 
1. Administrative Group 
2. Pharmacist Group 
3. Clinical Group 
 
• Iterative and 
coordinated efforts of 
work in the PBDMP 
were identified as 
critical elements to 
success of the 
program. 
• Supports Specific Aim 2, 
translating findings from 
the study to public health 
practice products. 
• Identifying the process 
steps supporting the 
structure and function of 
the program was integral 
for practice 
recommendations. 
Root Cause 
Analyses 
Completed lean 
brainstorming activity with: 
1. Administrative Group 
2. Pharmacist Group 
3. Clinical Group 
 
• The identification of 
overlapping major 
bones from the 
different brainstorming 
groups highlighted the 
elements of the 
PBDMP that were 
critical to its success. 
• Leadership and 
• Supports Specific Aim 2, 
Sub-aim 2b; translating 
findings from the study 
to implementation 
guidelines for future 
OCPPs. 
• RCA diagrams specified 
strengths/weaknesses of 
program structure and 
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Teamwork were 
identified as key 
elements for success in 
the PBDMP, 
overlapping in the 
major bone of 
“People” in the RCA 
diagrams. 
 
support assisting in 
guideline development. 
 
Research Design and Methods 
Case Study Rationale and Overview 
Case studies are used in studies of “systems, individuals, programs, and 
events.”(93)  According to Robert Yin, the case study research method is used to answer 
questions relating to “how” and “why” a change in practice may have occurred when the 
questions being asked are “about a contemporary set of events over which the 
investigator has little or no control.”(94)  The case study approach is a detailed 
examination of a phenomenon in its real-life context during which the researcher studies 
the “embeddedness,”(95) boundaries, and interactions between the event or activity and 
its contextual setting.(96)  The method is particularly well-suited for studying phenomena 
for which “boundaries between phenomenon and context are not readily evident.”(94)  
 The El Rio Health Community Health Center was chosen for a case study since it 
was a singular program bounded in a place and time.  To prioritize and best represent the 
diversity of perspective about the CDTM model at El Rio, a case study was chosen to 
present the program’s perception within El Rio and in the larger Tucson community.  
Due to the richness of the context and abundance of individuals to speak with, the study 
could not rely on a single data collection method, but needed to use multiple sources of 
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evidence.  According to Creswell, “besides dialogue and understanding, a qualitative 
study may fill a void in existing literature, establish a new line of thinking, or assess an 
issue with and understudied group or population.”(97)  The qualitative data included in 
the case study further develops the depth of the perspectives and fully explores one 
program bounded in time. 
Qualitative Research 
According to Creswell, “the research design process in qualitative research begins 
with philosophical assumptions that the inquirers make in deciding to undertake a 
qualitative study.  In many approaches to qualitative research, the researchers use 
interpretative and theoretical frameworks to further shape the study.”(97)  Creswell goes 
on to define that good research defines these assumptions with the awareness that they 
influence the research inquiry.(97)   
The data collected for this study were best analyzed through a mixed methods 
design with a heavy reliance on qualitative research methods due to the lack of qualitative 
data on the current El Rio program.  In addition, the data collected explored multiple 
perspectives about the program’s relevance and importance.  Data were then analyzed 
through NVivo coding to identify topics and phenomena that comprised and 
characterized the practices leading to successful program implementation.  
Specifically, qualitative research methods were used to characterize the structures 
and supports behind the El Rio Pharmacy-Based Diabetes Management Program.  The 
goal of this research was to determine whether the lessons learned from the El Rio 
experience could be applied to other community health centers.  In this case study, 
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answers to closed-ended survey questions may have concealed a variety of meanings.  
For example, asking the questions of “how?” and “why?” through qualitative research 
was more effective in this research than collecting numeric responses during interview 
questions.  To understand the structure of the program, “what?” was defined and then 
data was extrapolated through key informant interviews, root cause analysis diagrams, 
and process flow maps.   
 
Case Study: El Rio Community Health Center, Tucson, Arizona 
Background: Pharmacy-Based Diabetes Management Program 
 The Pharmacy-Based Diabetes Management Program (PBDMP) stemmed from a 
three year outpatient clinical pharmacy demonstration grant from the Office of Pharmacy 
Affairs under the U.S. Health Resources and Services Administration (HRSA)’s 
Healthcare Systems Bureau at the U.S. Department of Health and Human Services.  The 
demonstration grant from HRSA identified Federally Qualified Health Centers to run an 
outpatient clinical pharmacy program within their clinic addressing disease state 
management for one chronic disease.  El Rio was one of 17 grant recipients, and they 
began to develop a disease state management program for diabetes.  
 After three years, the program revealed progress when all clinical parameters 
monitored showed statistically significant improvements for diabetic patients enrolled in 
the pharmacist-based program as compared to a control group.(98)  There was a decrease 
in negative drug interactions, lower A1C levels, more stable A1C levels for hard to 
manage patients.  The initial demonstration project was a documented and validated 
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success in part due to the providers and patients alike recognizing the program’s potential 
power and embracing it early on into the program.  At the conclusion of the grant, El Rio 
created a formalized and clinic-wide PBDMP.(99)  
 Under the direction of Tony Felix, the El Rio Pharmacy Director, the PBDMP at 
El Rio officially began in August, 2004.  The program developed slowly working to 
augment care provided by physicians.  The program expanded over the following six 
years and the clinical roles of the pharmacists were defined over time.   
Legislative Processes 
 In January of 2011, the initial law “SB 1298 Pharmacists; Drug Therapy 
Protocols” was introduced to the Arizona state senate.(100)  The state bill described the 
State Board of Pharmacy’s clinical practice purview for Doctors of Pharmacy.  The bill 
defined the circumstances when a pharmacist could be “implementing, monitoring, and 
modifying drug therapy and use; conditions; definitions” in the state of Arizona.(100)  
From January to April, the bill was modified and the pharmacist community of Arizona 
worked to better define pharmacist’s role in Arizona state law.  On April 13, 2011, the 
bill was made into law defining pharmacists expanded roles in clinical patient care.  
Further legislation followed, including Arizona Revised Statute 32-1970 allowing 
qualified pharmacists in specified health care settings (such as a community health 
center) to implement, monitor, and modify drug therapy as described by written protocols 
in collaboration with physicians.(101) 
 Through these legislative processes and community advocacy, the practice model 
of Collaborative Drug Therapy Management (CDTM) was approved for use in Arizona.  
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The CDTM model, aspects of which were already in place at the El Rio Health Center in 
Tucson, Arizona, was quickly embraced.  Originally funded as a Clinical Pharmacy 
Demonstration Project by the Office of Pharmacy Affairs under the U.S. Health 
Resources and Services Administration’s Healthcare Systems Bureau, the El Rio Clinical 
Pharmacy Demonstration Project’s main objective was to provide comprehensive 
pharmacy services to the medically underserved in Tucson, Arizona.(76) 
 The program included increasing access to affordable pharmaceuticals, promoting 
efficient management of these services, and focusing on improved patient outcomes.  
Specifically, the clinical pharmacists at El Rio and the medical and administrative team 
determined that a diabetes-focused disease state management clinic would serve the 
needs of its members.(65)  The project initially hired one clinical pharmacist to begin the 
outpatient pharmacy program.  The initial demonstration project was a documented and 
validated success in part due to the providers and patients alike recognizing the 
program’s potential power and embraced it early on into the program.(9)  After three 
years, the program revealed progress when all clinical parameters monitored showed 
statistically significant improvements for diabetic patients enrolled in the pharmacist-
based program as compared to a control group of diabetic patients not enrolled in the 
program.(65)(101) 
This single instrumental descriptive case study describes the implementation of 
the CDTM model at El Rio within the pre-existing PBDMP in the context of the Arizona 
Revised Statute 32-1970.  Since Arizona is one of the oldest CDTM models in the U.S., 
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the implementation of the El Rio program was selected as the study case for learning 
about the processes of CDTM model implementation and development. 
 
Case Study Questions and Propositions 
The study questions, presented in Section 4, include questions about “how” the 
CDTM model was developed and implemented, and “why” clinical activities and actions 
occurred or did not occur during policy implementation.  Key informants recalled the 
program from memory and contemporaneous documents from this period were also 
reviewed.  Issues and topics that were studied include the set of activities used to put the 
CDTM model into practice.  Actions taken to implement and enforce specific aspects of 
the model on an individual patient basis and steps used to maintain changes made were 
addressed in the case study.  Individuals and organizations involved in developing and 
completing these activities, barriers to action and the context of the El Rio experience 
were also studied.  The study also looked to related policies and practices, larger public 
health frameworks, and trends in state clinical pharmacy initiatives in Arizona and 
throughout the U.S. to inform the larger context of the case study. 
Case study propositions identify the factors, issues, and elements that were 
examined, displaying the underlying theory or theories guiding the inquiry.  These 
theories provided direction in identifying evidence pertinent to the case.(94)  The 
questions that guided the case study propositions and purpose are described below in 
Table 6.   
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Table 6. Case Study Proposition Questions 
The case study was designed to examine the following questions:  
• Who were the organizations or individuals that took responsibility for the 
CDTM model adherence and compliance during the demonstration phase of 
the project? 
• What implementation mechanisms were in place? 
• What cost and economic implications of model adherence and compliance 
were potentially minimized or otherwise addressed? 
• Was the CDTM model sustainable and have (long-term) relevance to 
stakeholders? 
 
Next, the case study considered why simple implementation of the CDTM model 
was insufficient for statewide comprehensive implementation and adoption.  It identified 
how contextual factors, most notably other hospitals and clinical policies, had a strong 
influence on the amount of adoption and implementation of CDTM practices.  It studied 
characteristics of these policies and practices, such as setting, scope, timing, responsible 
parties, sustainability, and relevance that could have had an impact on program 
effectiveness.  It highlighted situations where CDTM model compliance occurred despite 
limited knowledge of the practice’s success in southern Arizona.  Last, the study 
identified how multilevel influences and relationships affected the actions taken or not 
taken by organizations and individuals involved in or responsible for the CDTM model 
compliance and adoption. 
 
Case Description 
Case Identification 
The sampling for the entire case study used the critical case approach, defined by 
Michael Patton as the selection of a small number of important cases that are anticipated 
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to “yield the most information and have the greatest impact on the development of 
knowledge.”(102)  As noted, El Rio runs the oldest and only disease-specific CDTM 
model in southern Arizona and one of only a handful of programs in the United States 
with the same program definitions.  Studying the El Rio experience thus represents an 
opportunity to obtain detailed information about the processes of developing, 
implementing and adopting an innovative model for a specific sub-section of the 
population.  Study findings hold promise for informing recommendations for policy 
development and implementation guidelines, in Arizona and elsewhere. 
Case Boundaries 
Pursuant to case study methodology, the case was be bounded by two dates: 
August 2001, when the original El Rio demonstration project was implemented; and 
August 2014, over thirteen years after the CDTM model first went into effect in El Rio.  
Documentation of the planning and development in the weeks or months leading up to 
the August 2001 implementation of the CDTM model at El Rio will also be analyzed.(94) 
Identification of Key Informants 
A stakeholder analysis is an approach, a tool or set of tools that generates 
information about a group of actors to help understand their behavior, intentions, and 
interrelation.(103)  For this research, a stakeholder analysis was conducted to map the 
positions of the actors in relation to El Rio’s implementation and current Pharmacy-
Based Diabetes Management Program.  The stakeholders identified had an active 
influence on the decision-making and implementation process of the program.(103)  
While the stakeholder analysis was not used to draw conclusions, it solidified the list of 
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key informant interviewees and participants for the lean management group sessions for 
the data collection. 
The methods followed for the stakeholder analysis were in line with 
recommendations from stakeholder analysis resources and documents.(103)(104)(105)  
Individuals and organizations were recommended as stakeholders during initial data 
collection stages of the research.  Stakeholders were identified though informal 
conversations with community and El Rio leaders. Potential stakeholders were also 
identified by using a controlled vocabulary search of research and grey literature 
databases (PubMed, Web of Science, LexisNexis, Google Scholar), search engines 
(Google), and individual websites (state websites, organizational websites). 
From the brainstormed list of potential stakeholders, a chart was created for each 
stakeholder.  The stakeholder’s name was placed at the top of each sheet and two 
separated columns were drawn.  One column listed the stakeholder’s expectations of the 
organization, and the second column described how the stakeholder perceived the overall 
health of the organization.  The researcher wrote down thoughts about the potential 
stakeholders and compared the columns.  The responses were identified through color 
coding as they corresponded to the questions: good (green), fair (yellow) or poor (red).  
The data was color coded and the longer-term issues with each individual stakeholder and 
with stakeholders as a group were created in a separate column.(105)   
The scope of the stakeholders chosen for the research was helpful for the 
stakeholder analysis since the analysis was directed specifically at the current El Rio 
program.  The analysis showed that not all of the stakeholders knew about the Pharmacy-
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Based Diabetes Management Program, but had different insights about CDTM, the 
Tucson diabetes advocacy community, and El Rio.  The stakeholders were chosen to 
bring different perspectives to the study.  This research and in-depth analysis sought to 
add value through obtaining and analyzing stakeholders’ current perceptions of the 
“historical processes which have led to the present.”(103) The stakeholder analysis was a 
critical tool in identifying interested parties that should be incorporated into the decision-
making process, in addition to understanding the basis for their inclusion.(104)  Other 
informal interviews with staff members of the PBDMP at El Rio were conducted to 
further inform the research.  These interviews are cited throughout the research to support 
and augment a priori themes from the key informant interviews. 
 
Working Definitions 
Implementation 
For this research, implementation describes the set of activities involved in 
applying a collaborative care model within the confines of a clinical practice.  These 
activities include, but are not limited to:  
1.1. dissemination of clinical regulations or policies; 
1.2. development of formal practices and procedures to put the CDTM policies 
into operation;  
1.3. allocation of funds and resources for implementation; and  
1.4. state or county enforcement of the regulation. 
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Collaborative Drug Therapy Management (CDTM) 
CDTM is a “team approach to healthcare delivery that seeks to maximize the 
expertise of the pharmacist and the physician in order to achieve optimal outcomes 
through appropriate medication use and enhanced patient-care services.”(5) CDTM is 
most commonly provided under mutually agreed upon practice protocols and guidelines 
for health care teams.  Health care programs administered by U.S. Public Health Services 
(such as the Indian Health Services and the Veterans Health Administration), as well as 
independent practice settings in over 40 states across the U.S., now support pharmacist 
participation in CDTM.(65)  Most of these 40 states require drug-or disease-specific 
collaborative practice agreements or drug therapy management plans approved by 
physicians participating in and supervising programs. (65)  The majority of these 40 
states that allow pharmacist-inclusive Collaborative Practice Agreements utilize the 
CDTM model for medication therapy in tem-based care.(59)  The CDTM Model at the El 
Rio Health Center limits the pharmacists’ clinical activities to those found in the 
physician approved guidelines.  CDTM activities include, but are not limited to, the 
following pharmacist activities: 
•  “Initiating, modifying, and monitoring a patient’s drug therapy 
• Ordering a performing laboratory and related tests 
• Assessing patient response to therapy 
• Counseling and educating patients about their medications 
• Administering medications”(2) 
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Key Informant Interviews 
The first key informant interview was conducted on July 29, 2014 and the last 
interview was completed on November 3, 2014.  The data collected from the 
brainstorming activities at El Rio spanned from August 4, 2014 through August 6, 2014.  
A sample of key informants were identified using emergent or snowball sampling with 
knowledge of aspects relevant to the case.(106)  Key informants were identified at the 
state, local, and clinical levels.  All of the interviews were conducted in-person or by 
telephone to gather information about respondent experiences during the development, 
implementation, and adoption of the CDTM model at El Rio. The interviews included 
closed- and open-ended questions about the implementation of the model with no 
personal identifiers or questions of opinion.  All questions were tailored to only ask 
factual and objective questions about the process behind the implementation of the 
CDTM model (e.g. based on clinical 30-day re-admission data, patient feedback, and 
satisfaction surveys, what were the successes and failures of the program within the first 
few years of implementation?)  Introductory questions were identical between each 
interview, but questions were also tailored to the interviewee and focused on their area of 
expertise or employment.  See Appendix A for the full interview guide.  
Interview topics included the following:  
• contextual conditions and factors relevant to a clinic’s ability to make changes 
to comply with the model (implementation climate and resources),  
• communication about the model and about strategies for compliance,  
• El Rio implementation activities,  
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• potential programmatic supports for implementation and monitoring of the 
model.  
Contextual conditions and factors of interest included the following:  
• other state, county policies and practices relevant to the CDTM model in the 
community;  
• organizational characteristics and priorities; and   
• resources available for clinic’s use in implementing changes to comply with 
the model, such as staff, technical assistance, or funding.  
 All of the key informant interviews were recorded and responses were transcribed 
into QSR NVivo Software.  The key informant interviews were conducted with the 
following six individuals/organizational representatives described in Table 7: 
Table 7.   Key Informant Interviewees 
Name Degree Position Title Location Interview 
Method 
Interview Relevance 
Program 
Director 
PharmD, 
MPH, 
FAPhA, 
CDE  
Clinical Director, 
Pharmacy-Based 
Diabetes 
Management 
Program 
(PBDMP), El Rio 
Community 
Health Center 
Tucson, 
AZ 
In-Person El Rio Health Center currently 
runs the Pharmacy-Based 
Diabetes Clinic—a CDTM model 
program for patients with T2DM. 
Questions focused on how the 
clinic was created, current patient 
volume, future plans, how other 
clinics can make a clinical 
pharmacy program.(98) 
Admini-
strator 
RN, PhD Officer, El Rio 
Community 
Health Center 
Tucson, 
AZ 
In-Person Questions about the clinic’s 
priorities and perspective about 
the Pharmacy-Based Diabetes 
Management Program were 
addressed.(99) 
Program 
Director 
PharmD, 
RPh 
Clinical Director, 
Marana Health 
Center, (MHC) 
Marana, 
AZ 
In-Person Tucson-based community 
network of health clinics in 
southern Arizona.  Marana Health 
Center recently created a CDTM 
model.  Questions focused on 
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their approaches to an outpatient 
clinical pharmacy program, what 
they have done to create the 
program, what they are looking to 
do, barriers/successes they faced 
in the process, and their future 
plans.(107) 
Program 
Director 
Pharm.D., 
CDE, 
CPP, 
BCACP, 
FASHP 
Clinical Director, 
University of 
North Carolina, 
(UNC) Internal 
Medicine 
Enhanced Care 
Program 
Chapel 
Hill, NC 
By Tele-
phone 
Questions about the UNC 
Program and potential similarities 
and differences with El Rio were 
explored.  Specifics about the 
development and implementation 
of the UNC program were also 
described.(108) 
Inter-
viewee 
1 
BS, 
Account-
ing 
Accountable Care 
Organization 
(ACO) of Tucson, 
Arizona 
Tucson, 
AZ 
In-Person Oversight of the Accountable 
Care organization of Tucson, 
Arizona.  Questions focused on 
the ACO, how it was formed, the 
impact (if any) of CDTM models 
and other collaborative practice 
agreements on the ACO, and how 
ACA will impact community 
health, and future plans.(109)  
Inter-
viewee 
2 
MD Accountable Care 
Organization 
(ACO) of Tucson, 
Arizona 
Tucson, 
AZ 
In-Person Questions about total costs of 
diabetes care management and 
community-wide chronic care 
disease management were 
discussed.(110) 
 
Lean Management Brainstorming Activities 
Structure 
A series of three group meetings of El Rio employees occurred the week of 
August 4-7, 2014.  Individuals were recruited to the three group sessions through e-mail 
inviting them to participate in the group brainstorming session to discuss the Pharmacy-
Based Diabetes Management Program (PBDMP).  The study participants were identified 
based on their role in managing the program (Administrative Group), working with or 
referring patients to the program (Clinical Group) or employed by the program itself 
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(Pharmacist Group).  Names and e-mails were furnished by members of the PBDMP staff 
from El Rio internal list-serves. 
 All meetings were voluntary and occurred within a two-hour time frame.  The 
Pharmacist and Clinical Group sessions took place at El Rio in a conference room near 
the PBDMP’s main offices.  The Administrative Group session took place in a 
conference room at the main El Rio administrative office building.  All groups were read 
the IRB Research Consent Form before participating in the research and a verbal 
approval was recorded from each participant.  The activity was twofold for all groups: 1) 
the group diagramed a process flow of how the CDTM model currently works at El Rio, 
and 2) as a group, the participants created two root cause analysis fishbone diagrams 
(Ishikawa Diagram) describing the main ‘bones’ that consisted of successes and barriers 
to the Pharmacy-Based Diabetes Management Program (PBDMP).  The RCA diagrams 
were conducted to understand the depth of reason leading to a success or barrier of the 
PBDMP.  The fishbone diagrams are presented in Appendix D. 
 Each session started with an introduction of the goals of the meeting, the study 
research and goals, and introductions from each participant.  After introductions, and to 
emphasize the importance of process, a quote from W. Edwards Deming was read, “If 
you can’t describe what you are doing as a process, you don’t know what you’re 
doing.”(85) The concepts of a process and a process flow chats were described using an 
example process flow chart on how to diagram a complete cycle of laundry.  The 
diagramming tools were posted on the wall of the conference room and printed in 
handouts for each participant.  As the RCA diagrams were created I probed any vague 
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response with “5 Why’s,” asking the study participant “why” five times to best define the 
actual variable they were identifying.  Asking “why” for responses that are not yet fully 
formed is helpful for the participant to specifically define the attributes of their comment 
before adding it to the diagram.  Each session completed one process flow chart together 
except for the Pharmacist Group—where three process maps were created—due to the 
large size of the group.  See Appendix C for the complete set of group process flow 
maps. 
Study Groups 
The three groups consisted of the following individuals: 
a) Clinic Administrators: El Rio’s Chief Operating Officer, Chief 
Clinical Officer, and the Executive Director of the El Rio Health 
Center Foundation. 
b) Clinical Group: One Nutritionist, One Nurse Care Coordinator and 
Associate Health Manager, Two MDs—one Family Medicine 
practitioner and the Family Medicine Medical Director. 
c) Pharmacy Group: Five Medical Assistants (MAs) for the PBDMP and 
six PharmDs—including the Pharmacy Director and Clinical 
Pharmacy Coordinator. 
Process Maps 
To begin the process mapping portion of the brainstorming sessions, each study 
participant was given a blank piece of white paper to map their personal perception of the 
current process flow of the PHBMP.  After 10-15 minutes, group members were 
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encouraged to interact with their neighbors and compare and contrast their individual 
maps.  After the individual mapping and initial discussion was complete, the group-wide 
process map was created.   
 To create the group map, one volunteer from the group came to the front of the 
conference room and scribed onto poster paper as the group discussed the flow of the 
PBDMP.  Each group presented their findings independently of the other groups and no 
information was shared between the study groups.  The volunteer added to the discussion 
and diagram along with the rest of the group, but only one individual wrote on the poster 
paper. If issues or confusion in the diagram occurred; the map was amended to fit the 
revision.  The group physically re-created each process, decision point, start, and end of 
the process cycle of the CDTM model.  These diagrams served as a visual representation 
of the current status of the program.  After the group finished the process map, a different 
volunteer from the group—who did not scribe the process—stood in front of the group 
process map and verbally described the diagram to help understand the efficiencies and 
inefficiencies within the program.  The rationale for having two separate volunteers to 
diagram and then describe the process aims to assure that the whole group understood 
what was interpreted and scribed by the volunteer drawing the diagram. While this 
measure does not ensure that all members of the group agree with each process described, 
it is one step that can be taken toward data validity.  In all of the groups except the 
Administrative Group, the diagram was hand drawn on the poster paper.  In the 
Administrative Group Post-its were used to define each process step and then each step 
was place in chronological order.  After the second volunteer described the process and 
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worked through each step of the process map, there was a short break for study 
participants. 
 The first group meeting included the El Rio clinic administrators.  The group 
included El Rio’s Chief Operating Officer, Chief Clinical Officer, and the Executive 
Director of the El Rio Health Center Foundation.  The Administrative group was the 
smallest of the brainstorming sessions.  In the Administrative Group, participants wrote 
each step of the process map on Post-its and then placed the Post-its onto the poster 
board.  While there was still one diagram scribe connecting the Post-its, this step was 
slightly different for the Administrative Group.  This minor inconsistency in process most 
likely did not impact the process map or data gathering since the group size was much 
smaller than the other study groups.  The fluidity between the Post-its and diagram 
drawing in other groups were almost identical.   
 In the Pharmacist Group, a total of 12 pharmacists, medical assistants, and 
pharmacy technicians participated in the group mapping session.  In an effort to represent 
the medical assistant (MA)’s and pharmacy technicians’ opinions along with the 
PharmD’s, the larger group was split into three smaller groups.  The Pharmacist Group 
was split equally—by degree type and number—into three smaller groups for the process 
mapping exercise so all group members could participate and provide input.  Each group 
consisted of at least one pharmacist, medical assistant, and pharmacy technician.  The 
decision to split the Pharmacist Group into three separate groups for the process mapping 
exercise was recommended by the group itself due to the different personalities and 
power dynamic between the MA’s and the PharmDs.  All of the MAs present during the 
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data collection, directly reported to the PharmDs in the room.  While the methodology 
was the same for the Pharmacist Group as the other study groups, three smaller groups 
within the Pharmacist Group created process flow maps for a total of three maps—each 
of the three groups created one process map.  At the end of the brainstorming session, the 
group re-convened and discussed the similarities and differences between each of the 
smaller group’s maps. 
 The last group session was the Clinical Group, which was composed of four 
clinicians who all either referred patient into the program or worked directly in the 
PBDMP.  There were two Family Medicine physicians, a Nutritionist and Registered 
Nurse who participated in the brainstorming sessions.  The methodology followed for the 
clinical group was identical to the Pharmacist Group, however the group worked to create 
one process map together due to the manageable group size. 
 
Root Cause Analysis Diagrams Using Fishbone Diagrams 
 After the break, about 20 Post-its were passed out to each study participant.  A 
root cause analysis (RCA) diagram in the form of a fishbone diagram describing the 
success and barriers to completing a cycle of laundry posted on the wall was used as an 
example for each group.  The RCA diagrams were conducted to understand the depth of 
the reasons for the efficiencies and inefficiencies within the program.  After the 
discussion about why RCA diagrams matter and how to create them, a list of the 4P’s 
(People, Products, Process, and Performance) and 5M’s (Manpower, Machines, 
Methodologies, Measurements, and Materials) of lean management were posted on the 
wall and given to each study participant as a hand out.  The study participants were then 
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given 10 minutes to brainstorm which P’s and M’s most closely described the barriers 
and successes of the PBDMP at El Rio.   
 Due to the small size of the group, the Administrative Group session held a 
discussion as to which P’s and M’s were most appropriate to be the ‘bones’ of the RCA 
diagrams.  From the discussion, the bones of the RCA were defined and drawn onto the 
poster board.  In both the Pharmacist and Clinical Group, all of the P’s and M’s were 
written out on separate sheets of paper and placed around the room.  Individually, 
participants anonymously described their perceived barriers and successes of the PBDMP 
and wrote them onto Post-it notes.  The participants then placed the specific Post-it note 
under the specific M or P that best described the barrier or success they identified on the 
Post-it.  Study participants silently wrote and posted each of their Post-it notes for about 
10-15 minutes under the appropriate M or P around the room.  When a participant felt 
that they had completed the task, they sat back in their seat and waited for the rest of the 
group to complete the assignment.  
 After the exercise, participants discussed the experience in a group format.  One 
participant volunteered to read all of the barrier Post-it notes and another volunteer read 
all of the success Post-it notes.  After an initial discussion, the number of Post-it notes 
under a specific M or P barrier or success became the primary bones in the RCA diagram.  
As the bones of the diagram were identified, the group modified their elections to most 
accurately define the topic (e.g. Manpower may be re-envisioned as Clinicians).  As a 
group, the fishbone RCA diagrams were created from the M’s and P’s previously 
identified with the most amounts of Post-its and then the minor bones were identified 
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from the main M or P.  For example, the major bone, ‘Price’ was identified as a barrier 
due to the high number of Post-its under the Price sheet of paper.  Under Price there were 
multiple Post-its that became the minor bones—lack of provider status for pharmacists, 
no insurance, etc.   
 As a group, the major and minor bones of the RCA were defined and drawn onto 
the respective poster boards—successes of the program and barriers to the program.  
Minor bones were read and transcribed onto the diagram, and minor bones that were not 
previously identified under the M’s or P’s around the room during the exercise were 
added to the final diagram as well.  Some of the minor bone Post-its were re-envisioned 
or further described to fit within the constraints of the major bones selected.  At the end 
of each session, after a complete process map and RCA diagram were created, an 
informal conversation ensued to identify aspects of the data collection methods that were 
successful or challenging to understand.  Study participants discussed how the exercise 
made them feel about the PBDMP, the program’s successes and failures, and their role in 
the program.  A central aspect of the debriefing conversation after the mapping exercise 
was how the current system evolved from what was originally planned—given the 
importance of flexibility in sustaining a process during implementation. 
During both the process mapping and the RCA analysis, the primary researcher 
took photos, video and notes describing the process and methods of the research.  During 
the discussion, the primary researcher also noted key quotes and side bar conversations to 
follow-up on and mention during my analysis.  After each of the sessions, the primary 
researcher took ten minutes to write down her thoughts and reflected on the group 
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dynamic, conversation and outputs. The interview data collected from each of the group 
sessions ended in six RCA success and barrier diagrams and five process maps as the 
physical representations of the data collected.  
 
Analysis 
The analytic strategy for Specific Aim 1, to identify the ways in which the CDTM 
model became and remains a clinically and cost-effective model at the El Rio Health 
Center, used a theoretically and empirically driven approach. Specifically, propositions 
(Table 8) were used to guide the data collection and analysis. Analyses focused on using 
data to prove or disprove the study propositions and to generate alternative explanations 
as needed.  The study propositions in Table 8 were based on the literature review, 
preliminary informal interviews, and personal experience. 
Table 8. Study Propositions 
1. While El Rio did not base the CDTM program on the PRECEDE-PROCEED or 
organizational transformation theoretical frameworks, implementation and adoption of 
the CDTM model was effective when characteristics of these theories were present 
during their decision making management processes.  Specifically, the PRECEDE 
segment of the model served as the foundation for organizational change. 
2. While necessary for pharmacists to practice collaboratively with other health care 
providers, passage of a supportive state policy was insufficient for comprehensive 
implementation and adoption of the model for El Rio outpatient clinics. 
3. Contextual factors, CDTM programs, and state support for a community-based chronic 
disease care management program, most likely a strong influence on the decision to 
implement a CDTM model at El Rio. 
4. Simple passage of the CDTM model within El Rio was insufficient for comprehensive 
implementation and adoption of the program.  Knowledge of the CPA agreements and 
potential benefits from the model increased employee willingness to embrace the 
program. 
5. Multilevel influences from the Tucson ACO, the El Rio Finance and Operations 
Department, and other community relationships affected the actions taken (or not 
taken) by organizations and individuals involved in or responsible for CDTM 
implementation or adoption. 
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Specific Aims: Context for the El Rio Case Study 
Case studies use multiple forms of evidence to provide a detailed and in-depth 
summary of case events, triangulate data, and develop themes.(94)  Data used in this case 
study to provide case facts and context include key informant interviews and the lean 
management brainstorming activities. Based on the qualitative inquiry and research 
design methods outlined by Creswell, “evidence from prior implementation research and 
case study literature will inform data collection.”(97)  As described below, data collection 
followed an iterative process, where search terms and strategies and data collection 
procedures were adapted throughout the study to best address the study aims.(82)  Three 
main sources of data were collected for the research: key informant interviews, process 
maps, and root cause analysis (RCA) diagrams in the form of a fishbone diagram from 
three groups affiliated with the PBDMP.   
Specific Aim 1:  To identify the ways in which the CDTM model became a: 1) 
clinically effective, 2) cost-effective, and 3) sustainable model at the El Rio 
Community Health Center. 
Case Facts 
In a case study, the primary analysis is, as Creswell describes, the development of 
a “detailed description of the case and its setting.”(97) To identify the ways in which the 
CDTM model was implemented and adopted between August 2001 and August 2013, the 
analysis began with the development of a draft of what Ellinger et al. refer to as a 
“descriptive account of important components of the case” including case facts and 
context. (93)  In the account, the following was documented:  
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• administrator, organizational, and clinical experiences, actions, and methods 
used implementing and enforcing the CDTM model at El Rio; 
• state and community-level parties involved in adoption and implementation; 
and 
• the context for implementation and adoption activities. 
 
Sub-Aim 1a: Identify key aspects of the clinical management processes through 
lean management brainstorming exercises and key informant interviews that 
served as structure and support for the CDTM model at El Rio.   
 
The key informant interviews were transcribed and coded using software to 
identify the key themes serving as structures and supports for the CDTM model at El Rio.  
The lean management brainstorming activities and products created from these activities 
were examined to define the process of the PBDMP at El Rio.  Together these data offer 
a picture of the implementation and sustainability of the PBDMP at El Rio for analysis.   
 
Pattern, Trend, and Theme Identification 
In addition to a careful documentation of the facts, data analysis in case study 
research includes linking case information and elements to the study propositions or 
purposes. The overall analytic goal is to identify the linkage that best connects 
information from the case to a theoretical, chronological, or logical construct; and to 
reject alternative explanations.(94)  
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Leverage Points, Strategic Decisions, and Communication Techniques 
The published reports documenting El Rio’s experience developing and 
implementing the CDTM model were compared to the information from the key 
informant interviews, lean management brainstorming activity, and observational data.  
The information collected from the lean management activity and key informant 
interviews also informed the process information on how the CDTM model works in the 
clinic.  As part of the analysis, individuals and groups who could have been involved in 
implementation and adoption will be identified and reasons for their lack of participation 
were documented. The factors that influenced the initiation, trajectory, and success of 
implementation and adoption processes and actions were also documented. Such factors 
may include the following:  
• demographic and other characteristics of El Rio;  
• knowledge of benefits from a collaborative practice model for outpatient 
clinical pharmacy such as CDTM;  
• costs and savings associated with changes;  
• availability of resources to complete implementation tasks; such resources 
may include staffing, funding, partnerships, or information on collaborative 
practice alternatives; and  
• acceptability of the model.  
Broadly, these actions, actors, and factors comprise the leverage points, strategic 
decisions, and implementation techniques that affected the success of the CDTM model’s 
implementation and adoption.  The theoretical constructs of the PRECEDE section of the 
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PRECEDE-PROCEED framework provided an understanding of case events and the 
actions taken or not taken by El Rio when implementing the CDTM model. Specifically, 
findings were compared from the descriptive accounts in the key informant interviews 
and lean management activities with the key aspects of the CPAs and dimensions of the 
CDTM and medication management framework. 
Sub-Aim 1b: Apply the PRECEDE portion of the PRECEDE-PROCEED model 
and organizational transformation model to an analysis of the El Rio CDTM 
model implementation in order to identify the supportive structures enabling the 
creation of the El Rio Pharmacy-Based Diabetes Management Program.  
As noted, the key elements of the case context are other federal and state policies and 
practices that were in place in Arizona during the study period.  These elements 
influenced or could have influenced the extent and content of the El Rio CDTM model 
and the promotion of clinical pharmacy programs.  Information about the case context is 
summarized in a descriptive chronology of events as well as using other groupings, such 
as themes or characteristics using the PRECEDE section of the PRECEDE-PORCEED 
model.  An example of a grouping and theme is: 1) Grouping—the CPAs in place 
throughout El Rio as part of the CDTM model implementation and, 2) Theme—how 
these agreements increase or decrease organizational transformation. 
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PRECEDE-PROCEED and  
Organizational Transformation Models in a CDTM Context  
The data from the El Rio model and other CDTM models were applied to the 
theoretical constructs and frameworks of the PRECEDE-PROCEED and organizational 
transformation models.  Using the PRECEDE section of the framework, a roadmap was 
created showing the sequence of El Rio’s intervention.  Identifying the aspects of 
successful implementation and failed implementation were also analyzed and studied. 
Summary Themes and Case Contextualization  
The findings were summarized by documenting patterns, identifying trends, and 
characterizing themes of the topics and phenomena that comprise and characterize the 
implementation and adoption experience of CDTM at El Rio. The relationships between 
groups of events and processes, patterns, trends, and/or themes were examined and 
summarized. This analysis includes an assessment of relationships between case events 
and themes and other contextual factors, such as the following: 
• the history of CDTM;  
• the public health policy setting in Arizona, specifically policies related to 
outpatient clinical pharmacy;  
• collaborative practice agreements in Arizona and elsewhere; and  
• local and national trends in CDTM models. 
Summary findings include a description of needs for complete implementation 
and adoption of CDTM in the context of other related policies and practices. Needs may 
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include programmatic supports to help accomplish changes, information and/or 
awareness-building, and staffing and resources, among others.   
 
Data Analysis 
Iterative Cycle Approach 
 Analyses are drawn from all available data sources, including research and 
program literature, documents, interviews, and observations. The technique outlined by 
Ellinger et al. was used to identify pattern, trend, and theme identification.  The “iterative 
cycles” of data collection and analysis described by Ellinger trim down the information to 
include facts and concepts that a) match or comprise the case story and b) relate to 
underlying theories that clarify or predict the associations between case components 
(phenomena).(93)  The data and analysis evolved over time as data were analyzed and 
added and theories are confirmed or rejected. Specific analytic approaches used in these 
iterative cycles will include one or more of the following, selected based on availability 
of data and appropriateness to the analytic question of interest:  
1. Pattern identification and matching, where the data was reviewed for a 
predicted pattern or patterns and for relationships between two or more 
categories of themes, issues, or meanings.(94,95)  Patterns of interest will be 
drawn from the study propositions and initial analyses.(93) 
2. Categorical aggregation, where a subset of the data was reviewed to identify 
possible themes, issues, or meanings related to the research questions and 
study propositions.(95)  
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3. Direct interpretation, where a single instance from the data was reviewed to 
identify possible themes, issues, or meanings related to the research questions 
and study propositions.(95)  
4. Time-series analysis, where data points were organized chronologically and 
compared with a time-based theoretical explanation/study proposition.(94)  
5. Logic models, where data are identified to support or rebut cause-effect 
patterns between specific events, actions, or decisions and implementation and 
adoption outcomes. Relevant events and actions include activities to put the 
CDTM model into operation and to ensure ongoing and consistent compliance 
with the core components of the model.(94)  
 Each iterative cycle included a review and incorporation of contextual and 
background information, to ensure the case study is as detailed and thorough as possible. 
Patterns and themes were identified by using qualitative content analysis.(94)  This 
approach is a “data reduction and sense-making effort that takes a volume of qualitative 
material and attempts to identify core consistencies and meanings.”(106) 
 
Interview Data Coding and Theme Identification 
Data Coding 
 Codes used in qualitative research are described as, “most often a word of short 
phrase that symbolically assigns a summative, salient, essence-capturing, and/or 
evocative attribute for a portion of language-based or visual data.”(111)  For this 
research, pre-specified codes using theoretical frameworks and a literature review were 
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identified, defined, and listed in a code book.(112)  The pre-specified (a priori) codes 
were identified from the research questions, study propositions, and theoretical constructs 
assigned before data analysis began.(112)  New codes were created during the coding 
process using open coding.(97)  All of the code definitions were listed in a code book and 
refined over the course of the data analysis.  
The a priori codes directly address focus areas for all of the key informant 
interviews.  These focus areas were defined as: program successes and failures, 
processes, and teamwork.  A priori code categories were created to characterize program 
supports and structures that lead to program impediments or successes. The process of 
identifying the codes was iterative with feedback from the dissertation committee.  The 
code book was created and approved before text coding began.  The coding categories 
added during the coding process related to program sustainability and maintenance.  
Secondary themes that became a coded category during the interview analysis were 
assertions and generalizations made by key informants during the interviews.  These 
coding categories served as a conceptual coding practice when individuals spoke at 
length regarding a specific topic or concept.(97)  See Appendix B for a complete 
description of each code.  
Theme Identification  
 The content of textual data from the interview transcripts were analyzed manually 
through the qualitative data analysis software package NVivo 10 by QSR International.  I 
used the software to code and analyze recurrent themes from each of the key informant 
interviews.  NVivo allows the user to organize data into containers called “nodes.”  A 
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user may catalogue notes into a hierarchy with main categories—“Tree Nodes”—
identifying the key themes of the interviews.  The tree nodes are organized from the more 
general “Parent Nodes” groupings to the more specific “Child Nodes.”   
 First, I listened to the audio recordings from each key informant interview.  I then 
transcribed each of the six interviews by transferring the interview from an Olympus 
recording device onto my computer.  I listened to the interviews and transcribed them 
into my computer.  Each interview was transcribed once and re-visited twice for editing.  
After the interview transcriptions were complete, they were then uploaded into the QSR 
NVivo software for analysis.   
 For each key informant interview, major topic categories—Parent Nodes—and 
subcategories—Child Nodes—were created for analysis.  These topic categories were 
created after each key informant interview was transcribed and before coding 
commenced on the transcripts.  Tools within the NVivo software were then applied to 
code the texts further into organized nodes and transcription response attributes.  The 
attributes were defined by the nodes and main themes were generated from the nodes for 
the attribution table.  Collective responses to the same question presented evident patterns 
or trends, which translated well into the predefined nodes.  
 If one Parent node included a grouping of similar comments or theme, a 
subsequent Child node was created to better identify the classification within the Parent 
node.  For example, the Parent node “Pharmacists” initially included only the Child node 
“scope of practice.” As the coding progressed, the primary researcher noticed that 
comments regarding pharmacist provider status were commonly coupled with a 
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conversation about pharmacists’ scope of practice.  In response, a separate Child node of 
“provider status” was created and the comments were re-coded accordingly under one or 
both of the Child nodes: “scope of practice” and “provider status.”    
NVivo Analysis  
 The quantitative multivariate tables and graphs created from the NVivo software 
were applied to each key informant interview and between interviews.  Word frequency 
queries and text searches were compiled and analyzed.  Word clouds and computer-
generated images were created for a visual representation of the qualitative data.      
 The first analytic tool applied to the interviews was a word search.  The frequency 
of words and terms used helped underscore the most important themes in the data.  From 
the word frequency results, a text search was completed to understand where and how 
these terms were used.  The query for in-text citations of the most frequently used words 
started to build the emergent themes discussed in the key informant interviews. The word 
frequency and text queries helped distill the substance of the interview texts to gain a 
better idea of word patters, frequencies and topic covered in the interviews.  The word 
cloud in Appendix E shows the words most commonly used to describe a success and a 
barrier in all of the interviews combined. 
Data Extraction from the Root Cause Analysis Diagrams and Process Maps 
 The root cause analysis (RCA) diagrams and process maps from each of the three 
group sessions with the Administrators, Clinicians and Pharmacists were transposed from 
the poster boards in each group session into Microsoft Visio Software to create computer-
generated visual maps of the processes, RCA success and barriers.  After the maps were 
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printed, the process maps and RCA diagrams were color coded with different color 
highlighters to determine similarities and differences between diagrams.    
 The process maps were examined for similarities and differences between the 
groups by identifying similarities with a yellow highlighter and circling differences with 
a blue highlighter.  As the Pharmacist Group created three separate maps, these mas were 
compared to each other for examination as well.  Each process was noted and analyzed 
with close scrutiny to show subtle differences between processes, decision points and 
start and end points.  Close attention was paid to the specifics and timing of each process 
step.  Comparisons between ordering, prioritization, and description were made.  Specific 
words and phrases used to describe each process was also noted and studied.  
 The main bones of the RCA diagrams were coded with a yellow highlighter to 
find the overlaps between diagrams.  The minor bones off of the major bones were color 
coded with a blue highlighter for similarity as well.  Tables were created with similar 
theme identification and to further analyze the data.  After similarities became clearer, the 
differences became more apparent.  Employing these tools and methodologies, 
similarities and differences were studied and results were drawn. The variables that were 
identified on the RCA diagrams and process maps were also aggregated and compared to 
the key informant interviews.   
 
Strategies to Ensure Validity and Reliability 
Stake (1995) underscores the “importance of confirming the data collected in a 
case study and suggests the use of triangulation and member checking.”(95) 
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Triangulation was achieved by using multiple sources of evidence to confirm facts.(113) 
To complete the member checking activities, only a few of the interviewees were 
consulted when the voice recording was not clear, or a segment of the transcript did not 
flow linearly in order to review drafts of case study text that contain their quotes and 
ideas. 
Threats to construct validity were addressed by creating operational measures—
how, when, why the CDTM program began and the current operational process of the 
program—for the constructs being studied.  External validity, or generalizability, was 
addressed by using theory to guide the research design.(114)  Threats to reliability were 
addressed by using a case study protocol and compiling a case study database with notes, 
documents, a data dictionary, and codebook.  Following the recommendations of Yin, a 
case study protocol “was developed for internal use and includes objectives, field 
procedures, questions (data collection instruments), analysis plans, and a description of 
the final report format.”(94) 
Two key measures were taken to ensure reliability during data collection.  As two 
of the key informants were also slated to participate in the group brainstorming sessions, 
their key informant interviews were conducted before their participation in the group lean 
management sessions.  While their participation in the group brainstorming sessions 
could have been affected, the one-on-one interviews were prioritized for the higher 
likelihood of potential re-call bias.  This decreased the probability of recall bias during 
their one-on-one interviews.  Moreover, one of the transcribed interviews was checked by 
a second coder for interrater reliability by a fellow doctoral student in Global Health at 
  
92
Harvard University, Julia Raifman.  The code book descriptions from NVivo and a 
complete transcript were provided to Mrs. Raifman.  Then, Mrs. Raifman re-coded one of 
the interviews for reliability and consistency.  This re-coded interview was compared to 
an interview the primary researcher coded and it was concluded that the coding had a 92 
percent overlap in codes—over 22 percent higher than the pre-identified goal of 70 
percent overlap. 
During the brainstorming sessions, a different volunteer scribed and explained the 
process maps from the lean management group sessions.  By encouraging participation 
from more than one group member, the results from the session had a higher likelihood to 
represent the perspective of more than just one individual from each group.  While not a 
perfect measure for participation or representation of multiple viewpoints, it was one 
small step taken to help with data collection reliability. 
 
Interpretation and Reporting 
Because case studies are analyses of a single event, condition, or group, they do 
not inherently produce statistical results that may be generalizable to other populations or 
settings.(94)  However, conclusions from case studies can contribute to the development 
or modification of theories (or in this research, implementation guidelines) and to a 
deeper understanding of the underlying processes and themes and the individual 
components of the real-world topic under investigation.(94)  
 El Rio’s experience implementing and adopting a CDTM model was summarized 
into three deliverables: 1) implementation guidelines for clinical administrators and 
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practitioners in other settings who are considering adopting the CDTM model, 2) a 
Google Forms Outpatient Clinical Pharmacy Program Worksheet for clinic self-
assessment before CDTM adoption or implementation, and 3) an educational 
management case study.  A single narrative was used to describe the case from El Rio 
and the management case study will follow a linear-analytic structure.(94)   
 
Limitations 
It is important to note the potential biases inherent in this type of single iterative 
case study research associated with historical document research within any given 
organization.  The documents accessible for this research had a certain amount of 
“selective survival” bias since the available documents were more likely to have a 
positive and not a negative opinion of the CDTM model.(114)  Since the CDTM model 
survived, so too did the positive feedback and argumentation supporting its 
implementation and existence.  The selective survival bias of both documentation and 
memory of those interviews inevitably influenced the analysis.  Many of the perspectives 
from the key informant interviews may have become more positive or remember the El 
Rio or clinical history in a more positive light since the program was set in place.  Many 
of the counter arguments to the program’s adoption or implementation may have been 
forgotten or overlooked.  The limitation of positive recall bias is compounded by the fact 
that key informant interviews are focusing on memory of the program alone during the 
interviews.(114)   
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While all the key informant interview questions followed the same framework 
and line of questioning, pre-approved by the Boston University Institutional Review 
Board (IRB), the questions in each interview were different.  The probe questions that 
followed each stem question were different per interview and may have shaped the 
interviewee’s answers.  Inherently, the probes and follow-up questions asked were 
included in the final transcript and coded for frequency values.  Since each interview was 
different and all of the probes per interview were different, this may affect the frequency 
data analyzed in the results.  Moreover, generalizability between interviews is also 
difficult to assess due to the lack of specific question uniformity among interviews. 
Another limitation of the research were the personal biases of the primary 
researcher.  Since the primary researcher volunteered as a Spanish-English medical 
interpreter in the Pediatrics department at El Rio during high school in Tucson, Arizona, 
she may have a slightly positive bias supporting El Rio and its endeavors.  While first a 
researcher during this project and not an El Rio volunteer, the primary researcher made 
steps to ensure her own even reliability.  Each question for the key informant interviews 
was written out as either a closed ended or open-ended question.  The primary researcher 
administered each key informant interview using the same questionnaire and added probe 
questions from the question stem, but not any further questioning that could potentially 
confer bias during the interviews.  Moreover, the primary researcher did not offer any 
personal identifiers about her connection to El Rio or past work experience before 
conducting any of the lean management brainstorming sessions or key informant 
interviews.  While these steps cannot completely ensure unbiased questioning, the 
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primary researcher worked to gather and ensure the most unbiased qualitative 
information available. 
 
Research Translation into Public Health Practice Products 
Specific Aim 2: To translate findings from the implementation assessment into 
public health practice products that support successful implementation and 
maintenance of CDTM models throughout Arizona and nationwide. 
The findings from research of the processes, successes, and challenges associated 
with the implementation of the CDTM model at El Rio is of interest because it can be 
translated into implementation guidelines for other outpatient clinical centers looking to 
create a CDTM model at their clinic or hospital.  The implementation guidelines help 
improve and guide public health practice by a) developing practical model and policy 
implementation tools and b) assessing mechanisms for more successful CDTM model 
implementation and adoption.(40)  Because El Rio has one of the oldest and still active 
CDTM models in an outpatient clinical care center in the nation, findings from this case 
study have policy implications of interest to health advocates and clinic administrators 
across the country. 
Accordingly, the second aim of this study is to translate findings from the case 
study into public health practice products to support successful implementation and 
maintenance of CDTM models in clinics and hospitals.  This section describes the 
methods that were used to create three products based on the information gathered in the 
case study. Products include implementation guidelines for clinics and hospitals, a 
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decision support tool or worksheet that will allow clinics to assess their capacity for 
implementation, and a teaching case.   
CDTM Model Implementation Guidelines 
Sub-aim 2a: To study the contextual information and literature to inform both the
 analysis of Arizona’s experience and the development of CTDM implementation
 guidelines and resources.   
Sub-aim 2b: Create CDTM model implementation guidelines for clinics and 
hospitals looking to implement a CDTM model in their health care setting. 
 Guidelines are commonly used as a way to compile a concise set of information 
and resources (tools) that help facilitate an implementation process for a specific 
initiative, for example, a new legislation, policy, program or regulation.(82)  Most toolkit 
or guideline authors seek to provide users with clear and consistent information, 
including concrete examples of approaches used to put a regulation, research finding, or 
theoretical concept into practice.(115)  The Agency for Healthcare Research and Quality 
(AHRQ) defines a toolkit as “an action-oriented compilation of related information, 
resources, or tools that can guide users to develop a plan or organize efforts to conform to 
evidence-based recommendations or meet evidence-based specific practice 
standards.”(115) A planned approach to guideline development, dissemination, and 
adaptation can promote more successful adoption of the implementation guidelines and 
its components.(115)  
 The results from the case study were used to develop a proposal for CDTM model 
implementation guidelines.  These guidelines were the starting point for many clinics in 
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the U.S. that would like to start an outpatient clinical pharmacy program, but do not know 
where to begin the process.   
 The implementation guidelines were modeled after existing resources from the 
CDC, including two toolkits addressing Collaborative Practice Agreements in health care 
settings.(59)  Guidelines may include fact sheets, technical assistance resources, such as a 
budget planning tool, a step-by-step guide that clinics can use to identify what programs 
their patient population would most benefit from, or sample language to explain CDTM 
to a patient population.(40)  The guidelines for this research incorporated selected 
existing tools of CDC’s CPAs and will expand on CDTM-specific intervention tools 
adaptable for all settings. While the intervention guidelines were based on the El Rio 
experience, all interventions will be generalizable to other settings.   
 Guideline implementation recommendations may include the following:  
• revisions to the current CPA to better address CDTM model 
implementation;  
• specific adoption guidelines and methods, such as requiring new 
employees working with CPAs attend a CDTM education session;  
• proposals for increasing the availability of resources to address at-risk 
patient populations through CDTM clinics; resources might include staff, 
funding, or technical assistance materials and sessions; and  
• methods for regular evaluation of compliance and of implementation 
successes and challenges. 
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• consideration of how the lessons from the El Rio program which focused 
on diabetes management would apply to other chronic disease 
management. 
   The draft intervention guidelines were developed in collaboration with El Rio 
clinical pharmacy staff, El Rio administrators, and other local and national stakeholders 
identified during key informant interviews.  Specifically, questions asked during the key 
informant interviews addressed intervention ‘steps’ translatable into guidelines.  The 
“how” and the “process” behind the CDTM model were addressed and then translated 
into intervention guidelines.  After drafting the first set of guidelines from important 
themes from the key informant interviews, a meeting of the clinical staff at El Rio was 
convened to discuss the initial implementation recommendations.  After the El Rio team 
of clinical pharmacists approved the feasibility of the guidelines, further feedback was 
gathered from El Rio administration and community.  All feedback was reviewed and 
summarized into edits of the guidelines or noted in a section of the guidelines addressing 
the limitations of the intervention guidelines themselves.   
 The final implementation guidelines will be provided to El Rio Health Center and 
Tucson stakeholders for use in state and local technical assistance activities. Draft 
guidelines will also be provided to national and state organizations working on outpatient 
clinical pharmacy, such as the ACCP.  Local, state and national organizations may 
disseminate final versions of implementation guidelines via list-serves and websites, 
presentations at conferences, published reports, and technical assistance workshops. 
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Outpatient Clinical Pharmacy Program Worksheet 
Sub-aim 2c. Build a worksheet that will allow clinics to assess their capacity for
 implementation of a CDTM model.   
 Regulations enabling new clinical practices frequently do not provide adequate 
information or advice for implementation or lack explicit guidance for model assurance 
or maintenance. Implementation guidelines published by the authorizing organization or 
agency help the entity responsible for implementation achieve the intended results. The 
primary technique used to ensure the implementation of the CDTM model was to outline 
explicit suggestions for the implementation, monitoring, and assessment of the 
regulation.  Other mechanisms used to support clinical model implementation included 
evaluating existing materials and developing action based learning among other ideas. 
 The guidelines annotate a step-by-step process that clinics can use to identify if 
they are a good candidate for a clinical pharmacy program.  The guidelines are distilled 
into a Google Forms worksheet that will allow clinics to assess their capacity for 
implementation.  The worksheet will be accessed through Google so availability to 
technologic software is not a barrier for use in low resource settings.  The worksheet will 
not be directive; it will identify areas the clinic may need to address to increase clarity 
before implementing a CDTM model. 
 The results from the key informant interviews and lean management 
brainstorming activity informed the self-assessment worksheet.  Pathways and methods 
each individual and group used to support the success of the CDTM model were distilled 
into a data input in Google Forms.  To develop the query inputs in Google Forms, the 
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themes and anecdotes from the case study were reviewed identifying potential needs for 
supports and resources that translate to clinic administration recommendations.  After a 
set of draft Google Forms inputs are created, they were shared with El Rio stakeholders 
to address ease of use and utility.  Feedback from El Rio was integrated and modified 
into the worksheet before final development.    
Teaching Case 
Sub-aim 2d: Develop and disseminate a management case study about the 
Pharmacy Based Diabetes Management Program at El Rio Health Center.  The 
management case study will focus on key administrative decisions made during 
program implementation used by the El Rio administration and other 
stakeholders. 
 The public health practice component of public health education and training 
should address the “translation of public health science into policy action.”(116)  Case 
studies documenting program implementation experiences are useful teaching or action 
tools to a) facilitate replication of effective strategies and discourage replication of 
unsuccessful approaches and b) promote professional dialogue.  Cases should be 
designed to illustrate specific policy theory, learning objectives, and skill sets.  The case 
study or teaching case approach aligns well with adult learning principles, which underlie 
many professional education initiatives in public health.(116)  
 The written case study report was adopted into a teaching case with study guide to 
communicate lessons learned about El Rio’s experience implementing and adopting the 
CDTM model.  The target audience for the teaching case included public health students, 
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public health and clinical pharmacy professionals, and clinical administration in 
outpatient clinical care centers.  The adaptation from case study to teaching case used 
established techniques to create a case suitable for use in a learning setting, including 
condensing and modifying text to include discussion questions and teaching points.(116)  
Following Yin’s advice, the goal of the adaptation was to “establish a framework for 
discussion and debate among students.” (94)  The teaching case will be piloted in a 
Boston University public health course and written and verbal feedback from students 
and instructors will be gathered.  All of the feedback will be reviewed and the case will 
be revised.   
 The teaching case will be made available for dissemination through national and 
state networks.  It may be adapted further as a white paper or a research paper for 
dissemination through national and state organizations and/or publication in a peer-
reviewed journal. 
 
Chapter Three Summary 
 Chapter 3 described the research and design methods for the Case Study of El Rio 
and the Pharmacy-Based Diabetes Management Program.  The background of clinical 
pharmacy in Arizona is described along with the case description and boundaries of the 
research.  The definition of a case study was identified and described in depth to support 
this application to this research.  Chapter 3 describes the methodology employed during 
the data collection for key informant interviews and group lean management sessions.  
The data analysis and tools used to code and extract data were also detailed in Chapter 3. 
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CHAPTER FOUR 
 
Results: Shared Practices that Contribute to Program Development,  
Adoption, and Implementation 
Introduction 
As outlined in Chapter 3, multiple quantitative and qualitative tools were used to 
examine the development and implementation of the Pharmacy-Based Diabetes 
Management Program (PBDMP) at El Rio Community Health Center.  This chapter 
highlights the results of this analysis, which point to a variety of conclusions and outputs 
that are discussed in further detail in Chapter 5.  Chapter 4 first identifies the emergent 
themes from each of the data collection methods.  The four themes defined were: 
teamwork, process, leadership, and challenges.  These four themes are categorized by six 
key practices.  The six practices that affect OCPP support and structure are: 1) Setting a 
vision and objectives, 2) Obtaining and using resources that support the objectives, 3) 
Defining the program structure of the PBDMP, 4) Leadership taking on roles in guiding 
the program development, 5) Collaboration and teamwork between program roles and 
individuals, and 6) Data and data analytics to inform decisions.  The PRECEDE section 
of the PRECEDE-PROCEED model and the Organizational Transformation Model are 
applied to the practices to help identify the supports and structures of the PBDMP at El 
Rio to inform the implementation guidelines and study products.   
Chapter 4 will provide an overview of the findings from all three data collection 
sources.  The chapter will begin with a data collection summary, and then offer 
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benchmarks for comparison between the three OCPPs interviewed.  The six practices are 
described in detail and then compared with each other.  Chapter 4 concludes with 
similarities and differences between the programs.  
 
Findings Overview 
Table 9 describes the three clinical sites studied: 
Table 9. Outpatient Clinical Pharmacy Program Sites 
 El Rio Community 
Health Center 
(PBDMP) 
Marana 
Healthcare 
(MHC) 
UNC Internal 
Medicine Enhanced 
Care Program  
Year of program 
foundation 
August, 2001 January, 2014 July, 1999 
Clinic Structure Stand-alone program 
housed within larger 
clinic setting 
Program based out 
of a drug-
dispensing 
pharmacy within a 
clinic setting 
Stand-alone program 
within an academic 
outpatient clinical 
setting 
Clinical Focus Diabetes-only focused Diabetes-only 
focused 
Program oversees 
medication 
management for 
diabetes, 
hyperlipidemia, and 
hypertension 
Pharmacist FTEs 8 Pharmacists (5.6 
FTEs) 
3 Pharmacist FTEs 4 Pharmacists (2.25 
FTEs) 
Diabetic Patient 
Volume 
275 to 350 individual 
patients per year, 4,500 
unique patient visits in 
2014 
3 patients total 6-8 diabetes patients 
daily 
Number of Visits per 
Year 
4,000 to 5,000 diabetic 
patient visits per year 
50 diabetic patient 
visits per year 
800 diabetic patient 
visits per year 
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Benchmarks for Program Comparison 
The El Rio Experience: Compared and Contrasted 
To enhance the relevance of the case analysis, the Pharmacy-Based Diabetes 
Management Program (PBDMP) was compared to other settings with successful and 
failed program development and implementation.  The case description of the PBDMP at 
El Rio has similar case boundaries and identification to the outpatient clinical pharmacy 
program at Marana Health Care (MHC), in Marana, Arizona and the University of North 
Carolina at Chapel Hill (UNC) Internal Medicine Enhanced Care Program.  Incorporating 
benchmarking to compare the three programs is useful to examine the structures and 
supports in place assisting or hindering the CPA development and implementation.  
Moreover, a comparison of the results from the multiple lean brainstorming sessions and 
key informant interviews from within El Rio is useful to reflect on the current state and 
genesis of the PBDMP.  Through this analysis, a comparison between these programs 
reveals the aspects of the PBDMP that could be applicable for alternative settings seeking 
to incorporate a collaborative practice model in an outpatient setting. 
This analysis suggests the key benchmarks for comparing outpatient clinical 
pharmacy programs include: 
• Patient volume utilizing the outpatient clinical pharmacy services; 
• 30-day re-admission rates for patients within the program; 
• Physical space dedicated to the program within the clinical/health system 
framework based on key informant interviews; 
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• Number of staff members (FTE) dedicated to the outpatient clinical 
pharmacy services; 
• Amount of time the program has been open and working with patients’ 
diabetes state management. 
To best understand the context of the results, a snapshot of the individual clinics 
was created based on first-hand observation of the clinical facility supplemented by the 
content of the key informant interviewees.  The three different clinical sites, Marana 
Health, UNC Internal Medicine Enhanced Care Program, and El Rio’s Pharmacy-Based 
Diabetes Management Program are described below. 
El Rio Pharmacy-Based Diabetes Management Program 
  The Pharmacy-Based Diabetes Program at El Rio began in August, 2001.  After 
receiving a clinical pharmacy demonstration grant, El Rio was committed to hiring a 
clinical pharmacist and beginning a clinical pharmacy program.  The program developed 
slowly by working to augment care given by physicians.  The program expanded over the 
following six years and the clinical roles of the pharmacists were defined over time.  The 
program currently has eight clinical pharmacists (5.6 FTE clinical pharmacists) on staff.  
The PBDMP sees about 4,000 to 5,000 unique patient visits annually.(98)  In 2014, there 
were 4,500 unique patient visits.(98)  Each pharmacist sees approximately 275 to 350 
individual patients per year—approximately 2,400 unique patients each year.  Most 
patients seek services at one specific clinical site and see the same clinical pharmacist on 
the clinic’s staff for all of their care.  A patient’s frequency of visits depends on the 
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individual’s diabetes control.  Depending on a patient’s control of their diabetes, a patient 
can see a clinical pharmacist between four visits a month and one visit every six months. 
The PBDMP started recruiting patients by contacting the department heads of 
Internal Medicine and Family Practice encouraging them to send 10 of their most 
complicated patients to the program.(117)  By working closely with these patients and 
providers, the pharmacists were able to document and show improvement with this initial 
group.(117)  The department heads then became the champions for the pharmacist when 
recruiting other providers to start referring patients to the PBDMP.(117) 
There is data to support a decrease in hospital 30-day readmission rate of patients 
participating in the El Rio PBDMP.(101)  There are clinical pharmacists physically based 
in eight of the 17 clinical sites of El Rio although they are available for remote 
consultation with all sites. Each clinical site has at least one exam room and shared office 
space for the clinical pharmacists to work.  While there is not clinical pharmacist 
coverage every day of the work week at each clinical site, usually four out of five days a 
week there is a clinical pharmacist on-hand at each clinic.  At the main El Rio office of 
clinical pharmacy at the Congress Clinic there are three dedicated exam rooms and three 
offices for the PBDMP Director and nutritional counseling services.  There is also a 
dedicated conference room for training and group classes of the PBDMP in the Congress 
Clinic. 
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The Case of El Rio 
Shared Practices and Topics that Relate to Program Development,  
Adoption, and Implementation 
The six themes or activities that were discovered in this investigation contain both 
external and internal activities carried out by outpatient clinical pharmacy programs.  For 
this research, the clinical steps and actions taken by the OCPPs will be referred to as 
practices.  These practices are activities carried out by the PBDMP as well as the other 
outpatient clinical pharmacy programs studied.  The six practices examined do not 
represent all of the program activities, only those that had an impact on the program 
supports and structures leading to program success.   
The four segments of the PRECEDE model and the six primary constructs of the 
Organizational Transformation Model were used as guidance to define the shared 
practices present in all of the data collection methods: key informant interviews, root 
cause analysis diagrams, and process flow maps.(82)(81)  These practices are somewhat 
chronological in order, as activities and processes evolved throughout the planning stages 
of program development.  Within the limited evidence available regarding the other 
outpatient clinical pharmacy programs, the same practices were observed in the primary 
case study of El Rio.  Although most of the evidence is from El Rio, supporting evidence 
from other sites was included when available.  This analysis will contain a description of 
the practice, the impact it had on program support, and examples of how the practice was 
identified in applicable case sites.  A brief summary concludes each practice section.  An 
overview of all the practices is provided in Table 10. 
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Table 10. Overview of Six Key Practices of Successful OCPPs 
Name of Practice Impact on Program Support 
and Structure 
Example Impact 
1. Setting program 
objectives 
Used to keep mission, vision, 
and priorities aligned through 
program development and 
implementation. 
Setting the scope and vision of the 
program to include or exclude 
specific programs, e.g. the inclusion 
of 340B medication discounts. 
2. Obtaining and 
using resources 
that support the 
objectives 
Determines the internal and 
external resources, and process 
of utilizing the resources 
efficiently and effectively. 
Identifying current clinic resources, 
e.g., clinic office and conference 
space, available for program 
execution.  
3. Defining the 
program 
structure of the 
PBDMP 
Sets the flow of the patient 
care services and 
pharmacist/clinician 
interaction. 
Specifying the cycle of care within 
the program, e.g. a patient continues 
to regularly visit a pharmacist and 
clinician until their diabetes is 
stabilized. 
4. Leadership 
taking on roles in 
guiding the 
program 
development 
Leaders guided and simplified 
the program’s processes 
through a series of program 
definition and re-definition. 
Strong leadership and vision was 
necessary during hiring practices, 
e.g. leaders understood the needs of 
the program and matched individual 
characteristics of new hires with 
those needs. 
5. Collaboration 
and teamwork 
between program 
roles and 
individuals 
Formal and informal 
teamwork impacted work 
practices of the programs. 
Defining formal roles for team 
members was integral for program 
success, e.g. CPAs outlining work 
relationships between employees. 
6. Data and data 
analytics to 
inform decisions 
The integration of data from 
multiple sources assisted in 
individual patient and 
program-wide decision-
making. 
Data platforms allowed pharmacists 
to assess individual health on a 
population level, e.g. a query of 
NEXGEN identified patients with 
A1Cs over nine who needed more 
support.  
 
 
 
PRACTICE ONE 
Setting Program Objectives 
In an organization it is critical that the vision, mission and organizational 
priorities are aligned for programmatic success.(81)  When mission, vision, and priorities 
of an organization are further defined, the Organizational Transformation Model points to 
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the importance of these strategies for organizational direction and priority setting.  The 
model framework shows priorities as integrated into the larger construct of mission and 
vision.  Priorities are defined as the vehicle to employ an aligned mission and vision. 
Mission 
In the PBDMP, the clinic administration defined the mission and vision of the 
program within El Rio’s purview.  The El Rio Community Health Center’s mission was  
“improving the health of our community through comprehensive, accessible, affordable, 
quality and compassionate care.”(74)  In line with the overall clinic’s mission, the 
PBDMP was expressly created to address a high burden of uncontrolled diabetic patients: 
“In the Hispanic and American Indian population they (El Rio’s leadership) were seeing 
a lot of people with uncontrolled diabetes.  So they felt that there was a really important 
need to address diabetes just because of the high volume of patients that they were seeing 
needing help.”(99)  The PBDMP’s Director defined the program vision as a collaborative 
drug therapy management program that “addresses diabetes self-management, education 
and training, and support.”(98)  The Director further elaborated on the vision by 
describing what was needed to overcome the clinical inertia to implement a program like 
the PBDMP: “we were able to sort of break that inertia and get people to activate sooner 
and then also in between visits with the providers, so you’re not always doing things 
when you’re seeing the patients—you’re doing it more frequently and then in between 
the physician visits so it’s a really nice relationship.”(98)  
The program’s mission was first defined by the leaders who applied for the HRSA 
demonstration grant in 2000. They defined the initial goal of the program to integrate 
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clinical pharmacists into ambulatory care for diabetes.  After a few years of existence, the 
program’s priorities shifted to cover the continuum of diabetes care management, and not 
just individual diabetes care visits.  The alignment of the vision, mission and priorities of 
the program assisted in patient retention and program success.  For example, due to the 
increase in patient volume, pharmacists were no longer able to see patients with 
recommended frequency.  In response, El Rio hired additional pharmacists and staff 
members for the PBDMP to serve the increased patient demand.  By increasing the 
number of pharmacists the volume of patient visits and retention increased thereby 
leading to a higher number of patients with diabetes control.(98) 
Vision 
Vision was described throughout the interviews in terms of both leadership and 
individual foresight.  In multiple brainstorming sessions the fact that the PBDMP was 
created as a free program within El Rio was seen as positive foresight from the clinic 
administrators.  The Pharmacy Group noted that the “free status of the clinic” was a 
leading reason for program success, for building program volume and retention. The 
same group also noted that the “help with medications” that the clinic offered was 
integral for program use by the El Rio patient population. One of the perceived benefits 
of the program for the patients was the access to free or low-cost frequent visits to 
clinical pharmacists for patients with diabetes in highest need. 
  Due to the HRSA 340B Drug Pricing Program, under which individuals can 
receive medications for free or at a reduced rate, many of the diabetes medications 
prescribed form the clinic were offered for free or at a low cost.(42)  Participants in the 
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brainstorming sessions discussed the high number of patients who did not take their 
medications as prescribed due to financial barriers.  Not only did the free clinic status 
increase patient volume, it also enabled patients who would otherwise not be able to take 
their medication regimen correctly, take all of their medications as prescribed.   
In other groups, vision was described as a perspective used when the clinic 
administrators hired staff for the program.  By identifying pharmacists as potential 
integral members of the care team, clinic leadership was able to define the set of skills 
that pharmacists added to the patient diabetes care management.  For example, in the 
Administrator Process Flow Map, a whole process step was identified to describe the skill 
set of the pharmacists: “assessment, learn needs, motivational interviewing, etc.” This 
step shows that administrators had identified a set of skills that a pharmacist added to the 
program and validated the pharmacists as an important member of the diabetes team-
based care.  
In one of the Pharmacist group process flow maps, a process step was dedicated 
to the fact that “someone [clinician, pharmacist, or nutritionist] decides a patient needs 
the program.” This step again describes programmatic vision of the PBDMP since an 
individual integrated in the program was able to and encouraged to make the decision if a 
patient entered the program.  The same process flow map showed individual knowledge 
of program vision, since the employees embedded in the program were making decisions 
about which patients should or should not enroll in the PBDMP.   
Administrators for the clinic and the PBDMP itself were also praised in the 
Clinical Group’s RCA diagram of success for their hiring and management processes. 
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The “experience of managers” was seen as a bonus for the program, adding to the depth 
of understanding of the patients.  The “management knowledge of staff” was also a 
success defined in the Pharmacy Group RCA diagram.  Being able to “hire well” for the 
program was also seen as a success in this diagram.  Similarly, in multiple diagrams the 
“motivated team” of the PBDMP was described in detail.  Hiring a motivated team and 
knowing the clinic gaps and patient needs was repeatedly cited.   
Therefore the depth of understanding of the clinical staff and their specific skills 
was seen as a key element to program success.  This understanding was also confirmed in 
the key informant interview with the Clinical Director of the PBDMP in describing the 
hiring process: “But, they did do a good job recruiting, because they hired me!  No, but, 
they were very thoughtful in how they recruited for the position.  They were looking for 
residency-trained bilingual clinical pharmacist—that’s me.”(98)   The importance of 
clinical administrative buy-in for the program was also highlighted in the interview: 
“Showing them the difference in outcomes that level of buy-in obviously helps, you can 
get there without that level of support, but it’s much faster and more easy [sic] if you 
have that level of administrative support coming from the top.”(98)  Clear 
communication of the PBDMP’s benefits between El Rio’s clinical administration and 
the pharmacists working in the PBDMP was a key element to organizational 
transformation. 
Priority Setting 
The OTM defined strategies that set and directed priorities as a key element for 
priority setting.(81)  For this research, the two key aspects of priority settings were: 1) 
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priority setting process on a clinic-wide level, and 2) priority setting within an outpatient 
clinical pharmacy program.  The participants from the brainstorming sessions identified 
priorities that were both pre-identified from program formation as well as additional areas 
employees identified as important for program success. 
Priority Setting: Clinic-Wide 
When key informants discussed clinic-wide priorities, interviewees discussed the 
program’s sustainability and maintenance or a specific patient population using clinical 
services.  For example, the Program Director at UNC Chapel Hill Program noted that:  
“So we are really fulfilling the role of the provider. And so ordering meds that need to be 
ordered and ordering labs that need to be ordered. And, at the same time we’re also doing 
multiple projects looking at population health and management in ways that we can all 
improve.”(108)  Clinical pharmacists at the UNC program were able to identify strategies 
that set the program’s direction and priorities.  The director described that the UNC 
program was founded based on two clinical pharmacist’s vision and priorities, “So that’s 
kind of what the physician’s envisioned, and that was very different than what the two of 
us envisioned, and so we began drafting up a disease management work that we 
envisioned for diabetes specifically.”  
The key informant interview with the PBDMP Clinical Director described 
program priorities through strategies for addressing a high patient volume: “Now we have 
an abundance of referrals.  That’s not an issue about whether or not the physicians 
understand what we do.  And, then also integration.  Not just the patient care level, but 
the organization promoting it to more higher administrative responsibilities that really 
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sets the strategy.  We’re looking at ways as a whole as to how we can improve 
prescribing and how we integrate the pharmacy.”(99) 
Priority Setting: Program Specific 
In the PBDMP, the results of the priority setting process from the Clinical Group 
RCA diagram map identified a “high quality of service” and “communication and 
affiliation” as important priorities and behaviors for employees.  One of the Pharmacist 
Groups defined patient education as a process step in their process flow map.  The step is 
a decision point asking if “patient knows their A1C?”  This concern with patient 
knowledge and patient ownership of their own health is a key aspect of the program and 
its success.  The Clinical Group described the “self-management” goals for the patients to 
understand their diabetes diagnosis and the prescribed treatment plan.  The group noted 
that one of the successes of the program was the consistency in messaging of the various 
providers—“same message from multiple people.”  The medical assistants, pharmacists, 
and clinicians participating in patient management all shared a vision for “what” and 
“how” to treat patients enrolled in the program. 
In addition, better “communication between patient expectation and providers” 
was identified as an issue between patients and providers. Identifying the priorities of the 
program and what a patient could expect from the PBDMP was important, but 
communicating those expectations clearly and effectively to the patients was paramount. 
While the priorities for the PBDMP were aligned with the vision and mission, the link 
between the providers and patients for program expectations was not as strongly 
communicated as necessary for program clarity. 
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Conclusion 
The combination of mission, vision and priority setting is integral for an 
organization’s success.  Since each of the aspects of organizational change supported 
each other at El Rio, not one of the areas was considered more important or imperative 
for program success.  The practice of identifying the vision, mission, and priorities at the 
PBDMP was a key element of organizational and programmatic success. 
 
PRACTICE TWO 
Obtaining and Using Resources that Support the Objectives 
There were two consistent types of resources discussed in the key informant 
interviews and brainstorming sessions.  In both of these data sources, resources were 
either described as internal or external support.  The support received was usually 
financial, while other resources were described as physical support for the program itself 
including, staffing, office space, and administrative engagement.  All types of resources 
and support that the PBDMP and other program sites received are important for 
considerations of transferability to other program settings.  
Internal Resources 
All of the outpatient clinical pharmacy programs received funding from line-item 
budgets internally from within their respective clinics.  More importantly, this financial 
support was coupled with philosophical support from the clinic’s administrative and 
clinical leadership.  Key informants frequently noted that program finances provided by 
the clinic were concrete manifestations of the buy-in from clinic leadership.  To secure 
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funding, program directors needed to provide evidence that an outpatient clinical 
pharmacy program would respond to the patient needs of the clinic, produce positive 
health outcomes for the patients enrolled in the program, and not serve as a financial 
burden to the overall clinic.   
The Program Director at El Rio noted that the support from the clinic leadership 
was integral to program development and implementation: “It was all about showing 
improved outcomes.  Solid, improved outcomes.  Provider acceptance and provider 
satisfaction.  Convincing our administrators we were a program that mattered.”(98) To 
garner the support of the key leadership, the PBDMP not only produced a plan for 
program implementation, but in addition clear outcome data was shared with clinic 
leadership to encourage continued programmatic support.  For example, patient outcome 
data was shared with El Rio leadership on a weekly and monthly basis.  The 
administrators also articulated their “full full [sic] support” of the program in the RCA 
diagram.  They went on to discuss their financial support for the program and the 
importance of providing funding for the PBDMP in the RCA diagram: “mobilizing 
funding: or helping to get enough for them.”  According to the Program Director at El 
Rio, funding creativity was also important for program sustainability, “We’ve created 
ways to fund our program.”(98) 
In line with the vision of the PBDMP, the “free status” of the program was 
identified as a major success in all of the data sources.  The Pharmacy and Clinical Group 
both said that the fact that the program was “free to all patients” enabled clinicians to 
refer individuals into the program without a financial consideration.  As noted in Practice 
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One, the pharmacists pointed out that the “needs exceed capacity” for the program 
explicitly since providers tended to refer patients to the program because it was free.  
This deluge of patients created a long wait time to see a pharmacist—almost three 
months—and major challenge for the PBDMP.  In the RCA diagrams, there were over 
eight references describing the types of “free” services offered by the clinic.  Notably, the 
Administrative Group was the only group to not mention the free status of the PBDMP.   
It was considered a benefit for the clinic and the patients with diabetes at El Rio 
that a PBDMP existed.  However, the pharmacists saw the program as potentially being 
‘over-used’ by providers referring patients that do indeed have diabetes, but who may not 
need the individualized care that the program offers.  Some of the groups argued that this 
increase in patient volume was beneficial for the patients at El Rio, while others noted 
that some patients “come to the appointment without the intention of participation” in the 
program. This lack of program engagement not only wasted pharmacists’ time, it also 
drained the program’s resources.      
Many types of resources were also described in the data in terms of education and 
knowledge directly received by patients.  In multiple RCA maps, “patient education” and 
knowledge of their current disease state was a positive outcome of the PBDMP. For 
example, the Clinical Group RCA diagram specifically identified “incorporates other 
quality services: eye/foot check, medical services” as a resource to patients.  And finally, 
on multiple diagrams, the “ABI” (Ankle-Brachial Index Test) checking for peripheral 
arterial disease in the legs was mentioned as a service of the PBDMP for patients.  The 
Clinical Group RCA diagram noted the “education in multiple formats” as a resource to 
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patients enrolled in the program.  Many of these resources were explicitly purchased by 
the PBDMP to use with patients enrolled in the program.   
Other educational resources for clinician interactions with PBDMP patients were 
identified by the brainstorming sessions as priorities of the El Rio leadership. The 
Pharmacist Group RCA diagram reflected “health education” as a major aspect of direct 
patient care.  Training providers on “patient education” and “motivational interviewing” 
were also specifically identified as skills clinicians were taught at El Rio.  In addition, the 
UNC Program Director described patient education as a type of resource: “I think the 
other thing is that we do an education session every time a new group of medical 
residents come in and we educate them about any health care programs and what 
resources we provide to them.”(108)  Training the PBDMP staff on how to effectively 
use program resources to educate and benefit patients within the program, was identified 
as a success on multiple RCA diagrams.   
Physical space, materials, and tools were also described as PBDMP resources in 
the brainstorming sessions.  The Pharmacist Group RCA diagram specified the “eye 
machine” and “exam rooms to see patients” as resources.  The Clinical Group noted the 
“help getting supplies/medications” as a success of the program and its potential for 
providing resources to patients.  The Clinical Group also said that the physical setting of 
the PBDMP within El Rio was a success of the program.  The group identified that: 
“services delivered in multiple venues” and “co-location on site with PCP” were benefits 
of the program.  Finally, the PBDMP and MHC program both identified as resources a 
dedicated conference room in the clinic for group education.  While the conference rooms 
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were used for large patient group education settings or clinic staff meetings, there were 
not seen as necessary for program success. 
Staff and personnel working in the program were described as program resources 
throughout the data.  The Program Director of UNC described that the individuals on 
staff for the program were shared with other departments within the academic setting: “I 
mean, there’s technically 4 of us, but we are faculty and other responsibilities so if you 
factor in the amount of time we are funded by the clinic to do clinical work it’s about 2 to 
2.25 or something like that.”(108)  The number of FTE staff equated financially to the 
program’s bottom line since the staff services were reimbursed.  UNC capitalized on their 
academic setting to create flexible part-time employees.  Similarly, many of the 
pharmacists on staff at the PBDMP and MHC program were part time drug dispensing 
pharmacists as well as employees of the outpatient clinical pharmacy program.   
External Resources 
In response to the question of buy-in from the clinic’s leadership, the Program 
Director at the Marana Health Center said: “So, those barriers have been overcome.  We 
have the full support of the health center to do this.  Basically, right now, it is just the 
financial impediment to get reimbursed.”(107)  The MHC Program Director continued to 
describe that the main financial impediment for the program was not internal, but external 
through medical insurance reimbursements: “So, that’s our stumbling block right now, 
because to really just to place one or two or three pharmacists into this position, to do 
what we want to do—develop this program—that costs money.  Because you’re pulling 
someone away from where our real income source is, which is still filling prescriptions, 
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and counseling.”(107)  External insurance reimbursement was a key factor for all of the 
outpatient clinic pharmacy programs, and a difficult impediment to overcome.  All of the 
programs placed the clinical pharmacists on an annual salary from their respective clinics 
and filed insurance reimbursements for services rendered. 
This external issue of reimbursement was reiterated in multiple data sources.  The 
Director of the UNC program commented, “But, it is frustrating that pharmacists are not 
providers, but we all know that.  And, that it’s hard to figure out the financials of the 
pharmacists in those particular models.  So, yes, we can show that we decreased hospital 
readmissions with our model, but pharmacists are expensive [and] they can’t technically 
charge for those visits, so how do we show the financials that are positive feedback to the 
hospital [or clinic]?”(108)  This cycle of care and lack of insurance reimbursement for 
pharmacists was discussed during the brainstorming sessions as well as in multiple key 
informant interviews.  The cycle of insurance reimbursement represents a barrier to 
obtaining further resources for the clinics.  In some cases, this barrier represents a need to 
obtain more resources to offset the costs due to the lack of insurance reimbursement for 
clinical pharmacists.  
One major barrier noted in the Pharmacy Group RCA diagram was the fact that 
patients have “no insurance” and “no money for medication” for medical services.  While 
the PBDMP was free, referrals outside of the program and some medications prescribed 
from pharmacists within the PBDMP were still too expensive for some patients.  The 
Administrative Group RCA diagram described these issues “social determinants” that 
highlight the “patient’s complicated patient history” making positive health impacts even 
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more convoluted and difficult in the long term. 
External support also came in the form of community engagement.  The Program 
Director at El Rio noted that “getting buy-in from the community” helped galvanize 
support in terms of payment reform and pharmacist provider status on a city and state-
wide level.(98)  The community advocates supported the PBDMP both financially and 
politically in community forums.  The Program Director for El Rio noted: “we had a lot 
of donors from the community who supported the program because they believed in what 
we were doing.  And they personally had family members who they sent here who had 
success that hadn’t had success and they tried different programs around the city and 
different things like that.  So, initially it was a lot of that and now we became an 
accredited diabetes site and so we can bill for the program...”(98)  While many of these 
supporters provided some financial assistance, their support mostly came in the form of 
community engagement for the PBDMP.   
The PBDMP received a HRSA demonstration grant in the initial stages of the 
program development and implementation.  The Program Director at El Rio noted that 
the administrators: “sort of had written for the money, but they didn’t know what they 
were going to implement. Or, what it really meant or how it was going to work.”(98)  The 
process of developing the grant helped clarify the current and future needs of the patients 
and the program structure.  Payment for pharmacists was first discussed during the HRSA 
demonstration grant: “since clinical pharmacists don’t get paid for their health care 
services in general they get paid for dispensing product I mean, pharmacists.  It is very 
hard to start a program.”(98)  The Program Director went on to note that: “You almost 
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need like seed money, or you just need somebody who can say, we’re just going to eat 
the cost of paying the salary.”(98)  The grant allowed the leaders of the PBDMP to 
implement the type of program they thought best addressed the needs of their patient 
population without directly tackling the issues of pharmacist salary head-on.  At MHC 
and UNC, the outpatient clinical pharmacy programs were created without federal 
external grants. 
Conclusion 
The outpatient clinical pharmacy programs obtained resources through multiple 
sources both internally and externally.  The support for the programs from within the 
clinics was through leadership buy-in and financial line-items.  External resources tended 
to be from of external grants and support from the community.  Together, these various 
resources supported the creation, implementation, and execution of the programs. 
  
PRACTICE THREE 
Defining the Program Structure of the PBDMP 
 The structure of the PBDMP and other outpatient clinical pharmacy programs 
studied were discussed and defined in the brainstorming sessions and by interviewees in 
three distinct categories: 1) Clinic-Wide Program Structure, 2) Referral Process, and 3) 
Program Structure of the PBDMP.  Through a process of program definition and re-
definition, these categories help describe the function of the OCPP and how the services 
offered by the programs fit into the larger landscape of the clinic.  Together, these 
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categories identify the form of collaborative drug therapy management and CPA in place 
at each clinic. 
Clinic-Wide Program Structure 
Program design and implementation differed among the clinic sites.  In the case of 
the UNC program, the Director described the brainstorming process leading to program 
creation as straightforward and methodical: “And so that’s kind of what the physicians 
envisioned, and that was very different than what the two of us envisioned, and so we 
began drafting up a disease management work [sic] that we envisioned for diabetes 
specifically, because they [the UNC clinic itself] did have data showing the huge amount 
of expenditure in meds and just care of our diabetes’ populations that were Medicaid.”  
According to the MHC Program Director, their program started, “Ad hoc and through my 
own brain.”  MHC focused on training the pharmacists on staff in diabetes disease state 
management.  The Program Director of MHC noted that, “The number one thing that I 
thought we had to do was, we had to be trained in these key areas because we needed the 
certification in order to prove that we had the skills to do these kind of things.”  The cycle 
of defining and re-defining the program and program structure evolved over time for all 
the clinics.  Many of the decisions made in the process of these cycles incorporated 
various practices supporting program efficiency and coordination.  The importance of 
constant re-definition and flexibility within each program was a common theme in the 
data underlining the critical step of program development and structure. 
In the initial stages of the PBDMP, clinic leadership looked into the possibility of 
a pharmacist-inclusive model after a recommendation from the University of Arizona.  
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Since the El Rio leadership at that time did not have a pharmacy background, El Rio 
applied for a HRSA grant to start their program.  The instructions to the PBDMP 
Program Director were cursory, “When I started here, they had given me no parameters. 
No direction.  They just said, “Start a diabetes program!”  The Director drew from past 
work experience to design and implement a clinic pharmacy program addressing the 
community of diabetes patients at El Rio.  In addition, the Director also compared the 
programs that addressed diabetes in use at El Rio to the future plans for the PBDMP, “So 
you could see how it [the past program] could be a burden on the clinic.  Versus if you 
just implement a very similar practice to any other one.  It’s seamless, and it’s accepted, 
and that’s what it is and sort of people get comfortable with that.   So, anyway, that’s how 
we started it.” 
The landscape of the clinics and states where the outpatient clinical pharmacy 
programs were created was an important element to program development and 
implementation.  The Director of the UNC Program mentioned that a familiarity with 
clinical pharmacists was a benefit for the program, “So, I would say that back in like 
1999 when we first started, most people were just familiar with the concept of clinical 
pharmacists on rounds within the hospital on the inpatient side, so they were familiar 
with what pharmacists could do as part of that team…they weren’t, in our clinic, as 
knowledgeable about what the pharmacists could do in an outpatient setting.”  A 
supportive medical community that understood the intent of an outpatient clinical 
pharmacy program was important for program awareness. 
The ability for pharmacists to practice under a Collaborative Practice Agreement 
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(CPA) in a given state is integral to program formation.  The PBDMP Program Director 
noted that, “I would say 47 out of 50 states allow some form of collaborative practice.  
But, you have to understand the scope of practice you’re allowed to do in each state and 
what the requirements are.  When I first started, there was no legislation for that.”  
Identifying if a state can house a pharmacist-inclusive CPA is paramount for program 
development.  Specifically, researching if a CDTM model is permitted within the state 
helped the programs plan for service delivery within a pharmacist-inclusive team.  It is 
critical for a program to link practice with the legal realities within a state to ensure the 
feasibility of the proposed program structure and process. Appendix C includes a process 
flow map from Pharmacist Group 1 depicting the structure of the current PBDMP. 
Referral Process 
Patients were referred to the outpatient clinical pharmacy programs through the 
family and internal medicine departments.  At MHC and the PBDMP patients were also 
recommended to the programs through the pharmacy.  In the case of the PBDMP, the 
Administrative Group process map identified nine separate points of entry to the 
program.  Some of these referral systems included, self-referrals, Missed Opportunity 
Reports, and Community Health Advisors.  The Pharmacy Group RCA diagram noted the 
“provider referrals” as a success of the program.  The Administrative Group RCA 
diagram also mentioned that “11 years ago: DO/MD could not opt out of PBDMP—now 
no opt out.”  This identified success of the program referral structure ensured that all 
clinicians were able to refer patients to the program. 
The Program Director of the PBDMP described the referral process as diverse, 
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“Referrals come from many many [sic] places.  I mean, the physicians refer—if they have 
people who are out of control or need help.  But, we also have other staff that refers.  We 
have our behavioral health counselors that refer. We have a pharmacy that refers if they 
see somebody who needs help. We have self-referral, family referral, we have other 
people in the community that have either read or heard about our program.”  There was 
not a one-size-fits-all method for successful patient referral for the programs.  However, 
the Clinical Group RCA diagram reflected that they thought there was much “confusion 
over referrals” and that there was “no easy way to enter the program.”  While the referral 
process was considered robust with a wide reach for patients at El Rio, the clinicians 
believed the process to be somewhat unclear.  The existence of multiple forms of 
referrals to the PBDMP was highlighted by the administrators; the referral process itself 
was not discussed in the brainstorming session.  The managerial tradeoff made by the 
administrators to cover the breadth of potential referrals to the PBDMP, may have come 
at a cost in terms of convenience of referrals by clinicians. 
The referral process itself was defined and then re-defined over time by El Rio’s 
administrative and clinical leadership.  The first type of referrals to the PBDMP came 
from clinicians: physicians, nutritionists, social workers, and nurses.  Referrals from 
missed opportunity reports and i2i queries were introduced into the referral process after 
El Rio migrated to an electronic medical record system.  Over time, the referral process 
was refined and expanded to try and reach the highest potential number of patients at El 
Rio.  The El Rio Administrator noted that the more referral pathways into the PBDMP, 
the higher the number of patients ultimately referred and enrolled in program services. 
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Program Structure of the PBDMP 
While each process flow map highlighted different aspects of the program in more 
detail, all of the basic steps and processes were identical.  Once a patient was referred and 
enrolled in the program, a medical assistant followed up with the patient to schedule an 
initial visit with the clinical pharmacist.  At the initial visit, the pharmacist conducted a 
patient intake and assessed the needs of the individual.  Medication reconciliation, 
baseline measures, and A1C levels were checked and documented.  Referrals for a patient 
to visit a dietician, behavioral health counselor, or ophthalmologist were made at the first 
visit or during future visits.  Goals were established with input from the patients and a 
follow-up appointment was made.  A patient continued to visit a clinical pharmacist in 
the program until they were in control of their diabetes care.  The Administrative Group 
RCA diagram noted these “Iterative process of [the] program” as a success in structure. 
Not all of the data about the program structure and flow were positive.  The 
Pharmacy Group noted “clinic consistency” and “lack of understanding about the 
program” as major barriers to program coordination.  This was identified as a barrier due 
to the potential difference in care or services offered to patients, depending on which 
clinic site they frequented.  The brainstorming group discussed the differences in care 
between the seven El Rio clinical sites due to personnel, resources, and program 
inconsistencies.  Monthly meetings of whole PBDMP team were held to address clinic 
consistency, difficult cases, and program current events.  Informal meetings or 
conference calls were held on an as needed basis for specific cases or issues that arose.  
However, the lack of one central site was felt to be both an advantage for patient services 
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and an impediment to equal care across clinic sites.  Importantly, this perceived 
difference between program sites did not create a noticeable impact on programmatic 
success. 
Another barrier described in the Pharmacy Group’s RCA Diagram included “wait 
times” for patients to see a pharmacist.  Steps to decrease patient wait times were taken 
over multiple years by hiring more pharmacists, expanding the services offered by the 
clinic, and addressing scheduling head-on.  As in Practice One and Two, wait time was a 
consistent complaint of program process—“needs exceeding capacity.”  The 
brainstorming groups discussed how long wait times tended to decrease the volume of 
referrals from clinicians to the PBDMP and lowered the likelihood of the patients 
wanting to enter the program.  Data confirming this trend was also provided during the 
key informant interviews.   
A final barrier identified during the discussion of program structure in the 
brainstorming groups was “Provider Status.”   The groups noted that provider status was 
a key element for reimbursement of medical care as well as pharmacist inclusion in 
clinical services.  The lack of insurance reimbursement for clinical pharmacists due to the 
absence of provider status affected how the program was designed.  Visits and group 
sessions were planned around the potential for clinical pharmacists to code for aspects of 
the patient visit combined with other clinicians with provider status. 
Provider status for pharmacists differs by state and a national decision about 
provider status would address health insurance reimbursements among other potential 
issues.  The ACA described integrated models of care utilizing pharmacists, medication 
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therapy management grants, and reimbursement tied to quality measures.  However, the 
ACA did not address pharmacist provider status and pharmacist reimbursement for 
services.  The Director of the PBDMP described the importance of provider status during 
the key informant interview, “Not having it [provider status] has been a barrier—
absolutely.  Having it will be very helpful.  I think there’s a double edged sword, though.  
And I always am very conscientious of this.  If we get paid, we will have to have this 
high volume [of patients] like the physicians have done in order to be sustainable.  So, I 
hope that doesn’t happen because then you would lose, you know, the benefit of provider 
status.”  While a national decision may complicate patient volumes for clinic 
sustainability, it is a discussion that has reached the national stage.  Provider status will 
be discussed in further detail in Chapter 5. 
The data also pointed to the “lack of perceived benefits (on the part of) the 
providers” as a major barrier to the program.  The diagram also noted that patients “do 
not receive all of the benefit” of the program.  The Pharmacy brainstorming group 
discussed the fact that there were so many potential resources available to the patients 
enrolled in the PBDMP, that many patients do not receive all of the program benefits. 
In terms of patient outcomes, the Clinical Group RCA diagram noted the “lower 
admissions due to complications” and the “high quality of service” for patients enrolled 
in the program.  The Pharmacy Group RCA diagram also described the “patient 
outcomes” as a success of the PBDMP.  The product and output of the PBDMP service is 
a key element to the current and future success of any outpatient clinical pharmacy 
program. 
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Conclusion 
The data describing the program development of the PBDMP and other outpatient 
clinical pharmacy programs focused on multiple important categories.  The clinics all 
discussed the community and state where the program was developed as well as the 
specific processes within the program itself.  There were multiple ways to develop and 
implement a program from the cases studied.  Notably, at the PBDMP, basic process 
steps did not markedly differ between brainstorming groups.  Moreover, the internal 
environment of an outpatient clinical pharmacy program must also be willing to change 
and transform as a result of the addition of the new program.  
  
PRACTICE FOUR 
Leadership Taking on Roles in Guiding the Program Development 
 Multiple types of leadership in the PBDMP guided the administration’s program 
development.  Institutionally, El Rio administrators and top clinic leadership were 
supportive of the project goals throughout the lifecycle of the program—from initiation to 
present day.  Departmentally, clinicians from the family and internal medicine 
departments were supportive of the program and took on leadership roles for care 
coordination for patients.   
Institutional Leadership 
The concept of leadership was discussed in multiple forms.  Influential individual 
leaders were specified and teams of leaders were also discussed.  The leadership choices 
that were made institutionally in support of the creation of an outpatient clinical 
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pharmacy program, were also described in many of the interviews.  The Program 
Director of El Rio mentioned the founder of the PBDMP, “And, so, I think he saw a need 
from the pharmacy director’s perspective, I think he really, like just understood the value 
pharmacists could bring in this type of model.  Moving away from the dispensing role 
and actually making clinical interventions.”  These types of decisions made at a high 
level to direct the focus of the future PBDMP were a key element for program formation. 
A key factor identified in the El Rio key informant interviews was the El Rio 
leadership creating an institutional culture of openness and experimentation.  The 
Administrator from El Rio discussed the culture of El Rio, “I mean there’s obviously 
entry barriers whether you need may resources or money or whatever you might need.  
But, from an organizational culture, perspective, nobody says, no, Julia, we don’t want to 
talk about that or we don’t want to do that.  So, any idea that’s presented, I find people 
are willing to talk about it and examine it and […] entertain it.”  This open attitude from 
the top leaders at El Rio instilled a culture of innovation throughout the clinic. 
Moreover, innovation was reflected during the Pharmacist Group brainstorming 
session about pharmacist education and best practices.  The El Rio Program Director 
created an internal website for pharmacists, RxPrescribingPearls, to share their best 
practices and innovations about drug therapy and patient care delivery.  The website 
innovation served as a tool for “Pearls” of information to be shared between PBDMP 
pharmacists.  As discussed in Practice Three, the freedom for the pharmacists at the UNC 
program to innovate and create the current UNC Enhanced Care Program was another 
example of the culture of support for new ideas. 
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The “Administrative support” was mentioned as a success of the program in 
multiple data sources and specifically identified in the Pharmacist Group RCA diagram.  
This support pointed to both financial and ideological support throughout program 
creation and implementation.  The Program Director of UNC noted that after receiving 
the buy-in from clinic leadership, they understood what pharmacists could offer to 
clinical services, “And so they’re very very [sic] receptive to what we can do and I think 
they’ve also shown other clinics the impacts that pharmacists can have and what they can 
do for them.”  The support from management was both a resource and a key element of 
leadership for the clinic as well as the outpatient clinical pharmacy program itself. 
Departmental Leadership 
 From a program standpoint, the strong leadership in the PBDMP was described 
through hiring practices that sought specific individual personality traits for program 
employees.  The administrators discussed the personality traits that were most desirable 
with the PBDMP staff for future employees and sought individuals to join the team that 
were most in line with these characteristics.  However, the identification and weight 
given to each of these specific skills in potential employees were less tangible from the 
data.  For example, the Pharmacist Group RCA diagram described the “motivated team” 
that was hired and mentioned that the leadership “hired well: [employees have] thick 
skins.”  Clinicians, administrators and pharmacists themselves described the PBDMP 
staff as “friendly/accessible,” “accountable,” and “highly qualified.”  These 
characteristics of individuals hired for the PBDMP team pointed directly to the clear 
vision and leadership of program directors in addressing personality matches within 
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program staff themselves.  The brainstorming group also directly credited the 
“management’s knowledge of staff” praising the program leaders’ involvement and 
familiarity with the PBDMP employees. 
 The Administrator at El Rio pointed to the specific involvement of the PBDMP 
Program Director’s leadership as a key driving force behind the program’s creation and 
implementation, “I seriously have to go back to [PBDMP Director]’s leadership…if 
[PBDMP Director] wouldn’t have shown up here, I don’t think that would have 
happened.  Because, you know, [PBDMP Director] was focused on that population.  
Very interested in connecting other resources around it, so I really think that would be the 
key driver.”  The PBDMP Program Director had experience working at the Veterans 
Administration and in the Kaiser Hospital system in anticoagulation and blood pressure 
clinics addressing chronic disease state management.   
Through these past work experiences, the Director was able to shape the current 
and future state of the PBDMP, “I was able to take a lot of the things I really loved about 
other practices that were successful and not in diabetes necessarily…there were elements 
of the care that the pharmacists were providing there that I really liked, that brought those 
in, and then there were things I didn’t like.  And, I didn’t include those.  And, then I made 
sure that we had things like, well, things that I saw that were deficient in other sites.  
Like, having a nurse, like a medical assistant assigned to the pharmacist.  Which in other 
practices, that’s not usual.  We make that the standard here.”  This vision and leadership 
combined with the experience of past working experiences shaped the PBDMP.  
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Program Leadership 
There was not one definite way to begin or develop a successful outpatient 
clinical pharmacy program.  However, clear vision and leadership were present in all of 
the clinics studied.  Program leaders creatively shared patient outcomes with clinic 
leadership reinforcing the importance of the program.  For example, systematically 
documenting positive impacts on a patient population and reporting those successes 
through a third-party reviewer in an objective format was imperative for administrative 
and clinical buy-in.  The Director of the PBDMP explains that, “We did a lot of objective 
third-party evaluations…so that they could give us objective feedback, so that they could 
say, hey, yeah-this has, you know—it works! So that was it.  And then we did a lot of 
things, publications, PR, we won awards that showed us to be exceptional like as 
compared to other practices in the country.”  Other programs, like the MHC just started 
the program and brought in the administrators after full program implementation, “So, I 
kind of know what I want to do as a Pharmacy Director.  And, I just pursue it.  I don’t 
really wait for anyone’s approval to do what I want to do.  I know it, it makes sense and 
it’s logical and then I present it to like my CEO—like, a year ago.  I think this is the way 
I think we should go—I think this is the direction things are moving.”  Strong vision and 
leadership were key drivers for program creation. 
The data showed that the individual “[PBDMP Director]” and the “Recruits from 
[PBDMP Director]” were major successes of the PBDMP.  The Administrative Group’s 
RCA diagram further identified the “PharmDs themselves” serving as leaders for the 
program.  Another outcome identified by the Clinical Group’s RCA diagram was positive 
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leadership and participation in the program “PCPs learn from PharmDs” which in turn 
“improves PCP [patient] management.”  The brainstorming group identified that the 
product of good leadership and communication between program employees led to 
“lower [hospital] admissions due to complications.”  These positive externalities of the 
PBDMP were attributable to the strong vision and leadership shown by the PBDMP 
Director. 
 One of the barriers to successful implementation of the PBDMP was the 
inundation of work that fell to the pharmacists.  The Administrative Group RCA diagram 
identified that the program leadership needed to “streamline process by clinical 
pharmacists to not do all the work.”  In addition, the group identified that “using the team 
well” and “pharmacists not working at the top of licensure” were major concerns for 
program leadership.  The administrators stressed that the program leadership needed to 
find ways to use all of the skills of each employee.  While the group reflected on how 
they had utilized the skills of their employees, they pointed out that improvement was 
still needed.  The Program Director at UNC noted that, “In the beginning, our manager in 
chief wasn’t as interested in pharmacy services, and so, wasn’t as big of an advocate 
within leadership and then that changed and luckily for us it became a physician that very 
much wanted to promote what pharmacists could do and utilize them to the top of their 
degree.”  Finding the management support necessary to empower pharmacists to work at 
the top of their level was important for program success.  While empowering employees 
to work to the top of their degree is still a barrier at many of the clinics, identifying the 
need for the delegation of work and beginning to seek solutions for these issues was a 
  
136
component of active leadership from program and clinic leaders. 
Conclusion 
There were multiple types of leadership that actively guided the development of 
the PBDMP as well as in the outpatient clinical pharmacy programs.  Leadership that 
actively guided the development of the PBDMP was identified at all levels of the clinics 
from the institutional, departmental, and programmatic level.  Leaders worked to include 
all employees and key stakeholders during program creation and implementation.  The 
culture of support and innovation at the PBDMP pointed to the clinic leadership’s and 
program staff’s willingness to change.  The types of leadership models these activities 
described will also be discussed further in Chapter 5. 
 
PRACTICE FIVE 
Collaboration and Teamwork Between Program Roles and Individuals 
 
Teamwork at El Rio: Formal and Informal 
 Teamwork was described as both formal and informal in the PBDMP at El Rio.  
Formal teamwork (e.g. CPAs) was described as containing a structured team created for a 
specific purpose. The formal working relationships identified by the upper level 
management, were defined by job description and patient care coordination.  Informal 
teamwork (e.g. informal check-ins about individual patients and their needs) did not 
include a set structure and tasks were interoperable between staff members.  Informal 
teamwork described communication between employees of the PBDMP and the 
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relational coordination between work practices.   
Formal Teamwork 
At the PBDMP, formal teamwork was identified in the CPA signed by the 
participating physicians, pharmacists and clinical team members.  The CPA outlined the 
formal working agreement behind the program and specific function of the clinical 
pharmacist.  Setting a CPA for structured work outlined the working relationships 
between key PBDMP staff members.  Clinical pharmacists’ patient care services, 
including those provided through CPAs, can reduce fragmentation of care and improve 
health outcomes.(59) Moreover, job descriptions and divisions of labor regarding patient 
care were identified in work contracts and departmental agreements within El Rio.  The 
CDTM was pre-identified by El Rio leadership before hiring a team of clinical 
pharmacists.  Importantly, all participating clinicians contributed to the CDTM model 
before implementation.  El Rio management tailored the CPAs and CDTM model to 
foster an environment of collaborative and functional teamwork under the auspices of 
mutual agreed upon contracts. 
Formal teamwork was most articulately described in the brainstorming group 
diagrams as “cycles of care coordination.”  For example, teamwork was noted as the set 
of “cycles” taken by a patient as they progressed through the different areas of the 
PBDMP.  An example cycle of care was described in the data: after a patient was seen by 
the pharmacist, the patient entered into a state of care with referrals to specialists, the 
primary care physician, and then back to the pharmacist.  This formal cycle of teamwork 
identified in detail in the Pharmacist Group 3 Map, addressed the needs of the patient at 
  
138
all stages of care identified the coordination necessary for program success.  This formal 
cycle of care was developed over time and through active reflection in the PBDMP 
through direct oversight by the El Rio Program Director.  The PBDMP arrived at the 
current structure after a series of trials and changes to the program’s teamwork structure. 
Another example of this formal cyclic care was described in the Pharmacist 
Group 1 process map, described in detail in Appendix D.  As presented in the diagram, 
the medical assistants checked the patient’s blood sugar levels, took vitals, completed a 
foot exam, and then sent the patient to the primary care provider.  The primary care 
provider then sent the patient back to the pharmacist or to other clinical referrals leading 
the patient back into the program cycle.  While each brainstorming session perceived the 
order of the teamwork process steps somewhat differently, the formal work cycles 
remained consistent.  Data presented in the key informant interviews described how this 
type of patient hand-off and teamwork directly correlated to improved patient outcomes 
in the PBDMP. 
 Interviewee 2 from the Tucson, Arizona ACO described the importance of formal 
teamwork during the key informant interview, “care coordination is either an embedded 
component, like at El Rio for example, has embedded care coordinators [sic] they hire 
their own people to help identify high-risk people.  Folks that are either at high risk for 
readmission, or admission in the first place, we can also call people on, you know, train 
wrecks, people that you know that something’s going to happen.”  Interviewee 2 pointed 
out the utility of the formal job descriptions that the El Rio leadership had created—
Registered Nurse Care Coordinators (RNCC)s—specifically for patient continuity and 
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team coordination.  This foresight on the part of El Rio to identify a need within the 
PBDMP directly addressing coordination and teamwork was notable.  
 The Administrative Group RCA diagram described the formal teamwork of CPAs 
during the brainstorming session.  The group noted that the “pharmacist-inclusive 
practice: CPAs” was a success of the PBDMP.  This recognition of the existence of CPAs 
within the structure of the program pointed to both the leadership’s deep knowledge of 
the inner workings of the program, but also to the success of the formal CPAs 
themselves. 
Informal Teamwork 
Formal teamwork identified each individual team members’ role and function.  In 
contrast, informal teamwork was not formulated or codified by clinic leadership.  The 
ways that employees related to each other informally to understand each other’s skills 
was reflected in multiple data sources.  The key informal teamwork practices included 
team communication and affiliation to identify the best individuals for a specific task.  
Allowing health care providers to interpret details of the CPA to best fit the group 
dynamic was also an important feature of informal teamwork at the PBDMP.(59) 
The Program Director of the UNC program described this informal understanding 
between pharmacists and physicians, “I think our physicians have always felt like we 
have functioned very much as a team, so, we’re helping.  They recognize us as part of 
that team and they recognize how we can contribute to the goals of an ACO and so we’re 
very team-based.  And, so if the patient is seeing me and I can address some of those 
issues then I should be held accountable to try to meet some of those while the physician 
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if they are meeting with the patient then they should be responsible.”  This collaboration 
surpassed typical clinical roles and expectations by arriving at a place of mutual respect 
between physicians and pharmacists.  In many cases, identifying a team leader at the 
outpatient clinical pharmacy programs was a simple process due to the small number of 
team members and division of labor.  Data showed that delineating formal team 
responsibilities was identified upon team formation, and informal working relationships 
developed over time. 
The UNC Program Director identified coordinated care through informal 
teamwork as the preferred model for outpatient clinical pharmacy, “I think that’s the best 
model—to have coordinated care.  Because everybody brings their strength to the table.”  
The Clinical Group RCA diagram described “communication and affiliation” as a success 
of the PBDMP reflecting this coordination of care between employees.  In addition, the 
Pharmacist Group RCA diagram specified “team-approach” and “group dynamic” as a 
success of program delivery.  This group dynamic was reflected in the group’s 
identification of the fact that “everyone is included in different projects.”  During the 
brainstorming sessions, these self-identified groups and affiliations were described as 
informal teamwork, pointing to the importance of program communication to achieve a 
common goal. 
While the data described the positive attributes informal team dynamics brought 
to the PBDMP, there were barriers identified relating to program consistency and 
expectations between employees.  The Pharmacist Group RCA diagram reflected both the 
necessity for better provider-to-provider communication as well as patient to provider 
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communication.  The data reflected that the need for “more communication between 
providers.”  The lack of this communication between providers described a potential 
breakdown in some team communication.   
Culture of Teamwork 
 Creating a team-driven environment with mutual understanding took time for the 
outpatient clinical pharmacy programs.  The Program Director at MHC reflected on the 
struggle to create shared work practices between clinicians, “For us, I really believe it is 
still really a work in progress.  We’re always talking about it in senior staff meetings.  
We talk about it between me and my medical director and other providers.  And, part of 
my goal, I’m not getting ahead of myself, is the development of our clinical pharmacy 
practice to coincide with the medical group so that we can work as a cohesive unit—
pharmacy to medical and back and forth and share the same stories and report data that 
we collect in pharmacy back to medical through our EMR system.  So, it’s still in 
development.  There’s a lot more to put together.”  The goal to achieve collective work 
between practitioners at MHC showed a desire for a culture of teamwork and 
cooperation. 
Work culture as it related to teamwork was described by a respondent from the 
Tucson, Arizona ACO as fiefdoms, “But, medicine tends to be a bunch of tribes.  And, so 
if they practice tribal medicine, in isolation, what I call—a consensus of one—then that 
isn’t going to work.”  The ACO Interviewee 2 noted the importance of teamwork, both 
formal and informal, since a consensus of one does not create the best patient outcomes.  
The respondent continued to describe the types of work cultures present within a clinic 
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and how teamwork reflected the organization’s attitude toward inclusion, “This is all 
important when it comes to team-care.  And, so, I think El Rio does [team-care] so don’t 
be afraid to interview or start to interview all the members of a team because I think you 
miss some of the sub-culture stuff that goes on there.”  These fiefdoms were not as 
present in the key informant interview with the Program Director at UNC, “…and it [the 
UNC program] really is to enhance the care of patients in a team-based approach.  So, 
we’re not here to take the care away from the physicians, we’re here to augment that 
care.”  The augmentation rather than the replacement of care was a common theme 
throughout the interviews with outpatient clinical pharmacy programs. 
 Clear communication leading to positive teamwork was discussed in multiple 
brainstorming sessions.  The data pointed to bilingualism as a key element of teamwork 
throughout the brainstorming sessions.  Importantly, lack of complete bilingualism 
among staff members could hinder patient visits. 
The presence of bilingual staff who could communicate with Spanish-speaking 
patients was highlighted as a strong and positive characteristic of the employees in the 
PBDMP.  The independent characteristic of bilingualism itself did not lead to successful 
teamwork, but the clear communication between patients and providers and also from 
providers to other providers led to better teamwork.  However, the lack of bilingual staff 
was also specified as a barrier to program success in the Clinical Group’s and 
Administrative Group’s RCA Diagrams.  While a number of reasons could lead to this 
dissonance in the data, it is noteworthy that the vast majority of the PBDMP staff was 
bilingual.  
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Conclusion 
 Teamwork took two main forms informal and formal in the PBDMP and other 
outpatient clinical pharmacy programs.  Cohesive health care teams not only have clear 
and measurable outcomes, but also have successful division of labor and effective 
communication.(52)  The El Rio leadership created the PBDMP with clinical teams and 
measurable goals.  Together, the formal and informal teams created by BDMP leadership 
contributed to the success of the program.  The communication between team members 
supported collaboration and positive patient health outcomes.  Teamwork was repeatedly 
cited as the backbone of the program structure which directly led to the successful 
implementation of the PBDMP and the other outpatient clinical pharmacy programs.  
 
PRACTICE SIX 
Data and Data Analytics to Inform Decisions 
 
Data that Informed Decision Making 
 The clinics collected data (biometric markers, medication lists, and behaviors 
among others) based on disease profiles for a given patient population.  These profiles 
were then described within the larger disease burden framework for the clinic and 
community.  The data on patient profiles and burdens were collected using technology 
and specific forms of documentation.  Together, these data collected served as 
background for informed decision-making by clinic and program leadership.    
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Disease Profile of Patient Population  
Key informants reflected on the difficulty in understanding the needs of their 
patient populations seeking services at their clinics.  The El Rio Administrator described 
what led to the creation of the PBDMP from the patient population at El Rio, “A large 
population of unmanaged diabetics who didn’t have resources. So, most of them, you 
know, uninsured, or on ACCESS/Medicaid, so, a population in need and also, the other 
piece about the El Rio population would be majority Hispanic.”  The Administrator also 
highlighted that the PBDMP offered an opportunity to really look at culture within the 
Hispanic population to learn lessons for diabetes and other chronic disease.  Identifying a 
specific patient population with a matching disease profile in need led to the creation of 
the PBDMP. 
Multiple data platforms and tools were in use at the PBDMP showing clinic 
leadership a snapshot of the program’s patient population.  For example, NEXGEN, was 
the medical record software used by El Rio clinic-wide.  El Rio bought and installed an 
i2i Track system within the PBDMP to monitor the pre-diabetic and high risk diabetes 
patients.  The i2i system could query the patient database and produce a list of patients 
who had an A1C level over nine or another specific cut-off point.  This tool enabled the 
pharmacists and leadership in the PBDMP to specifically identify the patients in highest 
need through the NEXGEN technology.  
 While tools like i2i Track and NEXGEN are modern systems assisting clinic 
leadership to track disease within the El Rio patient population, “common sense” was 
used in 2001 when the PBDMP was created.  The El Rio Administrator described the 
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disease burden when the program began, “And, then you know once again, 2001, all the 
focus around diabetes, looking at the cost, recognizing what a serious disease it is, and 
the burden on everybody, you would have had to have been deaf blind and dumb not to 
go…problem!”  The Administrator specified that the only method for large data analysis 
before the introduction of the electronic health record was chart review.  In 2001, the 
diabetes problem was so pervasive, that the Administrator noted that all of the leadership, 
“saw [diabetes] as a problem” as well as identifying it through chart review. 
 A needs assessment was the tool employed by the UNC program to describe the 
issues facing the patient population during their program creation in 1998-1999.  The 
Program Director at UNC noted, “So, in any effort in starting new programs, you have to 
do a needs assessment and so we always look at basically the data.  So, if you go back to 
’99 that’s how they came up with diabetes, and so we looked at the top ten health issues 
with our patient population and then looked at calls and then looked at ways that we 
could implement new programs and that’s how we came to diabetes.”  Multiple key 
informants incorporated a full needs assessment or aspects of a needs assessment to 
determine population needs.  Prioritization was determined through visioning meetings 
where data about the patient population was analyzed.  This analysis was then compared 
to the program mission, objectives, and clinic goals.  A prioritization decision was made 
ensuring alignment between the data presented and program goals. 
Disease Burden 
 At El Rio, pharmacists were seen as population health managers.  The 
pharmacists were responsible for not only the diabetes care of their patients, but also to 
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keep the patients from using emergency services as a source of primary care.  The El Rio 
Administrator described this job as, “So, they’re [pharmacists] population health 
managers in that regard and analyzing the patients that are assigned to them, keeping the 
needed team members engaged as to who needs to interact with this patient.”  The 
Administrator pointed to the PBDMP as a platform for the pharmacists to engage with 
other clinicians at El Rio working to keep their patient population healthy.  As population 
health managers, clinical pharmacists employed techniques to identify the disease burden 
within their patient populations to drive decisions about treating diabetes within a specific 
community. 
The El Rio Program Director described the clinic leadership in 2001 when the 
decision was made to create an outpatient clinical pharmacy program.  The PBDMP 
Director discussed the past program director, “Although, he wasn’t gung ho when we 
first met.  I think what drove it was…definitely some of the audits… like I was going 
through my files when we moved and we had some of the audits, some of the insurance 
plans were getting back to our medical plans and administrators saying, here’s the areas 
you’re deficient in, and here’s your HEDIS scores, and here’s the benchmarks that you 
have to get to.  So they already saw a need there because they weren’t scoring as high as 
they needed to for some of these elements.  So, that I think that drove some of our 
medical director—who was very data driven.  I mean, this guy was like, you know, here’s 
where we need to improve, here’s the accountability for that.  And, so, I think he saw a 
need from the pharmacy director’s perspective, I think he really, like just understood the 
value pharmacists could bring in this type of model.  Moving away from the dispensing 
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role and actually making clinical interventions.”  In former roles, El Rio’s previous 
medical director had exposure working with pharmacists in team-based settings.  It was 
this experience and understanding of pharmacist potential that contributed to the creation 
and development of the PBDMP.  Moreover, leadership used data to identify disease 
burdens and the highest cost centers of the patient population and this led directly to 
PBDMP formation at El Rio. 
Technology 
The importance for a pharmacist to appropriately code and notate a visit with a 
patient in the PBDMP was discussed both from a financial reimbursement and data 
standpoint.  The Clinical Group noted that “PharmDs have good codes” and an excellent 
use of “hierarchy of codes.”  The clinicians described that pharmacists were both able to 
specify exactly what was covered during their visit, and code accurately in a patient 
scenario.   
Al El Rio, pharmacists were able to code the patients more precisely with a 
hierarchy of CPT codes that gave more clarity regarding a specific diagnosis than 
clinicians.  More specific codes by pharmacists contributed to payers’ understanding of 
the complexity of the population.  The fact that the clinicians also pointed to pharmacists’ 
expertise in coding expressly described the pharmacists’ command of the coding 
hierarchy.  The clinicians commended pharmacists’ precision in coding as a clinical issue 
contributing to a ‘warm hand-off’ of patients between their departments. 
Similar to i2i Track but at a larger scale, the ACO of Tucson, Arizona queried 
their databases to look for disease trends.  Interviewee 1 for the ACO noted that, “Well, 
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when we go—into it we use OptumInsight.  It identifies the high-risk patients and 
actually scores them…it’s predictive software that tells you next year’s predicted costs.  
It’s not 100% accurate, but it’s probably at least 50% accurate.  It gives you a place on 
where to start.  If the ACO defined a potential issue for a clinic under their purview of the 
potential for a high-cost event that may occur, the ACO contacts the clinic for a heads-
up.”  Interviewee 1 further described the success the ACO has had from the use of 
OptumInsight, “And, so our readmit rate in an 18 month period of time went in half.  It 
went from 18% down to 9%.”  While it is unclear if these readmit outcomes were solely 
due to the software, Interviewee 1 believed that OptumInsight was integral to their 
success. 
Interviewee 2 from the ACO of Tucson mentioned issues with care coordination 
and technology.  The collaborative effort of patient care coordination was described in 
detail, “Just to care coordination, I would say [a barrier is] the lack of interoperability, 
technology, communication, said differently: having full access to people’s EHRs and 
being able to communicate through EHRs would just be phenomenal.”  This lack of 
electronic medical record interoperability within one community could lead to continuity 
of care issues if a patient sought services at multiple medical facilities in Tucson.  In 
many cases at El Rio patients had a break in care services at El Rio and collecting 
medical records and information on a patient was challenging.  However, even with 
imperfect data, care decisions still had to be made by the pharmacists at the PBDMP. 
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Electronic Health Record (EHR) Documentation as a Data Source 
 Documentation was also identified in all of the process flow maps from the 
brainstorming groups.  In most of the process flow maps, a documentation process step 
was added after patient contact.  The Administrative Group identified the highest number 
of documentation steps, while the Clinical Group did not specify any documentation 
steps.  The Administrative Group was also the only brainstorming group that recognized 
both medical records and computer programs in the process map.  In fact, the process 
map’s documentation steps were so thorough that the computer system where the 
documentation occurred was identified.  For example, after medical reconciliation 
occurred, “Document action in EHR” was identified.  In addition, if PharmD patient 
contact was not made, a “referral in the MRS system” was specified.  This attention to 
detail for the systems in place clinic-wide reflected a wide range of knowledge of clinical 
documentation data sources.  The information generated ranging from missed opportunity 
reports to referrals within the clinic, assisted with the data analytics to form conclusions 
about the PBDMP patient experience.  
 Many of the brainstorming groups also identified issues in terms of the EHR 
reporting system.  The Clinical Group RCA diagram discussed “EMR upgrades” that had 
a “lack of effectiveness” for patient care.  In addition, the Pharmacist Group noted the 
“EHR reporting problems” over five times within the same diagram.  The group also 
identified that “Man power for IT support” was lacking.  These perceived frustrations on 
behalf of the PBDMP staff were an impediment to successful information gathering using 
all of the EHR tools available.  These obstructions to effective data necessary to drive 
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decision-making were clear in both the Clinical and Pharmacist Groups. 
 The key informant interview with the Program Director for MHC discussed the 
future of pharmacy and clinical pharmacists.  In the Program Director’s mind, the need 
for clinical pharmacy will increase in coming years, “Eventually it’s going to go to an 
ATM machine and you’re going to walk in and pick up your med by putting in an access 
code.  That’s where it’s really going.  So, pharmacy is going to stay alive and vibrant but 
it has to get into another mode which is going to be more of what we were trained to do 
anyway which is intense counseling, more monitoring and follow-up.” 
 The Administrative Group’s RCA diagram went into depth on program promotion 
and data.  The group mentioned the “National info and data,” “longitudinal data,” and 
“Not just A1C: longitudinal data” available to document the work of the program as 
successes.  The Clinical Group RCA diagram reflected the “Documentation” and 
“Award-winning program” as indicators of success of the PBDMP.   
Specifically, “Documentation” was also noted twice on the Pharmacist Group 
RCA diagram as a major success of the program.  Documentation was turned into action 
steps for the PBDMP development by creating a public record of the program processes 
and activities, further contributing to the potential data that could be used for future 
publication.  The “data base for outcomes” and “internal list serves” were also described 
as resources for the program.  The brainstorming group commented that the program 
“works up to that, not below that” in terms of “Data standardization.”  Documentation 
was discussed in all of the brainstorming groups and was highlighted as a key factor in 
determining program outcomes. 
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Conclusion 
 The data collected from the outpatient clinical pharmacy programs was important 
through all key informant interviews and brainstorming sessions.  There was a clear 
connection between the power of data to inform decision making at the PBDMP and the 
utility of software used to support the program.  The disease profile of the patient 
population was the first step in defining diabetes as an interest area for programmatic 
intervention for the outpatient clinical pharmacy programs.  The next step the clinics took 
was to identify the disease burden of the specific patient population, e.g. diabetes within a 
specific age group of patients at the PBDMP.  Within the programs, the technology and 
documentation used to streamline the work was defined in detail in the data collected.  
Many participants in the brainstorming sessions aggregated technology and 
documentation to show the potential of data gathered from the program to affect future 
reports and publications.  While some headaches were described relating to technology in 
the PBDMP, the data generated from the program was seen as immensely powerful to 
show the success of the program. 
 
Similarities and Differences Between Programs 
 While the El Rio PBDMP is the largest of the three programs—both in unique 
patient visits and staff—there are many more similarities between all three of the 
programs than differences.  The goal of each program is to provide disease state 
management for diabetes.  While the UNC and MHC programs are more fully integrated 
with multiple chronic disease state management, the main reason all three program were 
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formed was based on diabetes education and management.  Each program is downstream 
treatment-based and not focused merely on a prevention-based model since all of the 
programs treat patients who are already diagnosed with diabetes, not those at risk for 
developing diabetes.  However, the main similarity throughout all of the programs was 
the barriers for their development and implementation due directly to billing and 
reimbursement.(39)  As of April, 2014, pharmacists in Arizona have provider status in 
title only.  Pharmacists in Arizona are not listed in the health insurance code for clinical 
payment or reimbursement.   
The UNC program began in 1999, and by 2000 the clinical pharmacists received 
state-recognized provider status and could bill for patient services within a set scope of 
medication therapy management.  Accordingly, upon program inception, each clinic 
found creative ways to pay for the pharmacists working with the clinical pharmacy 
programs.  While each program envisioned their clinical pharmacists’ roles and 
responsibilities differently, the impediments to their growth and future stability are the 
same for all clinics.  While provider status in North Carolina most likely positively 
affected the rate of program growth at UNC, the program began with the same obstacles 
as El Rio and MHC.  
 The major differences, other than size and longevity of the programs, are the 
payment and reimbursement systems in each program.  At the MHC, pharmacists are 
paid on salary from the drug dispensing pharmacy.  MHC does not have dedicated staff 
that work on the diabetes management program team—the pharmacists are primarily 
drug dispensing with credentials to work clinically.  In contrast, the UNC model and the 
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El Rio model have clinical pharmacists working only for the disease state management 
programs.  These clinical sites also have specific drug dispensing pharmacists and 
clinical pharmacists on staff.  The pharmacists from UNC and El Rio are placed on salary 
from the clinic or medical system and are not primarily paid for drug dispensing.  
Moreover, many of the staff members from the UNC and El Rio programs also have 
academic appointments, and a portion of their salaries are paid for by outside entities.  
The patient volume at El Rio and UNC allows for a larger and more developed program.   
Furthermore, both the UNC and El Rio programs began with seed money from 
federal or state partners assisting with the creation of the program.  The MHC program 
began from the ground-up from within the clinic itself under the direct influence and 
guidance of the MHC Pharmacy Director.  While MHC does not consider the program in 
its current form to be a complete success, the barriers the program has overcome came 
from the internal supporters from the clinic and the program itself without any external 
financial support.(107)  These similarities and differences between the programs as it 
relates to transferability for future program implementation will be further explored in 
Chapter 5.  
Marana Health Center (MHC) 
Marana Health Center, a Federally Qualified Health Center (FQHC), provides 
integrated team-based care to patients in Marana, Arizona (about an hour drive from 
downtown Tucson) and the surrounding communities.  MHC was incorporated in 1957 
and is the oldest continuously operating community health center in Arizona.  There are 
three full-time pharmacists and five pharmacy technicians on the MHC staff.  In January, 
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2014, with guidance from El Rio, the clinical pharmacy program at MHC officially began 
by supporting clinical pharmacists to receive training and certifications for diabetes 
education and management.  Over the past five years, the MHC clinical pharmacy 
program tried to get off the ground and only in 2014 has the program succeeded in 
securing space and staff for the program.   
There are three patients receiving ‘complete’ care through the clinical pharmacy 
program, and the patient volume is not expected to increase rapidly in the coming 
months.(107)  Many other patients with diabetes receive counseling through the program, 
their medication management is not under the auspices of the pharmacists at MHC.  
There is not data to support a change in 30-day readmission data based on the small 
sample size of patients utilizing services at the clinic.  The clinical pharmacy program is 
run out of the MHC dispensing pharmacy.  There is a conference room for patient 
consults next door to the pharmacy and a smaller space cordoned off from the pharmacy 
itself for medication management and consults. 
UNC Internal Medicine Enhanced Care Program  
 The information about the University of North Carolina at Chapel Hill program 
was gathered from an interview with the Clinical Director of the UNC program.  The 
clinical pharmacy program at UNC began in 1999 based on a grant from the North 
Carolina State Medicaid program encouraging better and more frequent patient 
interaction.  The initial program was designed by physicians and was started with two 
pharmacists on staff to address disease state management through chart reviews and 
medication reconciliation with patients.  Within a few years after the program started, the 
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two pharmacists working in the program drafted a new disease state management plan 
specific for diabetes and presented the plan to the physicians running the clinic.  They 
believed the program they created would better address clinic goals and patient needs.  
The pharmacist’s disease-specific plan became the UNC Internal Medicine Enhanced 
Care Program that focuses on disease state management for over fifteen conditions 
through team-based care.  There are four clinical pharmacists (2.25 FTE clinical 
pharmacists) on staff. 
Within the first three years of existence between 2001 and 2003, the UNC program 
met and exceeded their goals for care improvement.  They improved A1C levels by one 
percentage point and blood pressure by almost 10mmHg, compared with usual care.(118)  
Recently, there is data to support a decrease in 30-day readmission rate of patients 
participating in the UNC diabetes state management program.(108)   
Today in the UNC program, pharmacists see between six to eight diabetes patients 
daily and over 800 patient visits per year.(108)  In conjunction with hypertension, 
hypothyroidism, and diabetes, among other chronic diseases, the program also focuses on 
transitions of care for patients in and out of a hospital setting.  The program has consult 
rooms shared with the Internal Medicine Department for use by program staff within the 
UNC Internal Medicine Enhanced Care Program. 
As the program is based within a university setting, the UNC program is the most 
different of the three clinical sites.  There is more leeway and potential for 
reimbursements for pharmacists due to their academic standing.  Provider status and 
reimbursement for clinical services is approached differently under the auspices of a 
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learning or teaching hospital or clinic.  Hospital-based clinics are not as limited for 
reimbursements as Federally Qualified Health Centers due to the “core provider” 
regulation mandating clinicians oversee the medication prescribing.(119)  Moreover, as 
of July 1, 2000, clinical pharmacists in North Carolina received provider recognition 
under state law and can be reimbursed for direct patient care to implement predetermined 
drug therapies as outlined by a drug therapy management program.(120) 
 
Chapter 4 Summary 
Chapter 4 highlighted the results of the analysis, by identifying six practices 
consistent across multiple data sources and settings.  The six practices that affect OCPP 
support and structure are: 1) Setting a vision and objectives, 2) Obtaining and using 
resources that support the objectives, 3) Defining the program structure of the PBDMP, 
4) Leadership taking on roles in guiding the program development, 5) Collaboration and 
teamwork between program roles and individuals, and 6) Data and data analytics to 
inform decisions.   
The practices are organized chronologically based on recommended steps for 
action on behalf of program leadership.  Chapter 5 will continue to refine guidance for 
the creation and expansion of OCPPs.  These key practices identified the actions, 
strategies, behaviors and steps program leaders and advocates employed to create and 
sustain their OCPP.  While many key informants mentioned persistent barriers to 
program execution, the practices categorized the steps taken to overcome impediments 
and create ‘best practices’ for program implementation.  The key practices also point to 
  
157
the areas of the PBDMP that were the most applicable to assist other settings interested in 
creating or expanding an OCPP.   
Chapter 5 identifies two analytic frames to understand the six practices identified 
by Chapter 4.  The categories include: 1) Organizational and Strategic Alignment and 2) 
Program Execution.  The six practices are examined together under the two categories to 
highlight the most common actions and behaviors taken by successful OCPPs.  Chapter 5 
continues the discussion of the data collected and interpretation of the findings.  Further 
lines of research and conclusions based from this research will also be provided in 
Chapter 5. 
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CHAPTER FIVE 
Discussion 
 
Introduction 
Chapter 5 focuses on the discussion and interpretation of the findings presented in 
Chapter 4.  The key findings—organized by the six key practices—and their potential 
application to the implementation guidelines, self-assessment Outpatient Clinical 
Pharmacy Program Worksheet, and management case study will be addressed.  The six 
practices are organized into two categories for further clarity: 1) Organizational and 
Strategic Alignment and 2) Program Execution.   
 Recommendations for the field of clinical pharmacy will be made in Chapter 5 as 
well as potential barriers to the outpatient clinical pharmacy program’s potential success 
in the future.  Future lines of research and persistent gaps in knowledge will also be 
identified and described.  Chapter 5 summarizes the research and key findings from the 
study and their potential application to other settings.  The chapter will conclude by 
identifying study strengths and limitations, and positing final conclusions.  
 
Study Overview 
 The growth in physician, nurse practitioner, and physician assistant supply alone 
will not be adequate to meet the demand for primary care services by 2020.(12)  Without 
a rapid growth in these clinical specialties, other members of a team-based model for 
primary health care delivery will be needed.  Creating pharmacist-inclusive collaborative 
care teams for outpatient care is a potential solution to alleviate this health care workforce 
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shortage.  The purpose of this study is to assess the viability and transferability of the 
Collaborative Drug Therapy Management (CDTM) program through a case study 
examination of the Pharmacy-Based Diabetes Management Program (PBDMP) at El Rio 
Community Health Center (El Rio) in Tucson, Arizona.   
 A quantitative-qualitative mixed-methods investigation was conducted in Tucson, 
Arizona to determine the supports and structures behind the PBDMP.  Using literature 
and document reviews, key informant interviews from El Rio, other outpatient clinical 
pharmacy programs, and the Tucson Accountable Care Organization, coupled with usage 
of tools from lean management brainstorming group sessions, the study elicited 
information about how the experience of El Rio with the PBDMP can inform nationwide 
development and implementation guidelines for the creation of an outpatient clinical 
pharmacy program (OCPP). 
The findings identified ways that the PBDMP at El Rio can inform other 
programs interested in creating an OCPP.  Key contributing factors to success were the 
inclusion and identification of organizational strategic alignment and program execution 
in the development, adoption and implementation, phases of the PBDMP.  Challenges 
inhibiting success were pharmacist provider status and reimbursement of clinical services 
provided.   
Discussion of Results 
Through careful analysis, the results from the brainstorming sessions with the 
PBDMP pharmacists and administrators and key informant interviews led to the 
identification of six common practices among the OCPPs.  The six practices identified in 
  
160
the data were: 1) Setting a vision and objectives, 2) Obtaining and using resources that 
support the objectives, 3) Defining the program structure of the PBDMP, 4) Leadership 
taking on roles in guiding the program development, 5) Collaboration and teamwork 
between program roles and individuals, and 6) Data and data analytics to inform 
decisions.  Chapter 4 discussed how these practices were identified coupled with specific 
examples of each practice.   
For the purposes of simplifying and streamlining the discussion, the data from the 
six shared practices will be discussed and compared through two larger categories—
organizational leadership and program execution.  While the categories offer further 
insight into the specific areas of data differentiation, the overarching themes of 
organizational leadership and program execution were present in almost all of the sub-
categories defined.  The different types of organizational leadership and program 
execution present in the data will be reflected in the discussion as well.  
 
Category One: Organizational Strategic Alignment:  This category is comprised of 
Practice One: Setting a vision and objectives, Practice Four: Leadership taking on roles in 
guiding the program development, and Practice Six: Data and data analytics to inform 
decisions. 
 
Category Two: Program Execution: This category is comprised of Practice Two: 
Obtaining and using resources that support the objectives, Practice Three: Defining the 
program structure of the PBDMP and Practice Five: Collaboration and teamwork 
between program roles and individuals. 
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Category One: Organizational Leadership 
How Leadership Affected Program Adoption and Implementation 
As noted, this category is comprised of three shared practices: Practice One: 
Setting a vision and objectives; Practice Four: Leadership taking on roles in guiding the 
program development; and Practice Six: Data and data analytics to inform decisions.  
Many of the shared practices were managed or influenced by organizational leadership, 
which in turn, directly affected program adoption and implementation.  Through culture, 
direct action, and guidance, leaders were able to support and encourage aspects of the 
PBDMP and other OCPPs during program creation and adoption. 
The clinic leadership had the skills and experience to manage a diverse, and 
geographically dispersed group of clinicians, pharmacists, and program staff.  
Specifically, the clinic leaders had skills that related to multi-cultural staff integration, 
managing complex group dynamics, overseeing collaborative work under a CPA, and 
building understanding and trust between staff members.  Most importantly, these clinic 
leaders excelled in shared decision-making.  According to the CDC, the infrastructure 
and process changes that are necessary to implement a pharmacist-inclusive CPA model 
include: patient education, practice models, and business models.(59)  Leaders must keep 
well-informed medical and pharmacy teams, create an expectation for collaboration of 
the health care teams, and ensure the business model is scalable, sustainable, and 
profitable.(59)  These leadership skills, among others, outlined by the CDC are necessary 
to develop and implement a successful CPA agreement.  The consensus building and 
shared decision-making skills of the leaders studied in this research was also noteworthy.  
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In each of the three programs studied, the clinic leadership either identified an 
individual to run the proposed OCPP or to assist in identification of clinic needs.  These 
program directors were influential in developing a specific program with seamless 
pharmacist integration.  The preferred model by all program directors was a centralized 
model with comprehensive collaboration among all clinic departments.  However, this 
complex integration of multiple departments within a clinic required clear 
communication of the benefits the potential program would bring, and how the program 
worked directly impact other areas of the clinic.  For example, at El Rio, the director of 
the PBDMP met with heads of the Family Medicine and Internal Medicine Departments 
to describe the program, benefits to the patients and providers enrolled in the program, 
and how the PBDMP would contribute to patients’ control of their diabetes.  Initially, it 
was optional for practitioners to refer patients to the program.  However after a few years 
of the program’s existence, with data showing improved outcomes for patients enrolled in 
the program, clinicians could no longer opt-out of referring to the PBDMP. 
One of the first activities that the clinic leadership accomplished was to establish 
a long-term vision with broad objectives.  While this is a typical task for clinical 
programs under development, the leaders from the clinical sites studied leveraged these 
opportunities to include stakeholders from the community and at all levels of the clinic to 
support the goals of the OCPP.  The leaders continued to keep the clinic administrators 
in-the-loop (formally and informally) with program changes so that the buy-in the leaders 
garnered from the administrators was sustained throughout program adoption and 
implementation.(121)  The leaders of each OCPP were able to apply a CDTM model to 
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their respective clinics while also engaging all members of their team for their buy-in 
before a decision was made.  
The Asheville Project is a widely known example of a successful pharmacist-
delivered patient care in the non-federal sector.(122)  It began in 1995 as a result of a 
strategic planning committee meeting held by state pharmacy leaders.(122)  The 
Asheville Project utilized advanced practice pharmacists in North Carolina to coordinate 
diabetes state management services to people with diabetes.(34)  Similar to the findings 
from El Rio, it demonstrated that patients, providers, and managers believed aligned 
incentives and pharmacists providing health care services to patients offered a practical, 
patient-empowering and cost-effective solution to escalating health care costs.(34)  Due 
to the lessons learned from the Asheville Project, the long-term vision and objectives 
identified by El Rio were similar to the Asheville Project’s strategic visioning meeting 
before program implementation.  Alignment between the leadership’s goals and mission 
are critical for program success.(81) 
Throughout the program planning stages in all the clinic sites, clinic leadership 
and program directors were mindful of their role in facilitating and enabling information 
gathering for decision-making processes.  They understood that to keep program 
employees engaged they needed to share information, weigh the options, and engage 
program employees about intervention options.  The CDC recommends interactive 
discussions within a CPA to determine the appropriate incentives for practitioners that 
lead to meaningful process measures and outcomes for all providers involved in patient 
care.(59)  This active engagement allowed program practitioners, employees and 
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stakeholders to contribute their ideas for problem solving, while keeping the program 
vision, mission, and objectives on track.  The high degree of trust and respect among 
colleagues in each clinical site, demonstrated by clear communication between 
practitioners, contributed to the success of this management process. 
Organizational leadership directly impacting decision-making was present in each 
case site.  In the case of El Rio, organizational leadership recognized the benefit of 
sophisticated methods of information and data collection.  The clinic’s electronic medical 
records were queried to gather program statistics for high-level decision-making.  The 
clinic directors of the UNC program tasked two pharmacists in the clinic to design what 
would eventually become the UNC Internal Medicine Enhanced Care Program.  This 
shared tasking in a CPA within a set objective had positive outcomes on program 
development and creation.  Not only were the two pharmacists tasked with the program 
design engaged in the success of the program itself, they were given the option to rise to 
the leadership challenge within the UNC clinical setting.  Other studies on organizational 
leadership have found that ownership is a critical factor in ensuring sustained support 
during program development.(123)  The MHC clinic approached program engagement 
and leadership from a bottom-up perspective where the pharmacists from the MHC 
program taught the clinic administrators about the potential benefits of the proposed 
program. 
With the support of the top leadership and continual information sharing between 
clinic and program leadership about the progress of the program development, the 
program produced positive outcomes for enrolled patients.  All of the programs benefited 
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from increased information sharing, buy-in from clinic administrators to support the 
programs, and clear clinic and program objectives. 
Category One Summary 
Leadership was an important element of programmatic approval in all OCPPs 
studied.  In the case of El Rio, the clinic leadership engaged directly with program 
directors to actively reform and change the PBDMP.  The buy-in from El Rio 
administrators was integral at each stage of the PBDMP.  The data collected from the 
program outcomes at El Rio further supported the program’s effectiveness and potential.  
The data and information sharing process between program directors and clinic directors 
was used to make decisions, rather than personal opinion or experience alone. 
 
Category Two: Program Execution 
How the Program was Planned, Adopted, and Implemented through Shared Practices 
Category two is comprised of three shared practices: 1) Practice Two: Obtaining 
and using resources that support the objectives; 2) Practice Three: Defining the program 
structure of the PBDMP; and 3) Practice Five: Collaboration and teamwork between 
program roles and individuals.  All of these practices directly identified the PBDMP and 
other OCPPs’ execution and sustainability.  Funding coupled with effective teamwork 
helped guide program creation and development. 
As hypothesized, the PBDMP development and execution was effective when 
certain aspects of the “Impetus to Transform” and “Leadership” dimensions from the 
OTM were present.(81)  Specifically when clinic and program leadership were in line 
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with the program transformation goals, the PBDMP was more likely to achieve 
successful program adoption and implementation than without the OTM dimensions 
present.  While progress for program roll-out was initially slow, the buy-in and 
engagement from all levels of the clinic structure assisted in programmatic success. 
Program success was directly tied to support, both financial and non-financial 
from the clinic leadership.  The implications from obtaining financial stability were 
posited as a major barrier to program creation, expansion, and sustainability.  Clinics that 
looked to make changes in diabetes care management considered multiple chronic 
disease care management models before settling on a pharmacist-inclusive program.  
After deciding on a pharmacist-inclusive CPA model, the clinics decided they would take 
on the financial burden of pharmacist salaries or a combination of program staff salaries 
with hope that the pharmacist-led initiatives would be self-sustainable in the future.   
In 2011, a collaborative project through the Connecticut Medicaid tested a 
pharmacy practice model in patients with chronic conditions.(124)  The program was a 
demonstration project where nine pharmacists worked closely with 88 Medicaid patients.  
The pharmacists identified drug therapy problems within the population totaling an 
estimated $1,123 per patient on medication claims in addition to departmental savings to 
emergency departments at the case study hospitals.(124)  The project recommended that 
future projects study pharmacist medication management services in primary care 
medical homes and explore how to expand team-based care.(124)  The case study of El 
Rio adds to the lessons learned from the Connecticut case by exploring a potential 
response to pharmacist-inclusion in team-based care.  Program execution and 
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development was a critical element for the demonstration project in Connecticut to ensure 
the data captured all of the potential drug interactions with Medicaid patients.  The six 
practices identified as the conditions present during El Rio program development and 
implementation support the recommendations made from the Medicaid Connecticut 
demonstration project. 
A common theme from the interviews regarded the clinic administrators and 
funding of a CDTM program.  It was not only buy-in from the administrators that led to 
success—there had to be money, a line item, or actual dollars spent to create a program.  
Three of the interviews discussed a cycle of trying to prove the worth of the CDTM 
program without funding or initially securing funding from an outside source to prove 
program success with the hope for the program to eventually be internally funded.  While 
not unique to this case, it was not only difficult to show success without the financial 
support of the clinic, it was then difficult to convince administrators that dedicated funds 
from the clinic would lead to similar program outcomes.(122)   
The UNC and El Rio programs both received direct seed funding or 
demonstration grants to show how an OCPP could positively affect the clinic’s diabetic 
patient population.  From funding secured externally to the clinic, they were able to prove 
their current and potential future success to subsequently garner financial support from 
the clinic administrators.  MHC received financial support through a clinic-wide HRSA 
grant to track diabetic patients.  While this patient identification ultimately turned into the 
MHC clinical pharmacy program, they never received direct funds to start an OCPP.  
MHC directly addressed this lack of seed funding as a major barrier to program execution 
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since the program had the administrative buy-in for the program, but they did not have 
enough funding to make a program sustainable.  Clinic-wide administrative support was 
important to create a sustainable OCPP, however, administrative or external financial 
support was also as important for the success of a program.  
Addressing sustainability of OCPPs is important for generalizability and 
transferability of findings from the case study at El Rio.  While lack of funding and 
financial support was identified as a major factor that could impede future program 
creation, leadership buy-in from all levels of a clinic was the most important factor for 
sustainability.  Literature suggests that collaborative meetings and information sharing 
techniques between clinic leadership and program coordinators improves the likelihood 
of a more successful program implementation.(62)  It was necessary for program creators 
to share the future vision and objective of the OCPP for diabetes care management, to the 
clinic leadership, department heads, and pharmacists.  Without this understanding of the 
potential benefit an OCPP could bring the clinic, the program would never have been 
prioritized or supported clinic-wide. 
The attitudes and knowledge of the pharmacists who lead OCPP development 
were perceived to be key characteristics of program implementation and policy 
transformation clinic-wide.  There is agreement in the literature that engaging all 
members of the CPA is an important factor to sustain the health care delivery 
offered.(5)(59)(120)(125)  It is also suggested that pharmacist-inclusive team-based care 
models can have larger impacts on chronic disease care management in a specific 
population than traditional programs that do not include pharmacists.(3) 
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The view of health care and the active participation of pharmacists in outpatient 
ambulatory care are evolving.  The value of team-based care models documented in the 
literature has increased recognition among regulators and payers.(64)(126)(17)  The 
ACCP suggests that pharmacists working in an inter-disciplinary setting with 
practitioners and other health care providers, have demonstrated that they can improve 
the effectiveness, efficacy, and safety of drug therapy by providing CDTM.(64)  
Supporting creativity and innovation through formal and informal teamwork and open 
communication during program development, created an environment of inclusion and 
transformation at El Rio. 
Category Two Summary 
The data gathered regarding program execution revolved around financial 
viability, program structure, and effective teamwork.  Engaging clinic leadership in the 
active transformation of a clinic to an OCPP was the key variable for all of the program 
directors.  Even though El Rio benefited from an administrative culture of innovation, the 
program success was hard fought by program employees and leaders.  Program execution 
was as much political capital and buy-in from likely leadership as it was an effective and 
well thought-out program.  
 
Overall Summary of Results 
Multidisciplinary models of pharmacists working in community pharmacies, VA 
medical centers, and managed care settings have been previously described in the 
literature and have documented teamwork, directed ambulatory care services and 
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increased data on outcomes as being essential to success.(122)(2)(5)(6)  This literature 
includes longitudinal projects, such as the Asheville Project, to smaller research studies 
showing clinical effectiveness of team-based care with pharmacists in HIV primary care 
and pharmacist inclusion in urban private physician practices.(122)(78)(55)  The Ashville 
Project was a leader in the clinical pharmacy field pointing to collaboration between 
providers and employers as an important element in the success of a community-based 
project.  Disease-specific pharmacist models such as an HIV primary care, pointed to 
pharmacists assisting in drug adherence and continuity of care for a disease-specific 
regimen.(78)  
 This case study produced an in-depth examination of one community health 
center addressing diabetes chronic care management through pharmacist inclusion.  The 
methodologies utilized in the study helped unearth the supports and structures present in 
the program leading to long-term sustainability and success.  Unlike earlier studies which 
focused on outcomes, this case study addressed how and why an outpatient clinical 
pharmacy program showed success and identified key practices for other programs 
looking to develop or expand a pharmacist-inclusive model of chronic disease care 
management.  As El Rio previously published multiple studies citing the effectiveness of 
pharmacists in point of care testing, diabetes care, and chronic kidney disease, this 
research explores the implementation and management process through a description of 
the environment and variables present within the clinic supporting these improvements in 
disease outcomes.(7)(65)(66) 
  
171
Translating Findings into Practice: Relational Coordination, Organizational 
Transformation, and Dynamics of Work 
 It is important to consider the relational dynamics of work while interpreting the 
findings from Chapter 4.  Each of the groups were separated out into their own peer-
based group—an Administrative, Pharmacist, and Clinical Group—yet each group 
stressed the significance of interconnected work from each segment of El Rio for a 
successful PBDMP.  One theory that successfully incorporated coordination between 
roles in a relational process is the Relational Coordination Theory. 
Relational Coordination Theory 
 According to the pioneer of the theory, Jody Gitell, “relational coordination is a 
theory for understanding the relational dynamics of coordinating work.”(121)  Gitell et al. 
(2011) base the theory on James D. Thompson’s seminal work on organizations from 
1967.(127)  Thompson argued that “effective coordination in highly interdependent task 
settings is characterized by “mutual adjustment” among participants, as outcomes from 
one task creates new information for participants performing related tasks.”(121)   
 In the context of this larger body of work, the theory of relational coordination 
offers a unique way to conceptualize and apply the relational dynamics of coordination.  
Relational coordination is defined as “a mutually reinforcing process of interaction 
between communication and relationships carried out for the purpose of task 
integration.”(51) The theory of relational coordination differentiated itself among other 
organizational research by arguing that shared knowledge or shared understandings are 
necessary but not sufficient for successful completion of a work task.(9)  
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 According to Gitell, the relational dimensions form the basis for coordinated 
collective action for participants.  The participants must: 1) be connected by 
relationships, 2) have shared goals, and 3) have mutual respect.(8)  Together these three 
relational dimensions form the basis for coordinated collective action.(128)  
Fundamentally, relational coordination differs from other relationship-based approaches 
to coordination since relational coordination focuses on relationships between roles rather 
than on relationships between unique individuals.  Gitell argues that the “coordination of 
these work relationships is the management of task interdependence and is therefore a 
fundamentally relational process.”(51)  
 Relational Coordination theory assists in describing the organizational changes 
occurring between individuals and job positions when a new program or specific task is 
introduced.  Work relationships are key factors addressing the generalizability of the El 
Rio model to other clinical settings nationwide.  Figure 10 presents the key aspects of the 
relational coordination theory.(128)  
Figure 10. Relational Coordination Theory (121)(51)  
  
 
Source: Gittell JH. Relational Coordination : Guidelines for Theory , Measurement and Analysis 
Relational Coordination : Guidelines for Theory , Measurement and Analysis. 2011. 
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The PBDMP and Relational Coordination 
 Relational Coordination offers insights into the results from the lean 
brainstorming sessions to understand the nature of work dynamics within the PBDMP.  
Since the tasks performed in the PBDMP are completed through team-based CDTM, 
these efforts to care for a patient require a relational process.  When the PBDMP was 
defined through the process mapping and RCA diagramming exercises, it became clear 
that there was “mutual adjustment” between process steps for effective patient 
coordination.  Relational coordination theories are applicable for the care providers 
partaking and coordinating work system dynamics during these processes.   
 In the case of El Rio, coordinating mechanisms described in each of the group 
process maps highlighted this mutual adjustment to best coordinate their work processes.  
For example, the referral process was a cycle between three independent clinical roles (a 
medical assistant, clinician, and pharmacist) that adjusted when a patient entered a 
different disease state.  The timing and cycle of care differed depending on a patient’s 
A1C control.  The RCA diagrams confirmed this cycle of patient care and identified the 
care team’s roles during each step of the program.  The relationships between the 
departments and individuals with different work functions were clear through the 
interconnected process of how a patient flows through the PBDMP.  Each cycle or step 
reinforced what the process or step previously identified. 
It is this shared knowledge and shared understanding of the PBDMP process that 
was necessary for the successful completion of a work task between each component of 
the organization.  While aspects of the program were defined differently either through 
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immediate steps or iterative loops, it was the mutual understanding of each participant’s 
role in the process that led to success.  The shared goals and knowledge of the program 
and process defined how the individuals communicated between different roles to 
problem-solve together.   
El Rio practiced decentralized decision-making and allowed the managers of the 
PBDMP a creative license to create a program within certain parameters.  The 
Administrators did not micro-manage the program’s day-to-day functions and instead 
focused on the big picture framework and how the PBDMP fit into the clinic’s larger 
goals.  Importantly, relational coordination focuses on relationships between roles rather 
than on relationships between unique individuals.  For example, after a referral to a 
specialist, a patient was cycled back into the PBDMP from the specialist to the 
pharmacist if their A1C levels were not under control.  The RCA diagrams and process 
maps clearly identified the coordinated nature of the different clinical roles cooperating to 
reach the goals for collective action of the PBDMP. 
The process maps created from the Pharmacist Group were an excellent example 
of positive relational coordination.  The understanding, respect, and task interdependence 
between the clinical roles was clearly delineated in the map and discussed during the 
brainstorming session. (Appendix C)  For example, one of the medical assistants 
identified a process step (e.g. a patient no-show) and then continued to move on in the 
process mapping exercise showing how it affected the pharmacist’s schedule and future 
scheduling.  A pharmacist interrupted the conversation to explain why this patient no-
show not only affected the pharmacist’s schedule but the medical assistant as well.  The 
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pharmacist explained that if there was a patient no-show, the medical assistant would 
then follow-up with the patient by sending a written letter and placing a phone call.  The 
pharmacist suggested that these steps, along with the pharmacist’s steps after a no-show, 
also be reflected in the group’s map.  This example of interconnected work and mutual 
understanding of how one action sets into motion multiple reactions within one process is 
not unique to this study, but is still important to identify in this setting.   
Creating a culture of mutual respect and understanding where all individuals 
involved in a process rely on each other for shared success is necessary for an OCPP.  
Coordinating work efforts while keeping in mind that the dynamics for these tasks may 
change depending on the setting is important when clinics are thinking about adopting a 
CDTM model for an OCPP.  Adopting a culture of interaction for communication and 
relationships to succeed in task integration is important for the implementation of a team-
based OCPP model. 
An essential element to understanding the PBDMP’s success is based in El Rio’s 
innovative culture and trust.  Literature points to health care organizations that encourage 
a culture of safety leading to high-reliability between employees.(129)  High reliability in 
a health care setting focuses on three central attributes: trust, report, and improve.(129)  
In 2001, after a series of failed programs directed at serving the high burden of diabetic 
patients at El Rio, the administration agreed to take a chance with the Pharmacy 
Department and let them create a pharmacist-based solution to the high burden of 
diabetes at the clinic.  This leap of faith and trust was part of a larger organizational 
transformation for El Rio as they shifted into an era of embracing alternative solutions 
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and open-mindedness for patient-centered solutions.  The new perspective was brought 
on due to a high number of diabetic patients seeking services at El Rio coupled with 
instrumental leadership guiding grant applications and program development.  The 
Administrator at El Rio described this transformation in the early 2000s as part of the 
new ecology of El Rio: “You know if you think about the ecology of El Rio, as a general 
rule, is that it is an organization and culture of innovation.  Let’s try new things, you 
know, as far as that kind of gathering.  There aren’t barriers in this organization to try 
new things.”  
 
Study Findings and the Connection to Existing Theory 
 Relational coordination identifies the work between individuals in the PBDMP, 
while the organizational transformation model offers insight into the transition of El Rio 
to the adoption of the PBDMP.  While it is important to understand the factors that led to 
the successful creation of the PBDMP, it is also important to recognize the 
interconnectedness of the work between those involved in the PBDMP. 
 The Organizational Transformation Model assists in the identification of the 
major stakeholders, barriers, successes, and extrapolates these findings on a macro-level 
for overall clinic or organizational transformation.  These major leadership shifts in 
direction and alignment for a program are necessary for its success.  Transformation 
occurs over time with iterative changes being sustained and spread across the 
organization, organizational transformation takes leadership, dedication, and sustained 
support to succeed.(81)  At El Rio, successful transformation occurred with the inception 
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of the PBDMP.  Successful application of relational coordination was also present 
between the participants within the program. 
During the conversations with both key informants from the PBDMP, they 
mentioned the existing culture of innovation present in the late 1990s into the early 
2000s.  New Pharmacy Directors and Medical Directors joined El Rio and made creative 
patient-centered programs their mission.  Around this same time, there was a critical 
mass of Administrators able to influence decision making in favor of innovative projects 
utilizing current staff to the top of their licensure.  When the current Administrator at El 
Rio joined the team in 2009, the PBDMP was in already place.  The PBDMP was an 
original project identified by the Administration since it reinforced employee interactions 
between task integration, relationships, and communication within the program.(121)  
Importantly, this study connects Relational Coordination Theories to the Organizational 
Transformation Model by revealing interconnected work between roles in one system 
within the larger clinical landscape of innovation.(81)(121)  
 Clinics looking to participate in a CDTM model OCPP need to identify if 
organizational transformation is needed, or if the clinic administrative and leadership 
environment would be responsive to the addition of a new clinical program.  Interested 
parties should also consider relational coordination as a major aspect of the coordinated 
work needed for a successful OCPP.  Both organizational transformation and relational 
coordination theories are applicable for all settings independent of financing, patient 
volume, or potential workforce.(81) 
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Limitations of the Study 
  
Case Study 
While it is important to understand the key similarities and differences among other 
CDTM programs studied for this analysis, this research is a case study of El Rio and its 
PBDMP.  Since case studies are naturally difficult to generalize for other settings, the 
data collected in this mixed methods study combine both findings from a specific El Rio 
case study—the process mapping and RCA diagrams of the PBDMP—with key 
informant interview transcripts from multiple study sites. An important limitation for 
generalizability for this research is due to the imbalance between the amount of 
information gathered from one clinic site, El Rio, and the other sites.    
The three clinic leaders interviewed not only have different structures, patient 
volumes, and clinical staff—they are difficult to compare to each other at any one time, 
let alone over time.  While the diversity of clinical sites adds further dimension and 
strength to the study findings, it can also be considered a variable difficult to interpret for 
study generalizability.  The patient volume of the PBDMP at El Rio is almost ten times 
the size at MHC.  The study sites and key informants interviewed were chosen 
specifically for their perceived ‘success’ in settings that were different than El Rio.  Since 
this research is not a multi-site case study, comparing these disparate programs to each 
other was not a reasonable research methodology. 
While the triangulation of the data was hindered by the lack of primary documents 
from El Rio’s PBDMP creation, the convergence of multiple data sources, use of multiple 
data collection methods, and literature describing pharmacist team-based care, increases 
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the credibility of the results.  While the sample size for this research was small, the 
findings are valid.  The El Rio case study of the PBDMP was limited to the examination 
of the seven outpatient clinics within El Rio.  Moreover, the findings reported may be 
unique only to El Rio—it has yet to be applied to other settings using the implementation 
guidelines as a blueprint for the creation of an outpatient clinical pharmacy program.   
The study’s timetable may have impacted the outcomes of the lean management 
brainstorming activities.  As previously noted, The El Rio Program Director and 
Administrator participated in a key informant interview before the group brainstorming 
sessions.  Previous exposure to the study questions may have biased their participation in 
the lean management data collection. 
 
Practical Implications and Recommendations 
 There are multiple practical implications that can be gleaned from this research 
for practice and research in the field of clinical pharmacy.  
 
Implications for Practice 
1. Team-based care and leadership are necessary features for an OCPP to possess in 
order to address the development, adoption, and maintenance of a program.   
 
2. Strong support in the form of non-financial buy-in is integral for clinics looking to 
implement an OCPP program.  Support can also be in the form of financial support, 
but the non-financial support from the internal management of the clinic is most 
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important.  Strategic buy-in and engagement from clinic leaders is integral for 
program success. 
 
3. Provider status through the Social Security Administration is an issue for current and 
future CDTM model OCPPs. The data pointed to impediments such as the lack of 
reimbursement for pharmacists affecting their engagement in clinical practice and 
future program sustainability.  Multiple RCA diagrams from the brainstorming 
sessions also cited a lack of pharmacist provider status itself as the major impediment 
to development and implementation of more outpatient clinical pharmacy programs.   
 
4. Empowering a team with members from all educational backgrounds can be a 
challenge in group dynamics.  Pharmacist-inclusive OCPP teams allow for all 
members of a group to feel comfortable to express their opinions and strive to work at 
the top of their education level.  
 
Key Findings and Additions to the Field 
 This research unearths important truths about the creation and implementation of 
OCPPs.  Prior research has consistently shown that “health care organizations should 
now be working toward facilitating an interdisciplinary team approach to address the 
needs of their patients.”(81)(51)(5)(65)  Multiple national associations of pharmacists 
have printed guides for pharmacist to pharmacist program development.  What was 
missing from the literature was a clinic-wide guide for multiple audiences—specifically 
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clinic leadership and administration.  In the 2009 ACCP report, the implications, 
questions and conclusions from their research pointed to State and Federal legislators, 
examination boards, and the healthcare system to make changes in current practice to 
support pharmacist-inclusive teams.(130)  This case study adds to the literature to 
describe the inner workings of an effective team-based care model of chronic disease 
state management.  In addition, the products and findings from this research are written 
for the lay user to address patient-centered primary care in outpatient practice. 
 The CDC’s Action Steps outlined in the 2013 report on CPA agreements, points 
to setting up inter-professional teams and “showing relevant stakeholders the value of 
aligning incentives.”(59)  This case study directly addresses this action step producing 
results on how to support the structure and function of OCPPs.  The key drivers for 
transformation at El Rio were identified through the six practices.  These practices 
coupled with recommendations for the field of clinical pharmacy in this chapter will 
hopefully guide behaviors and attitudes of administrators and policy makers when 
considering whether or not to move into the field of clinical pharmacy.   
 
Applicability to Other Outpatient Clinical Pharmacy Programs 
 The findings from this investigation that are most applicable to other settings 
include the application of the six key practices reflected in this case study.  The practices 
identify attitudes, behaviors, and factors influencing the PBDMP during formative 
program creation and implementation.  The practices attempted to determine the type of 
information or processes that would best support decision-making and the maintenance or 
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creation of OCPPs. 
One of the strengths of the PBDMP is the focus on relationships between roles 
rather than on relationships between unique individuals.  The trust in the program to 
create iterative cycles of program referrals, specific physician or clinician visits, and 
pharmacist check-ups ensures the continual checks and balances of the program from 
within the PBDMP itself, but most importantly clinic-wide for diabetic patients. 
The buy-in of the administrators and managers of the clinic is necessary for 
program development as well.  The PBDMP was created under the guidance of El Rio 
leadership ensuring their support from the beginning of the project.  An OCPP needs to 
continue to remind the Administration of its value, reach, and patient impact to confirm 
its continued existence.  The El Rio Program Director pointed to the importance of this 
Administrative buy-in: “We [pharmacists] are with patients, but not with administrators 
or the business office or all of these other things that you really have to become very 
astute at being able to do so and do it effectively.”  
 While a business manager can assist or replace a clinician-led OCPP, those 
clinicians interested in creating an OCPP need to learn how to wear two hats: 1) as a 
business manager identifying why an OCPP makes financial sense for the clinical setting 
and 2) as a clinician caring for patients and their medication therapy management.  While 
these recommendations may not be limited to a clinical setting, they are applicable to 
OCPP development and implementation. 
Using a PRECEDE roadmap to cover the Social, Epidemiological, Behavioral, 
and Ecological Assessment of the program’s clinic and patient population is helpful to 
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identify potential barriers to program adoption and implementation.  The PRECEDE 
framework points to the key elements of leadership and teamwork as the most important 
factors for program success.  OCPPs can create a planning PRECEDE roadmap, or 
another theoretical framework that fits their clinic site, to map their program like a 
behavioral intervention for an individual, but in the case of CDTM—a cultural clinic-
wide behavioral shift for a large population of uncontrolled diabetic patients.    
Based on the six practices, Table 11 describes the actionable steps program 
directors and clinic administrators can take to replicate the successes of the El Rio 
PBDMP.  
Table 11. Actionable Steps for Program Directors 
Practice Actionable Step for Program 
Development/Maintenance 
Importance for Clinical Pharmacy 
Practice One: 
Setting a vision 
and objectives 
• Set clear priorities, a vision 
statement and mission for the 
program. 
 
• The combination of these steps is 
integral for an organization’s 
success. 
• The alignment and specificity of 
mission, vision and priority 
setting is important to support 
pharmacist inclusion in team-
based care. 
Practice Two: 
Obtaining and 
using resources 
that support the 
objectives 
• Consider all potential avenues for 
support—both internal and external 
• Do not overlook current staff, 
physical space and current 
infrastructure as potential program 
supports. 
• Work to secure the non-financial 
support of clinic leadership and 
practitioners. 
• The most likely barrier for 
sustainability in most outpatient 
clinical pharmacy program 
(OCPP)s is funding.   
• Consider all current clinical 
supports and how they can be 
leveraged for external or internal 
financial support.   
Practice Three: 
Defining the 
program 
structure of 
PBDMP 
• Create a Collaborative Practice 
Agreement for formal pharmacist 
inclusion in team-based care. 
• Make sure the program vision and 
leadership are in line for program 
sustainability. 
• The specific number of OCPP 
patients is less important than the 
overall attitudes and behaviors 
around the program’s structure.  It 
is important that clinicians and 
employees support the program 
process flow. 
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Practice Four: 
Leadership 
taking on roles in 
guiding the 
program 
development 
 
• Clinic and program leaders need to 
include all employees and key 
stakeholders during program 
creation and implementation. 
• Support innovation and foster a 
culture of openness within the 
program to support staff creativity 
and problem solving.   
• Identifying the administrative 
support from the clinic leadership 
is essential for clinic-wide 
program buy-in and acceptance. 
• The more buy-in and support the 
program receives from all sectors 
of a clinic the higher the 
likelihood of program success. 
Practice Five: 
Collaboration 
and teamwork 
between program 
roles and 
individuals 
 
• Identify formal and informal 
teamwork within OCPP staff to 
support program collaboration. 
• The culture of teamwork and work 
practices were defined both through 
formal agreements, but also through 
information working relationships. 
• Clear communication between 
employees leads to better 
collaboration in formal and 
informal working relationships. 
• Supporting the informal networks 
of team-based work strengthens 
program collaboration. 
Practice Six: 
Data and data 
analytics to 
inform decisions  
 
• Data collected from the OCPP is 
important for decision-making. 
• Technology and documentation 
assist in data collection. 
• Data platforms through the use of 
electronic medical records, among 
others, assist pharmacists in the 
assessment of a patient population 
and specific health needs. 
 
Implications for Research 
1.  Utilizing a theoretical road-map like the PRECEDE portion of the PRECEDE-
PROCEED model allows researchers to uncover the layers of program development 
present in an OCPP.  Applying theoretical frameworks to work practices and program 
structures can help identify supports and structures leading to a program’s successes or 
impediments.  
 
2.  Theoretical frameworks identifying the type of transformation that occurs at clinics 
when an OCPP is adopted, like the organizational transformation model, is helpful for 
identification of current processes and future recommendations. 
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Limitations for Future Lines of Research  
 
Benchmarks and Analytics Needed 
 Examining the PBDMP and other OCPPs in the future may require new and 
different approaches to data collection and analysis.  No benchmark data presently exist 
for assessing an OCPP like the El Rio PBDMP.  Future studies should explore how to 
codify and assess an OCPP given the variation of size and patient outcomes in the field. 
 To examine patterns, structures, and support mechanisms for OCPP success, 
researchers need to expand and crystalize their definitions of success for an OCPP to best 
identify the overarching themes and aspects that make a pharmacist-inclusive program 
function well.  Clinics should create benchmarks for themselves identifying when they 
have completed a task or reached a goal.  These benchmarks should be shared through 
pharmacist trade organizations and used nationwide.  Importantly, benchmarks along 
with the most important recommendations for OCPPs are integrated into Intervention 
Guidelines in Chapter 6.  The Implementation Guidelines focus on eight key areas: 1) 
People and Human Capital, 2) Political Environment, Legislation, and Rules Regarding 
Collaborative Drug Therapy Management (CDTM) and Collaborative Practice 
Agreements (CPAs), 3) Place, Environment, Setting for a CDTM model, 4) Patients, 5) 
Benchmarking, 6) Time, 7) Support, and 8) Finances. 
Gaps in Knowledge 
In addition to better benchmarking for the field of OCPPs, it is important that 
each clinic and program decide what is most important for the patient population, and 
work to address that clinical gap in patient needs.  Disaggregating outcomes from social 
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determinants is especially difficult in a low-income patient population.  The measure of 
success and prioritization for specific programs may differ depending on the metric used.  
Higher-income patient populations may experience a difference in patient outcomes when 
compared to a lower-income population.  Incorporating these potential nuances from 
social determents in the study population is important to note in the initial needs 
assessment.  From the needs assessment, the projected patient demand and volume can be 
determined.  Social determinants may also need to be accounted for in the calculation 
used to identify patient needs and potential solutions.(114)  The lack of research on 
OCPPs and longitudinal effects of patient enrollment in pharmacist-inclusive 
collaborative practice is necessary to address the current gaps in knowledge about what 
OCPPs are able to achieve.   
Field of Clinical Pharmacy 
The lack of a solid identification of the number of clinical pharmacists practicing 
nationwide is a major limitation in the field of clinical pharmacy, impacting the potential 
scalability and feasibility of OCPPs nationwide.  It is helpful to know the number of 
pharmacists interested in practicing clinical pharmacy and not solely drug dispensing.  By 
identifying the number of individuals practicing in the outpatient field, it is easier to 
advocate for other pharmacists to join the CDTM practice in other clinical settings.   At 
the same time, the opportunities available for these pharmacists to practice clinically is 
difficult to assess.  
While the Executive Director of the APhA Foundation, Mindy Smith was able to 
estimate the number of clinical pharmacists practicing nationwide, this estimation does 
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not include the number of OCPPs nationwide.(24)  These disparate estimations make 
extrapolation challenging for this research since it is not inclusive of all the OCPP-type 
clinics or programs nationwide.  Moreover, this investigation can only estimate the 
number of pharmacists interested in practicing clinically, but cannot identify if any of 
them are already working in a semi-OCPP type or full OCPP practice.  
 
Recommendations for Clinical Pharmacy 
The field of clinical pharmacy has many hurdles ahead since there is a dearth of 
literature, statistics, and knowledge of their existence or workforce.  There are multiple 
recommendations for the field of clinical pharmacy to gain momentum and a higher 
profile. 
Workforce Estimation Issues 
The annual American Society of Health-System Pharmacists national survey 
includes multiple choice options for pharmacists to identify their scope of practice.(23)  
The areas identified for current employment include the following sections: Community, 
Health Systems, Public Administration, and Other.  All drug dispensing pharmacists and 
pharmacists working in an inpatient setting are able to identify the most appropriate 
response given these options on the survey form.  One recommendation would be to 
disaggregate the “Other” field so pharmacists working in outpatient clinical pharmacy 
would be able to identify themselves more readily.  Codes could also be added 
specifically for “Clinical Pharmacy” and “Academic” to the survey as well.(23)  
Moreover, pharmacists splitting their time between academic positions and clinical 
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pharmacy are unable to identify either of their roles accurately given the current options.  
The survey needs to allow pharmacists to identify the number of hours dedicated to each 
role so that the number of FTE hours of clinical pharmacy can be accurately calculated.  
The practice sites should be more detailed and offer specific work sites to best address 
current pharmacist workforce numbers. 
The APhA and ACCP should work with the U.S. Department of Labor (DOL) to 
identify key differences in pharmacy practice.  While the DOL estimated pharmacy 
supply based on licensure, the number of pharmacists with multiple licenses in different 
states and how they are counted in their statistics is unclear.(50)  Since ACCP defines the 
potential for a pharmacist to work in a state by the number of licenses they hold, the DOL 
estimated the number of pharmacists by their licensure number.  Reconciling these 
numbers and how pharmacists are counted for workforce estimations are paramount and 
especially important for the future of clinical pharmacy.  The statistics used to estimate 
the number of pharmacist are only as good as the data collected from the annual surveys 
and number of licensures used by APhA and the DOL. 
Patient Demand 
To identifying potential patients for an OCPP, clinics need to assess the burden of 
pre-diabetics and current diabetics.  Conducting a database query on the electronic 
medical record software or through a chart review, will usually allow a clinic to see 
which of their patients with diabetes have an A1C level over 9 indicating the number of 
uncontrolled diabetic patients enrolled at the clinic.  One approach would be to include an 
EMR dashboard notifying caregivers if a patient’s biometric markers or A1C levels reach 
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a certain level.  Estimating the need for a diabetes management program as a CDTM or 
MTM model is directly linked to the number of pre-diabetics, diabetics, and projected 
diabetics seeking services at a clinic.  The threshold level of demand to begin a program 
is site specific, but creating a baseline for comparison is important for the field of clinical 
pharmacy.  The determination of the patient demand threshold would be a major 
contribution to the field of clinical pharmacy.    
El Rio was able to estimate the projected demand for patient services based on 
current numbers of patients with diabetes.  El Rio was then able to show that diabetes 
was a major burden for primary care clinical services and create a program for patients 
and providers.  El Rio identified that the burden of diabetes was high enough to create a 
program specifically targeting all aspects of diabetes itself during one visit and not as a 
comorbid or underlying disease while seeking other services.  After trying to use 
physicians for diabetes management and then nurse case managers during “Diabetes 
Day,” El Rio was open to pharmacist-inclusive programming suggestions.  These steps 
are important to identify since estimating patient demand and appropriate program 
development can be complex depending on the patient population. 
Moreover, clinics and hospitals looking to implement an outpatient clinical 
pharmacy model need to also make estimations for the potential future demand of 
outpatient clinical pharmacy services based on chronic disease medication use and not 
only on the number of patients enrolled in a program.  The likelihood that a patient will 
develop diabetes if they have a specific disease profile may increase and impact future 
demand projections. Creating an algorithm or mechanism to determine a clinic’s current 
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and future diabetes burden would be a recommendation for the field of clinical pharmacy 
to create through future research.  In 2008, Thomas Johnson published a paper estimating 
the pharmacist workforce in 2020.(20)(38)  While it would be feasible to use a similar 
systematic review to estimate patient demand, this calculation, research, and discussion 
will hopefully be addressed in future publications by Johnson and other researchers. 
When potential OCPPs are thinking creatively about patient demand and potential 
patient volume, it may be worthwhile to consider combining an OCPP within a pre-
existing outpatient clinical model.  Integrating an OCPP within a physician, NP or PA 
clinic where patients make appointments when they are sick, or even during their weekly, 
monthly, or annual check-ups, it is conceivable that a pharmacist could be on the clinic’s 
staff to run an OCPP as part of the outpatient model.  Instead of creating a whole 
independent program as a separate entity to the clinic, one option would be to integrate it 
into outpatient family practice like at the UNC program.  For example, the key informant 
from the Tucson ACO cited an ophthalmology practice where a successful program was 
in place.  The practice offered routine ophthalmologic visits and additional services, 
within a formal program for specific disease states, were offered when needed.  Not only 
did the program save the overall practice money, the patient outcomes were successful.  
This type of program would increase patient volume for an OCPP almost immediately 
due to the high number of patients who would be able to seek their diabetes check-ups at 
the same time as their primary care clinical visits.  Since potential OCPP participant 
clinics already have a high volume of diabetic patients in their clinical care practice, 
adding a pharmacist to the team-based care may work well for specific clinics. 
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Future Lines of Research 
 This study uncovered multiple gaps that can be addressed with future research.  
While conducting the case study research within El Rio, numerous future potential 
studies became apparent within El Rio itself.  Addressing collaborative practice 
agreements in OCPPs may also add to the current literature especially due to the future 
expansion and necessary cooperation of primary caregivers in the next decade. 
El Rio 
Research participants readily suggested that this type of program analysis should 
be conducted in multiple El Rio clinical sites to see the differences among the El Rio 
program itself.  Without even comparing the PBDMP to other national programs, there 
was enough data to support a case study within a case study of the differences between 
how the PBDMP functions at the eight different El Rio locations participating in the 
PBDMP in Tucson. 
Conducting an analysis comparing the nurse care coordinator system at El Rio 
with the pharmacists working with the PBDMP may uncover areas of synergy between 
the nurses and pharmacists at El Rio.  There could be more collaboration between the 
primary care nursing staff and the pharmacists at the PBDMP to treat patients as a 
primary care team.  Adding more people to the PBDMP may not seem like a typical 
solution, but there may be an area where nurses and pharmacists could work together to 
address a patient enrolled in the PBDMP. 
Following-up with the other 16 grantees of the HRSA demonstration project 
would provide even further insight into supports and structures of OCPPs.  Comparing El 
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Rio to the other 2001 HRSA study sites could potentially add a new perspective to the 
literature of federal seed grants and OCPPs.  Identifying OCPP development within the 
clinics from other demonstration grant recipients would also be worthy of future study 
and add to the gaps in current knowledge. 
Collaborative Practice Agreements (CPAs) 
Studying an outpatient clinical pharmacy program through Collaborative Practice 
Agreements as a methodology would address a gap in the literature: comparing similar 
programs utilizing different types of licensed health care professionals.  For example, a 
study comparing a CPA agreement utilizing Nurse Practitioners as compared to a CPA 
with a pharmacist-inclusive practice would be beneficial to the field of applied team-
based care for chronic disease state management.  Studying programs based on the type 
of licenses of employees may not be as beneficial as the mechanism and methodology of 
the program itself. 
Provider Status 
A study directed at comparing all the professions without provider status that 
practice clinically would inform pharmacist provider status.  Researching clinical and 
cost-effectiveness with Naturopaths and other allied health professionals without provider 
status would address current gaps in knowledge, especially when compared to a 
pharmacist-inclusive outpatient practice model.  Conversely, studying the previous 
passage of provider status with health professionals as it relates to pharmacist provider 
status, may also be worthy of study. 
A complete case study of the most restrictive states for pharmacist collaborative 
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practice models would add to the current gaps in literature in the field of clinical 
pharmacy.  In addition, interviewing pharmacists and state legislators in Alabama and 
Delaware where the scope of practice governing pharmacists is the most restrictive may 
help define key issue areas facing pharmacists nationwide.(120)  A socio-ecological 
study addressing provider status at all layers of policy, community, and pharmacy would 
help identify the potential impediments to the passage of pharmacist provider status and 
consequences of not allowing CDTM models.   
Creating a research project that followed the path of drug dispensing pharmacists 
joining an OCPP would add a first-hand report to the literature.  A follow-up study could 
also research how to potentially combine drug-dispensing pharmacy into a pre-existing 
OCPP.  Looking to drug dispensing pharmacists for more active engagement in OCPPs is 
important for MTM and the future of chronic disease state management.  Studying the 
incorporation of drug dispensing pharmacy into an OCPP is most applicable and 
important in rural or hard to access communities where there are few pharmacists who 
cover the spectrum of disease state management.  
Patient Protection and Affordable Care Act (ACA) and Current Legislation 
 The overall goal of the ACA is for health care reform to improve patient care, 
quality and outcomes while reducing cost.  The ACA health care reform implementation 
process at the state and federal levels will continue for years to come along with ongoing 
Congressional discussions about different provisions and aspects of the law. The APhA is 
advocating for the inclusion of pharmacist-provider patient care services throughout this 
process.(131)  Numerous provisions within the law either impact directly or could impact 
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pharmacists.  The provisions directly addressing CDTM, MTM and OCPPs include 
integrated care models, transitional care models, and Accountable Care Organizations 
(ACOs).  Notably, patient-centered medical homes (PCMH) are expected to increase care 
coordination and communication that will hopefully transform primary care in the 
coming decades.(132)  CDTM models are an excellent response to ACOs seeking PCMH 
options for outpatient practice.(5) 
 Importantly, the creation of nationwide ACOs that address wellness at a 
community and not at an individual level will hopefully look to CDTM models to address 
chronic disease care management.  The ACOs interviewed for this research were very 
supportive of the PBDMP but knew that the program was not financially independent and 
received funds from the El Rio administration.  If an OCPP were able to show clinical 
and cost effectiveness, more ACOs may be more willing to look to alternative 
community-based long-term care management programs.  Future lines of research could 
focus on the potential of ACOs to fund CDTM models to address chronic disease care 
management at a population level.  
 In January 2015, two bills, H.R. 592 and S.314, were introduced in the U.S. 
House of Representatives enabling Medicare patients in medically underserved 
communities to better access health care through state licensed pharmacists.  These bills 
directly address pharmacists serving in a medication dispensing and counseling role 
similar to MTM.  Both bills could have a large potential impact for CDTM, MTM, and 
OCPP awareness and legal status nationwide.  As of July 2015, both bills are still active 
and adding co-sponsors.  While the likelihood of these bills passing both the House of 
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Representatives and Senate may be low, H.R. 592 currently has 166 co-sponsors and 
S.314 has 24 co-sponsors.(133)(134)  Moreover, while the feasibility of these bills 
serving as actual solutions may be low, it is important to recognize that language and bill 
creation around the issue of pharmacists practicing clinically is currently being debated. 
 
Transferability 
 There are many factors that influence an OCPP in their nascent stages including; 
funding, non-financial buy-in and support, establishment of a vision and mission, and a 
clinic’s impetus to transform, among others.  There were many unique contextual factors 
in each of the case sites.  As the case study methodology allows for isolation of a 
phenomenon of interest, in this investigation, the existence of clinical management 
processes served as structure and support for the CDTM model at El Rio.  Through the 
application of the PRECEDE section of the PRECEDE-PROCEED model and OTM, the 
identification of the foundational aspects of the El Rio program inception were defined. 
 The question of transferability and application to other settings was addressed 
through the identification of six common practices used across the clinical sites to 
support program execution and function.  The inclusion of multiple methodologies to 
define, adopt, and sustain an OCPP can be used in future settings seeking to expand or 
create a pharmacist-inclusive practice.   
 There are potentially multiple issues regarding transferability for this research.  
Since the patient volume of each of the three CDTM programs studied were drastically 
different, it is difficult to assess if comparing them between each other will lead to any 
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larger transferability or generalizability for future OCPPs.  While the case study 
methodology can provide a framework to study multiple organizations, groups, or 
structures, the scope of this research was to study just one case: El Rio.    
To increase potential transferability for other settings, all three data sets (the 
process mapping and RCA diagrams of the PBDMP and key informant interviews) were 
combined and analyzed together.  The question of this research was to identify the 
supports and structures of each program—the genesis of the program, impediments, 
successes, etc., and extrapolate implementation guidelines for a broader audience from 
the research.  While the programs are undeniably different, they shared similar barriers 
and successes to program adoption.   
 The pharmacy at MHC worked to prove that there was a patient population in 
need of a long-term chronic disease management program to receive clinical funding, 
while El Rio’s administrators identified that a pharmacist-inclusive demonstration grant 
would address the burden of diabetes among their patient population.  The fact that both 
clinics felt there was a need for a team-based OCPP is the key factor for transferability.  
If data is gathered and analyzed to address the question of a pharmacist-inclusive team-
based care model, it would be possible to potentially identify the benefits of pharmacists 
working with chronic disease state management.   
Perhaps the biggest challenge for OCPPs is that most clinics nationwide likely do 
not know they exist—or are even a potential solution for their chronic disease care 
management.  OCPP program adoption can be more of a question of promotion rather 
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than an issue of fit for clinics since an obstacle to program adoption is promoting OCPPs 
even as a potential clinical solution.   
 Transferability of leadership characteristics is the hardest piece of the OCPP 
model to explain and encourage in potential clinical adopters, outside of senior officials 
in clinic leadership.  Identifying leaders within an institution for day-to-day program 
execution is difficult, and then promoting OCPPs as a potential clinical option is even 
more difficult.  All of the clinics identified have undeniably charismatic leaders who 
spearheaded the entire CDTM models at their clinics.  Bottling up this leadership is 
impossible, but creating awareness about OCPPs and hoping it reaches similar leaders in 
other organizations is a potential solution. 
 This case study struggles with attributing success due to the environment in which 
the PBDMP at El Rio flourished or program structure itself.  Specifying the conditions 
and critical pathways present during the PBDMP creation and implementation were 
integral to the identification of the six practices in Chapter 4.  Disaggregating the 
presence of a supportive environment from a well-thought out program is difficult to 
analyze.  Together, these critical elements within the El Rio community coupled with a 
unique staff supported PBDMP core development.  Literature supports the idea that “the 
ability of an organization to innovate or adopt new programs will vary based on 
context.”(123)  All three case sites presented a supportive environment and staff, while 
the outcomes of each program were drastically different.  Addressing which 
characteristics are sufficient versus necessary for successful program development and 
maintenance is an area for future study. 
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Conclusions 
  Thinking ahead to 2020, the need for expanded access to primary care forces us 
to look more broadly within the healthcare system to identify opportunities to expand 
capacity to provide quality primary and preventative care services especially related to 
chronic disease care management.(5)  In response to the serious projected shortcomings 
in primary care, the U.S. can benefit from considering pharmacists as a potential source 
of support for primary care delivery and medication management.  This case study of the 
Pharmacy-Based Diabetes Management Program at El Rio Health Center contributes to 
our understanding of team-based and pharmacist-inclusive collaborative care model 
research by proposing methods for adapting the implementation and adoption of a 
collaborative drug therapy model at El Rio for nationwide guidelines.  By utilizing a 
mixed-method research approach, this study also advances the position of pharmacists 
within a clinical setting where an outpatient clinical pharmacy program is a potential 
clinical program addition. 
 The key practices and conditions that were present in all of the OCPPs studied 
included: 1) Setting a vision and objectives, 2) Obtaining and using resources that support 
the objectives, 3) Defining the program structure of the PBDMP, 4) Leadership taking on 
roles in guiding the program development, 5) Collaboration and teamwork between 
program roles and individuals, and 6) Data and data analytics to inform decisions.  The 
six key practices were best characterized by two categories of qualitative findings: 1) 
Organizational strategic alignment and 2) Program execution.  These two categories 
described how the practices interfaced with the clinics and outlined the set of behaviors 
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and actions taken to support OCPPs.   
 This study is part of a growing effort to understand how to explore pharmacist-
inclusive practices in outpatient care settings.  Derived from the PBDMP and other 
clinical sites, six practices detail the development and implementation of an outpatient 
clinical pharmacy program.  El Rio’s vision of a pharmacist-inclusive team-based care 
model from chronic disease care management provided the inspiration for this 
investigation.  Hopefully the practices can be adopted and used by other OCPPs working 
to reduce the burden of diabetes or other chronic conditions in their communities.  These 
findings point to practical implications and recommendations for how clinics can utilize 
the Intervention Guidelines and Outpatient Clinical Pharmacy Worksheet to improve 
pharmacist engagement. 
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CHAPTER SIX 
Implementation Guidelines 
 
The Implementation Guidelines for Outpatient Clinical Settings Assessing the 
Potential Integration of Pharmacist-inclusive Collaborative Drug Therapy Management 
(CDTM) are described below.  The document includes four sections: 1) Purpose of this 
document, 2) Definitions of collaborative care, 3) Responsible organizational decision 
making, and 4) Implementation guidelines. 
Purpose 
The Implementation Guidelines for Outpatient Clinical Settings Assessing the 
Potential Integration of Pharmacist-inclusive Collaborative Drug Therapy Management 
(the “principles”) have been created to provide direction and guidance to outpatient 
health care providers and administrators in identifying and advancing the potential role of 
pharmacist-inclusive chronic disease care management teams. 
These implementation guidelines provide further details on how participating 
outpatient clinical pharmacy settings will put the principles into practice.  The purpose of 
this document is to: 
• Describe a set of actions that applies and adopts the principles. 
• Provide direction for clinics on how to implement the principles. 
The principles consider the development of different versions of the implementation 
guidelines that may be tailored to specific regions or sectors. 
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Importantly, the implementation guidelines are intended to direct practitioners and 
administrators through the initial stages of development or expansion of an outpatient 
clinical pharmacy program.  The information provided in the guidelines is an overview of 
the initial requirements of an outpatient clinical pharmacy program coupled with sets of 
generalized recommendations for each category.  Table 12 elaborates on the 
recommendations by providing primary sources (books, websites, and forms) dedicated 
to specific subject areas. 
Table 12. Sources for Further Research on Outpatient Clinical Pharmacy Programs 
Organization/Division Resource Description Accessing the Resource 
Federal Resources 
Centers for Disease 
Control and Prevention 
(CDC) 
Collaborative Practice 
Agreements and Pharmacists’ 
Patent Care Services: A Resource 
for Pharmacists 
http://www.cdc.gov/dhdsp/
pubs/docs/Translational_T
ools_Pharmacists.pdf 
Veterans 
Administration (VA) 
Veterans Administration 
Handbook for Patient Aligned 
Health Care Team (PACT) 
http://www.va.gov/vhapubl
ications/ViewPublication.a
sp?pub_ID=2977 
Health Resources and 
Services Administration 
(HRSA) 
340b Pricing Programs: The 
340b pricing programs refer to 
entities that participate in 
HRSA’s drug discount program.  
Certain federal grantees, 
federally qualified health centers, 
and qualified disproportionate 
share hospitals can participate in 
this program for affordable 
medication for patients.   
http://www.hrsa.gov/opa/in
troduction.htm 
 
Centers for Medicare 
and Medicaid Services 
(CMS) 
More information on SWOT 
(Strengths, Weaknesses, and 
Opportunities and Threats) 
analyses is provided. 
https://www.cms.gov/Outr
each-and-
Education/American-
Indian-Alaska-
Native/AIAN/LTSS-
Roadmap/Step-4.html 
Medicare This website describes 
information on Medicare Part B 
and the potential for pharmacist 
reimbursements. 
http://www.medicare.gov/
what-medicare-
covers/part-b/what-
medicare-part-b-
covers.html 
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Medicaid This Medicaid website provides 
information on State 
Reimbursement Programs and 
State Prescriptions Drug 
Resources. 
http://www.medicaid.gov/
medicaid-chip-program-
information/by-
topics/benefits/prescription
-drugs/state-prescription-
drug-resources.html 
National Associations 
Association of Health-
System Pharmacists 
(AHSP) 
ASHP provides sample business 
plans, profit and loss statements, 
among other templates for 
participating clinics. 
Building a Successful 
Ambulatory Care Practice, 
A Complete Guide for 
Pharmacists 
American Pharmacy 
Association (APhA) 
For more information on creating 
a CPA agreement visit the 
American Pharmacist 
Association for directions on 
how to include key aspects of a 
pharmacist-inclusive CPA. 
http://www.pharmacist.co
m/collaborative-practice-
agreements-stimulating-
increased-integration 
American College of 
Clinical Pharmacy 
(ACCP) 
More information is provided 
regarding state policy and 
pharmacist scope of practice. 
http://www.accp.com/govt/
positionPapers.aspx 
 
 
Definitions of Collaborative Care 
According to the Centers for Disease Control and Prevention (CDC), “a CPA is a 
formal agreement in which a licensed provider makes a diagnosis, supervises patient care, 
and refers patients to a pharmacist under a protocol that allows the pharmacist to perform 
specific patient care functions.”1  CPAs can be arranged between any type of licensed 
health care provider in both inpatient and outpatient settings. CPAs define certain patient 
care functions that each care provider on a team can provide autonomously under specific 
situations and conditions.2  While CPAs provide one option for increased collaboration, 
they are one of many tools used by hospital and clinical administrators to address a 
                                                        
1 Services UD of H and H. Collaborative Practice Agreements and Pharmacists’ Patient Care 
Services: A Resource for Pharmacists. US Dept Heal Hum Serv Centers Dis Control Prev 2013. 
2013. 
2 Lisa Zubkoff. Using a Virtual Breakthrough Series Collaborative to Reduce Postoperative 
Respiratory Failure in 16 Veterans Health Administration Hospitals. Jt Comm J Qual Patient Saf. 
2014;40(1). 
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patient-centered team-based approach to care.  The CDC collaborative practice 
framework is outlined in Figure 11. 
Figure 11. Framework for Successful Collaborative Practice Agreements.3  
Adapted from: Centers for Disease Control and Prevention. Collaborative Practice Agreements 
and Pharmacists’ Patient Care Services: A Resource for Pharmacists.  Atlanta, GA: US Dept. of 
Health and Human Services, Centers for Disease Control and Prevention; 2013.  
 
Many types of employment and practice agreements exist between NPs, MDs, 
and PAs, however, a Collaborative Drug Therapy Management (CDTM) Collaborative 
Practice Agreement is specific to pharmacists.  The CDTM contract identifies and 
clarifies a pharmacist’s clinical practice role when pharmacists are working with other 
clinicians in a collaborative manner.  These pharmacist-specific CPAs are the foundation 
                                                        
3 Services UD of H and H. Collaborative Practice Agreements and Pharmacists’ Patient Care 
Services: A Resource for Pharmacists. US Dept Heal Hum Serv Centers Dis Control Prev 2013. 
2013. 
Align Incentives
Patients, providers, and payers 
receive appropriate incntives 
while collabrorating to advance 
patients' health.
For patients: A product, 
service, experience, or added 
value that motivates the patient 
to take actions that will 
improve health.
For health care providers: 
Appropriate compensation for 
products and services provided.
For payers: Minimizing total 
health care expenditures while 
providing high-quality, 
necessary services.
Improve Outcomess
As pharmacists, patients, and 
others on the team work 
together, patient health 
outcomes improve.
Tracking progress and 
reporting outcomes ensures all 
members of the health care 
team involved in the patient's 
care are aware of the impact of 
the collaborative efforts.
Control Costs
The aligned incentive for 
the health care system is 
similar to that for each 
payer: control overall 
health care costs.
Improved health status 
unltimately decreases 
health care costs.
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of pharmacist-inclusive CDTM models that have been shown to reduce fragmentation of 
care4, lower health care costs, and improve a patient’s health outcomes.5 
According to the AACP, “CDTM is a team approach to healthcare delivery that 
seeks to maximize the expertise of the pharmacist and the physician in order to achieve 
optimal outcomes through appropriate medication use and enhanced patient-care 
services.”6  The Academy for Managed Care Pharmacy (AMCP) describes CDTM 
models as a formal partnership between a pharmacist and physician or group of 
pharmacists and physicians to allow the pharmacist(s) to manage a patient’s drug therapy 
autonomously.7  The CDTM designation is used primarily because it is descriptive of the 
usual scope of practice between the physician and the pharmacist; e.g. drug therapy 
management.8  
Practice Setting 
In 2010, the American Society of Health-System Pharmacists (ASHP) Section of 
Ambulatory Care Practitioners conducted a survey of ambulatory care pharmacies.  Of 
the respondents, 70 percent reported their ambulatory practice was associated with a 
hospital or health system, and 22 percent stated they practiced within a medical 
                                                        
4 Koll BS. A Collaborative to Reduce Central Line Infections The CLABs Collaborative : A 
Regionwide Effort to Improve the Quality of Care in Hospitals. Jt Comm J Qual Patient Saf. 
2008;34(12):713–23. 
5 Giberson S, Yoder S LM. Improving Patient and Health System Outcomes through Advanced 
Pharmacy Practice A Report to the U . S . Surgeon General 2011 [Internet]. Washington, DC; 
2011 p. 95. Available from: 
http://www.accp.com/docs/positions/misc/Improving_Patient_and_Health_System_Outcomes.pdf 
6 Manolakis PG, Skelton JB. AACP REPORTS Pharmacists ’ Contributions to Primary Care in 
the United States Collaborating to Address Unmet Patient Care Needs : The Emerging Role for 
Pharmacists to Address the Shortage of Primary Care Providers. 2010;74(10). 
7 AMCP. Practice Advisory on Collaborative Drug Therapy Management: Academy of Managed 
Care Pharmacy. 2012. p. 1–7. 
8 Ibid. 
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office/clinic or community health clinic.9  The most common clinics with pharmacist-
provided services identified at each practice site included, but was not limited to, 
anticoagulation (73 percent), diabetes (68 percent), hypertension (67 percent), 
hyperlipidemia (61 percent), and smoking cessation (45 percent).10  
Many of the practice sites held clinical days for disease state management while 
others identified multiple health issues and risks during one visit.  Each of the ambulatory 
practice settings brings with it particular strengths and weaknesses.  Conducting a 
strengths, weaknesses, opportunities, and threats (SWOT) analysis as you choose what 
practice model to adopt will better prepare the program for the implementation stage.   
Responsible Organizational Decision Making 
Implementation guidelines for Outpatient Clinical Settings Assessing the Potential 
Integration of Pharmacist-inclusive Collaborative Drug Therapy Management may be a 
beneficial clinical direction for outpatient settings looking to address a high burden 
population of chronic disease management.  However, the adoption of pharmacist-
inclusive practice may not be the best solution for all clinics looking to increase their 
scope, depth, or breadth of chronic disease management programming.   
Since it is difficult to assess if a CDTM-type program may work for a specific setting, 
evidence has shown that implementation guidelines can be adopted in individual 
                                                        
9 Kliethermes M. Building a Successful Ambulatory Care Practice. A Complete Guide to 
Pharmacists. Bethesda, Maryland: American Society of Health-System Pharmacists; 2012. 
10 Kliethermes M. Building a Successful Ambulatory Care Practice. A Complete Guide to 
Pharmacists. Bethesda, Maryland: American Society of Health-System Pharmacists; 2012. 
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segments.11  While integrating all aspects of the CDTM model may have the highest 
likelihood of programmatic success, there is no restriction in applying the implementation 
guidelines in parts or as a whole. 
 Clinics need to be responsible and realistic with what they think is feasible within 
a specific time frame, political environment, and financial constraints to adopt the 
implementation guidelines.  Nurse care coordination programs and physician-based 
collaborative team practices are just two of the many examples of integrated care 
management for disease state specific patients.  It is important to consider all clinical 
options before prioritizing a pharmacist-inclusive practice.  Pharmacist-inclusive CDTM 
models are one of several potentially successful programs from which a program can 
prioritize and assess programmatic fit.    
Prioritization of which implementation guidelines to adopt, when to integrate 
them, and in what order, are decisions for each specific clinic and team.  Adding locally 
relevant programmatic ‘weights’ to assist in the prioritization process may benefit the 
decision making process.  A weight could be added to a specific set or individual 
guideline if a clinic identifies it as a priority area.  There are currently no weights 
attached to any of the implementation guidelines or the worksheet.  It is recommended 
that if a clinic wants to add weights and prioritize specific aspects of the principles that 
the outpatient clinical pharmacy program worksheet—attached to these guidelines—can 
assist in identifying the areas of greatest need and highest priority.  
                                                        
11 Cranor CW, Bunting B a, Christensen DB. The Asheville Project: long-term clinical and 
economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash) 
[Internet]. 2003;43(2):173–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12688435. 
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The intervention guidelines outline a CDTM model of patients with uncontrolled 
diabetes somewhat case specific to El Rio Health Center in Tucson, Arizona.  The model 
and guidelines can be applied to any number of chronic disease states such as 
cardiovascular or endocrine disease.  
Implementation Guidelines 
1.  People and Human Capital 
• Participating clinics need to gather information about the local health care 
labor market in their community.  It will be easier to make clinic-specific 
inferences of the People and Human Capital section if the data is 
previously collected. 
• Conduct a needs assessment or market analysis to understand the gaps 
between the current level of care and the level of care that is desired. 
• Personnel needs depend on the practice model, setting, and the services 
the clinic provides, but most typically the needs are represented by direct-
care providers (i.e. pharmacists), support staff (i.e. pharmacy technicians, 
clerical staff), and administrative support. 
• Clinics need to consider the nonproductive time (e.g. such as vacation and 
education leave) by adding a 10 percent to 20 percent correction time to 
the current staffing needs estimate.12  
• Table 13 describes the Minimum Standards of Care for an Ambulatory 
Care Practice through the seven standards of ambulatory patient care. 
                                                        
12 Kliethermes M. Building a Successful Ambulatory Care Practice. A Complete Guide to 
Pharmacists. Bethesda, Maryland: American Society of Health-System Pharmacists; 2012. 
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Table 13. Minimum standards of Care for a Pharmacist-Inclusive Ambulatory Care 
Practice13 
1. Interviewing patients and caregivers to gather pertinent information for patient care 
2. Assessing the legal and clinical appropriateness of medication regimen 
3. Identifying, resolving and preventing medication-related problems 
4. Participating in pharmacotherapy decision making 
5. Educating patients and caregivers on disease, pharmacotherapy, adherence, and preventative 
health 
6. Monitoring the medication effects and patient’s health outcomes  
7. Maintaining medication profiles and other documentations 
Kliethermes M. Building a Successful Ambulatory Care Practice. A Complete Guide to 
Pharmacists. Bethesda, Maryland: American Society of Health-System Pharmacists; 2012.  
 
1.1. Pharmacists: Total Number of Pharmacists and total Pharmacist Full-Time 
Equivalent (FTE) 
• The total number of pharmacist FTE workforce in the clinic currently is 
important to assess the staffing of an outpatient clinical pharmacy 
program.   
• There are no minimum FTE hours that need to be spent on the program, 
since a pharmacist can be on an as-needed basis for difficult or 
uncontrolled patients with diabetes while working in a drug-dispensing 
capacity. 
• Participating clinics and outpatient settings need to identify the total 
number of registered and licensed pharmacists on their staff.  The total 
number of pharmacists and the FTE workforce may be different.  Keep in 
mind a pharmacists may be splitting their time between a drug 
dispensing, academic, or policy role.   
                                                        
13 Kliethermes M. Building a Successful Ambulatory Care Practice. A Complete Guide to 
Pharmacists. Bethesda, Maryland: American Society of Health-System Pharmacists; 2012. 
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• At minimum, one pharmacist is needed to support the program. 
• Understand your state’s current scope of practice and payment for 
pharmacists as they are continuously changing.  
• According to the Veterans Administration Handbook for Patient Aligned 
Health Care Team (PACT), 1 clinical pharmacist is recommended per 3 
providers.14  The guidelines also recommend 1 anticoagulation clinical 
pharmacist for every 5 clinicians.15  
1.2. Primary Care Providers: Physicians, PAs and NPs. 
• At minimum, one physician (or individual with provider status who is 
considered the primary care giver or medical home of a patient)—PA, 
NP, or physician—is needed to support the program.  This individual is 
necessary for patient continuity, diagnosis, treatment, and prescribing.   
• Under a collaborative practice agreement in many states a pharmacist can 
change medication doses of pre-prescribed medications and prescribe 
new medications, within a CPA in collaboration with a provider.  
• Providers need to be willing and able to refer patients to the CDTM 
program.  Discussing potential referral strategy with physicians and care 
providers before rolling-out a program is imperative. 
• The minimum number of primary care providers willing and able to 
participate and refer to the program: 1. 
                                                        
14 VHA Handbook 1101.10 [Internet]. [cited 2015 Mar 21]. Available from: 
http://www.va.gov/vhapublications/ViewPublication.asp?pub_ID=2977 
15 Ibid. 
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• The VA PACT guidelines recommend 3.0 FTE staff for 1 primary care 
physician per “teamlet” (provider, RN, LPN, and clerk).  Patient referrals 
stem from clinician patient visits among other referral pathways.16  
1.3. Care Team: Total Number of Pharmacy Technicians, Nutritionists, Social 
Workers, RNs, and Clinical Care Coordinators 
• The total number of clinical FTE workforce that could support the 
program is important to assess the staffing of an outpatient clinical 
pharmacy program. 
• There are no minimum FTE hours that need to be spent on the program, 
since a team member can be on an as-needed basis for uncontrolled 
diabetic patients. 
• Participating clinics and outpatient settings need to identify the total 
number of potential team members whom could be listed on the CPA.  
• The total number of care team members and their total FTE equivalent 
status will be different in every clinical setting.  Keep in mind that the 
clinical team can split their time between primary care and care 
coordination roles.  
• There is no minimum requirement for the care team—a CDTM model can 
function with only one provider and one pharmacist.   
• It is recommended that there is at least 1 clinical care team staff member 
per area (e.g. social work, nutrition, etc.). 
                                                        
16 VHA Handbook 1101.10 [Internet]. [cited 2015 Mar 21]. Available from: 
http://www.va.gov/vhapublications/ViewPublication.asp?pub_ID=2977 
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• VA PACT guidelines recommended one registered dietitian for 
approximately 6,000 patients.  The guidelines also recommend 1 social 
worker for every 2 clinicians.17  
• Participating sites should work with the clinical staff to see if there are 
nutritionists, social workers, RNs, etc. who are willing to work in the 
clinic at least part-time, if not full-time.  If the program has sufficient 
funding, hiring at least one medical assistant to assist with the patient 
volume is recommended. 
2. Political Environment, Legislation, and Rules Regarding Collaborative Drug Therapy 
Management (CDTM) and Collaborative Practice Agreements (CPAs) 
• Evaluating the political and legal environment of the state where a 
participating clinic is looking to implement the principles is necessary. 
• At minimum, one CPA needs to be in place legally supporting and 
defining the relationship between pharmacists and clinicians in the CDTM 
program. 
• There are no specific recommendations for the number of CPAs as they 
are clinic specific due to number of providers and pharmacists. 
• The CPA guidelines can be service line or disease state specific.18  
 
 
                                                        
17 VHA Handbook 1101.10 [Internet]. [cited 2015 Mar 21]. Available from: 
http://www.va.gov/vhapublications/ViewPublication.asp?pub_ID=2977 
18 Kliethermes M. Building a Successful Ambulatory Care Practice. A Complete Guide to 
Pharmacists. Bethesda, Maryland: American Society of Health-System Pharmacists; 2012. 
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2.1. Legality of CDTM 
 
• In forty-seven states in the U.S. and the territory of Guam, pharmacists 
are authorized to enter into collaborative drug therapy management 
agreements with physicians in clinical settings. 
• In forty-seven states, the District of Columbia and the territory of Guam, 
pharmacists are authorized to enter into collaborative drug therapy 
management (CDTM) agreements with physicians in clinical settings.19  
Laws and regulations permitting pharmacists to authorize either a limited 
or broad scope of drug therapy management have been adopted. 20, 21   
• As of December 2013, only Tennessee, South Carolina, Michigan, and 
Alabama did not have a law or identified legal authority condoning or 
eliminating clinical pharmacy practice.22   
• Participating clinics should reference Figure 12 which identifies state 
authorizations regarding drug therapy management by pharmacists.  For 
                                                        
19 Manolakis PG, Skelton JB. AACP REPORTS Pharmacists ’ Contributions to Primary Care in 
the United States Collaborating to Address Unmet Patient Care Needs : The Emerging Role for 
Pharmacists to Address the Shortage of Primary Care Providers *. 2010;74(10). 
20 Giberson S, Yoder S LM. Improving Patient and Health System Outcomes through Advanced 
Pharmacy Practice A Report to the U . S . Surgeon General 2011 [Internet]. Washington, DC; 
2011 p. 95. Available from: 
http://www.accp.com/docs/positions/misc/Improving_Patient_and_Health_System_Outcomes.pdf 
21 Services UD of H and H. Collaborative Practice Agreements and Pharmacists’ Patient Care 
Services: A Resource for Pharmacists. US Dept Heal Hum Serv Centers Dis Control Prev 2013. 
2013. 
22 Giberson S, Yoder S LM. Improving Patient and Health System Outcomes through Advanced 
Pharmacy Practice A Report to the U . S . Surgeon General 2011 [Internet]. Washington, DC; 
2011 p. 95. Available from: 
http://www.accp.com/docs/positions/misc/Improving_Patient_and_Health_System_Outcomes.pdf
. 
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updated listings of regulations visit the CDC: 
http://www.cdc.gov/pcd/issues/2015/14_0504.htm 
Figure 12.  Map of States with Laws Explicitly Authorizing Pharmacist Collaborative 
Practice Agreements, 201223
 
Source: Pharmacists. C for DC and PCPA and PPCSAR for. Agreements and Pharmacists’. 
Atlanta, GA US Dept Heal Hum Serv Centers Dis Control Prev 2013.  
2.2. Creating (CPAs) in clinical settings 
• Participating clinics interested in creating a team-based care model will 
need to create formal CPAs between clinicians and departments to engage 
in CDTM. 
• Every clinic and CPA will include different provisions, but the formal 
team-based care model necessitates departmental agreement as to which 
                                                        
23 Services UD of H and H. Collaborative Practice Agreements and Pharmacists’ Patient Care 
Services: A Resource for Pharmacists. US Dept Heal Hum Serv Centers Dis Control Prev 2013. 
2013. 
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aspects of patient care will be addressed as a team. 
• If CPA agreements already exist in participating clinics, amending the 
CPAs to include pharmacists as part of the clinical care team is necessary. 
3. Place, Environment, Setting for a CDTM model 
• A program needs to be housed within a physical space and organization. 
• Creating a mission or vision statement for the program is important to 
determine the optimal desired future state of the program. 
• The mission and vision of the program help identify the program so 
departmentspecific co-location can be established.24  
• At minimum, one clinical space (exam room, conference room, drug 
dispensing pharmacy private alcove or area, etc.) is needed to support the 
program. 
• While there is not specific algorithm recommended, based on the case 
study of El Rio, the recommended number of clinical exam spaces is: 2-6, 
depending on the clinical staff size, patient volume, and need. 
3.1. Clinical Program Location 
• Outpatient clinical settings include, but are not limited to: FQHCs, 
outpatient clinics within a hospital setting, public and private clinics. 
• One key aspect of a CDTM is the support structure of a larger 
organization.  The CDTM model should serve as an additional service for 
                                                        
24 Kliethermes M. Building a Successful Ambulatory Care Practice. A Complete Guide to 
Pharmacists. Bethesda, Maryland: American Society of Health-System Pharmacists; 2012. 
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patients who may need more support than what they receive with their 
primary care provider.  
• To protect patient privacy, finding a space away from other patients, 
health care providers, and the public is imperative.25  
• In the case of El Rio, a CDTM model under the auspices of a larger 
organization not only increased potential patient volume, and referring 
providers, it allowed patients to visit one clinical site for all of their 
appointments.   
3.2. Office Space 
• Participating clinics need to have a programmatic home.   
• The program can be run from one department (e.g. Family Practice, 
Internal Medicine, etc.), but it is ideal to have a separate office space for 
the program administrator.   
• Physical space needs to include all the square footage a program may 
need to conduct their services: patient care areas, waiting rooms, storage 
areas, conference and meeting rooms, restrooms, etc. 
• According to a 2009 report, the average cost for medical office space was 
$23.90 per square foot per year (or $2 per square foot per month).26  Due 
to this program expense, it is wise to make use of any available resources 
that may be at a program’s disposal in the current clinical environment: 
                                                        
25 Kliethermes M. Building a Successful Ambulatory Care Practice. A Complete Guide to 
Pharmacists. Bethesda, Maryland: American Society of Health-System Pharmacists; 2012. 
26 Ibid. 
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personnel, equipment, physical space, and supplies.27  
3.3. Conference room for education 
• Conference rooms are recommended, but not necessary to hold group 
patient education sessions. 
• Conference rooms for the program can be shared space within a clinic as 
well. 
3.4. Clinical services/exam rooms 
• Exam rooms are recommended and not necessary for program success. 
• Exam rooms are used for patient eye exams, diabetic foot checks, 
checking A1C levels, and consultation, among other uses. 
• An exam room can also be considered a segment of the drug dispensing 
pharmacy that is private and set apart from the line of patients filling or 
picking-up prescriptions. The exam room or consultation area needs to be 
secluded and big enough for both a patient and a pharmacist to converse 
with HIPAA compliance. 
• Medical supplies needed for the program should be considered as well: 
blood pressure cuffs, stethoscopes, thermometers, and weight scales 
among others.  Point-of-care testing devices should also be considered: 
INR, blood glucose, lipids, sharps waste containers, among other items. 
• Office furniture and supplies recommended include: computers, printers, 
a fax machine, exam tables, lighting, file cabinets, etc. 
                                                        
27 Ibid. 
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4. Patients 
• For program success, identifying the patient demand a patient volume is 
important to evaluate if the CDTM model program will satisfy the 
community’s needs. 
• At minimum, there needs to be at least one patient enrolled in the CDTM 
model and one pharmacist caring for that patient to constitute a program.   
• The 2010 ASHP survey found that more than half the clinics reported 
having 3,000 or fewer documented patient encounters per year, yet 23 
percent reported having more than 9,000 patient encounters per year.28  
The results demonstrate a variety of clinic types that are wide-ranging. 
• According to the VA Handbook, the recommended number of patients to 
pharmacist ratio is about 1 pharmacist per 2,000 patients.  The target 
patient volume is: 4,000-5,000 unique patient visits a year in the CDTM 
model.29  
• For an accurate estimation of patient volume and time involved in 
providing direct care clinics need to determine: 1) the number of potential 
candidates for the service, 2) the frequency and duration of visits, and 3) 
the visit completion rates. 
• Estimate that in a standard 8-hour work day pharmacists can generally 
accommodate 8-12 patients in disease management-style services and 15-
                                                        
28 Kliethermes M. Building a Successful Ambulatory Care Practice. A Complete Guide to 
Pharmacists. Bethesda, Maryland: American Society of Health-System Pharmacists; 2012. 
29 VHA Handbook 1101.10 [Internet]. [cited 2015 Mar 21]. Available from: 
http://www.va.gov/vhapublications/ViewPublication.asp?pub_ID=2977. 
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20 patients in services with more focused care (e.g. anticoagulation and 
diabetes).30  
• Table 14 describes an example direct-care pharmacist staffing needs for 
the clinical services. 
Table 14. Determining Number of Patient Monthly Visits31 
Total: 60 patients with uncontrolled diabetes 
• 80 percent will have routine visits 
every 12 weeks=48 patients every 12 
weeks, or an average of 16 patient 
visits per 4-week intervals (roughly 
12/mo) 
• 20 percent will need more frequent 
visits every 4 weeks=12 patient visits 
every 4 weeks (roughly 13/mo) 
Total: 35 patients on Warfarin (Anticoagulation medication) 
• 80 percent will have routine visits 
every 4 weeks=28 patient visits per 4 
weeks (roughly 30/mo) 
• 20 percent will need more frequent 
visits: 1 visit every 2 weeks=14 visits 
per 4 weeks (roughly 16/mo)  
Total percentages of visit frequency: 
• 48 patients (50 percent) will visit every 12 weeks 
• 40 patients (42 percent) will visit every 4 weeks 
• 7 patients (8 percent) will visit every 2 weeks 
Total monthly visits= 76 (30 for diabetes and 46 for anticoagulation) 
Kliethermes M. Building a Successful Ambulatory Care Practice. A Complete Guide to 
Pharmacists. Bethesda, Maryland: American Society of Health-System Pharmacists; 2012. 
 
4.1. Patient Demand 
• Evaluate factors that may impact the patient demand estimate such as 
changes in the local health care market or organizational emphasis on 
areas of care and government policy shifts in insurance coverage in the 
service area.32  
                                                        
30 Kliethermes M. Building a Successful Ambulatory Care Practice. A Complete Guide to 
Pharmacists. Bethesda, Maryland: American Society of Health-System Pharmacists; 2012. 
31 Ibid. 
32 Ibid. 
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• Clinics can use chart review or electronic medical records to query their 
database and see which patients have an uncontrolled A1C level over 9, 
have indicators for pre-diabetes, or are at high risk for developing 
diabetes. 
• When thinking about patient demand, it is important to consider staffing 
needs of the pharmacist care provider’s time related to activities and 
possible responsibilities such as: performing prescription refill 
authorization, reviewing laboratory results, consulting with providers, 
addressing external inquiries, precepting students, academic 
appointments, and research.33  
4.2. Patient Referrals 
• Consider whether the program service will be a mandatory referral 
system (i.e., automatic transfer of care for anticoagulation services for all 
identified patients) or referral based on physician or patient discretion 
(i.e. diabetic patients determined to be in poor control).34  
• Participating clinics need to visit with providers and clinicians within 
their clinical setting to explain how the program functions and why 
patient referrals are important to create a patient-centered medical home. 
• Describing the potential points of entry into the program is important for 
buy-in at all levels of the clinic. 
                                                        
33 Kliethermes M. Building a Successful Ambulatory Care Practice. A Complete Guide to 
Pharmacists. Bethesda, Maryland: American Society of Health-System Pharmacists; 2012. 
34 Ibid. 
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4.3. Patient Volume 
• Frequencies of patient visits are also important indicators for program 
planning.  Identifying how often a specific patient population visits the 
clinic is key data to figure out how and when patients may be able to seek 
services at the CDTM program. 
• Collect billing and financial data tied to ambulatory care visits, on the 
patient diagnoses (ICD codes), services provided, insurance/payer codes, 
and basic demographic information from the financial office in the 
clinic.35  This information is valuable for helping determine patient and 
visit volumes, but also for evaluating other aspects of the program’s 
services. 
• Consider the clinic’s ‘show’ rate for patient visits.  According to ASHP, 
this number can vary as widely as 40 percent to 75 percent depending on 
the population served.36  
• It is recommended for participating clinics to identify if diabetes is a 
major disease burden (defined as a disability-adjusted life year (DALY)37, 
that quantify the number of years lost due to disease) within the patient 
population seeking services.38  If diabetes is found to not be a major 
                                                        
35 Kliethermes M. Building a Successful Ambulatory Care Practice. A Complete Guide to 
Pharmacists. Bethesda, Maryland: American Society of Health-System Pharmacists; 2012. 
36 Ibid. 
37 A disease burden can be identified in multiple formats—a DALY is one option for this 
calculation. 
38 Yang W, Dall TM, Halder P, Gallo P, Kowal SL, Hogan PF, et al. Economic costs of diabetes 
in the U.S. in 2012. Diabetes Care. 2013;36:1033–46.  
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burden of disease, then the next step would be to analyze the data to see 
what other disease profile is more applicable: e.g. cardiovascular or 
endocrine health.   
• One DALY can be thought of as one year of healthy life lost, and the 
overall disease burden can measured as the gap between current health 
status and the ideal health status of a patient. 
• Patient volumes will ultimately determine the total time needed to 
provide direct patient care.  To connect these pieces, a clinic will need to 
determine the expected duration and frequency of visits which depends 
on the patient treatment severity and complexity as well as efficiency of 
the pharmacist provider. 
• Table 15 describes an example template for the duration of pharmacy 
visits. 
Table 15. Example Template: Duration of Pharmacy Visits39 
Appointment Type Length of Visit 
New Referral 30 minutes 
Initial Visit 30 minutes 
Regular Office Visit 20 minutes 
Phone Visit 15 minutes 
Kliethermes M. Building a Successful Ambulatory Care Practice. A Complete Guide to 
Pharmacists. Bethesda, Maryland: American Society of Health-System Pharmacists; 2012. 
 
5. Benchmarking 
• Each clinic individually needs to create benchmarks for their own 
perceived success.  Demonstrating the program’s impact is an important 
                                                        
39 Kliethermes M. Building a Successful Ambulatory Care Practice. A Complete Guide to 
Pharmacists. Bethesda, Maryland: American Society of Health-System Pharmacists; 2012. 
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component for stakeholder support financially and administratively 
within a clinic and with external granting institutions. 
• The supporting evidence for pharmacy services will also provide 
examples of possible metrics for tracking value.40  
• At minimum, data needs to be collected at baseline from enrolling 
patients in the CDTM model, and from each patient encounter. 
• There are no specific recommendations for benchmarks a clinic adopts 
for the program, however, all of the benchmarking tools are 
recommended for the clinic to collect to identify areas of strengths and 
weaknesses of their program. 
• Benchmarking data is needed for future quality improvement projects and 
recommended changes to the program.   
5.1. Tracking hospital 30 day re-admission rate to the Emergency Department (ED) 
• ED re-admission rates for diabetic patients enrolled in the program due to 
diabetic complications are important to track, since lowering the rate of ED 
admissions brings down total costs for patients and clinics.  ED visits are often 
used a metric to identify the poorest performers within a health care system.  
As most ambulatory care centers do not have an ED, these visits are an 
indicator of the patients most at-risk for illness and negative health outcomes.   
• For outpatient clinical settings, these statistics are not a financing model 
likemany hospital systems. 
                                                        
40 Kliethermes M. Building a Successful Ambulatory Care Practice. A Complete Guide to 
Pharmacists. Bethesda, Maryland: American Society of Health-System Pharmacists; 2012. 
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5.2. Lower A1C levels 
• Tracking patients with uncontrolled and unmanaged diabetes before the 
program implementation is important. 
• Use A1C levels as an indicator of program efficacy and success.   
5.3. Clinical Benchmarks Specific to Participant’s clinics 
• Each clinic needs to identify what they perceive as success data.  This 
could be a range of indicators including but not limited to: increase in 
patient volume, increase in patient demand, increase in number of clinical 
referrals, number of program staff, increased funding from the clinic, 
grants from external sources, publicity, etc. 
• This benchmarking data will be important to collect for discussions of 
program success and future funding both internally within the clinic and 
for external funders. 
• Regardless of which benchmarks a program selects, it is important to 
proactively determine the comparator data (baseline data) to demonstrate 
the program’s impact on patient services. 
6. Time 
• Time is usually not considered a financial consideration in program 
development, but is important for a CDTM model due to lengthy program 
implementation that can take up to a few years for complete program 
development. 
• At minimum, one pharmacist or FTE program manager needs to be 
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identified to be the point-person for the program internally within the 
clinic. 
• There are no specific recommendations for the number of hours or years 
that a CDTM model program should take to create and implement.  In the 
case of El Rio, program implementation spanned three years, while other 
programs are created in 6 months or 7 years.   
6.1. Project Management 
• Identifying one programmatic head (1 FTE) per clinic that is able to liaise 
between the administrative staff and clinical staff is mandatory for 
program implementation. 
• Conducting monthly meetings where all the participants in the program 
meet face-to-face are important for program morale and program 
efficiency. 
• A collaborative team should be involved in the establishment of project 
and program aims so that the influence of the various program aspects is 
optimally considered. 
6.2. Programmatic Bandwidth of Program Participants 
• Each clinic should decide how to assess each individual participant’s work 
projects by assigning their work and projects times or weights.  Assessing 
what is on each team member’s work ‘plate’ allows program tasks to be 
spread evenly among peers participating in the program. 
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• Assigning projects and tasks evenly within a program is important so that 
everyone feels invested in the program and is tasked to the fullest ability 
(and top of their educational level). 
6.3. Staff time for education 
• Integrating professional development into the program for the clinicians 
and support staff in the program is recommended. 
• Encouraging staff to teach group education sessions for patients (e.g. 
healthy eating, healthy lifestyles, etc.) are also encouraged. 
• Training staff to identify the patient population’s specific health literacy 
needs and maintain educational materials in the office space and exam 
room is an optional educational outlet for program staff and patients. 
7. Support 
• Programmatic support is defined by both financial and non-financial 
support. 
• At minimum, the political and bureaucratic support of the administrators is
 necessary for CDTM creation and implementation. 
• It is recommended for the program to gain administrative and financial 
support before program implementation. 
• There are three major steps to successfully marketing the ambulatory care 
clinic: 1) basic understanding of the customer’s behavior and their 
connection to the services offered, 2) conducting marker research to 
understand the target group’s wants and needs from the program, and 3) 
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crafting a message that will convey the value of the CDTM model 
program.41  
• Consider clinic Administrators as program customers in that a program 
needs to demonstrate that the pharmacy services fit as the best provider for 
a set of services provided by the organization. 
• CDTM program leaders need to identify, communicate, and empower the 
stakeholders internally within the program (e.g. pharmacists and clerical 
staff) and from all levels of the clinic administration. 
7.1. Clinical Support: Internal 
• Internal clinical support is categorized by: 1) financial support from within 
a participating clinic’s budget, and 2) political/ bureaucratic support within 
the clinic to increase the program profile within the clinic.   
• Financial Support: 
o Financial support: In the case of El Rio, the program received 
funding directly from the clinic administrators for the explicit 
purpose of funding an outpatient clinical pharmacy model.   
o Financial support can also come from within another department’s 
budget to assist in the creation of the program (e.g. Family 
Medicine Department pays for a diabetes program out of their 
annual departmental funding). 
 
                                                        
41 Kliethermes M. Building a Successful Ambulatory Care Practice. A Complete Guide to 
Pharmacists. Bethesda, Maryland: American Society of Health-System Pharmacists; 2012. 
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• Bureaucratic Support: 
o This refers to support offered by administrators to fight internally 
for the program’s creation or existence.  This is most likely an 
administrator who is a CDTM model ‘champion’ who is 
persuasive and effective within the clinic administration.  
o Assessing which administrator to target within the clinic is 
important as well.  Find the leader with the most in common with 
the mission and vision of the program and most to gain from a 
successful implementation of the program. 
o It is necessary that clinical managers and administrators are in 
support of the program’s creation, adoption, and implementation.   
o Collect medical literature supporting CDTM models; obtain health 
plan information (e.g. covered lives in the plan, number of 
members with high-cost chronic diseases), payer mix, average 
health care costs per member per year, and average health care 
costs per member per year for patients with certain high-cost 
chronic diseases. 
o Discussion of these costs with the Administrative team allows 
them to estimate how much the clinic could save by implementing 
a CDTM model program. Table 16 describes The Asheville Project 
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in North Carolina as an example of how program leaders can 
advocate for a CDTM model programs with Administrators.42  
Table 16. Approaching Potential Decision-Makers: The Asheville Project 
The Asheville Project, one of the most widely recognized and replicated models of CDTM 
models published outcomes data on diabetes, asthma, hypertension, and dyslipidemia 
management, all demonstrating the ability of pharmacists to decrease health care costs.  
Program leaders need to be well versed in medical literature supporting the creation of a 
CDTM model program.43  
o The Asheville Project showed a mean direct medical cost decrease of $1,200-$1,872 per 
member per year.44  
o If a given clinic had 100 members with diabetes and each member had an average of 
$5,000 in mean direct medical costs per year (total costs = $500,000), then 
implementation of the pharmacist CDTM program could decrease clinic mean direct 
medical cost to $3,128-$3,800 per member per year for patients with diabetes (total cost 
= $312,800-$380,000).45  
o This would demonstrate a potential cost savings on average of $120,000-$187,200 in 
direct medical costs per year for patients with diabetes if all members participated in the 
CDTM program.46  
Source: Kliethermes M. Building a Successful Ambulatory Care Practice. A Complete Guide to 
Pharmacists. Bethesda, Maryland: American Society of Health-System Pharmacists; 2012. 
 
• It is also important to consider the program from the patient’s perspective 
to ensure that the program will be perceived as value-added from the 
patient’s perspective. 
• Patient Support: 
o Participating clinics need to ensure that spending the clinical and 
staff time to implement these principles will be well received not 
                                                        
42 Cranor CW, Bunting B a, Christensen DB. The Asheville Project: long-term clinical and 
economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash) 
[Internet]. 2003;43(2):173–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12688435. 
43 Ibid. 
44 Ibid. 
45 Kliethermes M. Building a Successful Ambulatory Care Practice. A Complete Guide to 
Pharmacists. Bethesda, Maryland: American Society of Health-System Pharmacists; 2012.  
46 Ibid.  
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only from within the clinic’s administration but also from patients 
interested in enrolling in the program.  
7.2. Clinical Support: External 
• External program support mainly includes funding from outside the 
clinical settings.  These can include grants, contracts, etc. that can fund the 
program directly.  
• Clinics and pharmacists can apply for HRSA’s 340 B Drug Pricing 
Program that delivers medications to qualified clinics at a reduced cost 
for low-income patients. 
• Clinic Foundations can also be an excellent source of fundraising in the 
community. 
• In the case of El Rio, a relationship was built between the Pascua Yaqui 
Native American Tribe to fund one pharmacist FTE and one medical 
assistant FTE stationed within the reservation to serve the patients with 
uncontrolled diabetes within their population.  This innovative model is 
similar to a self-insured group or employer-based insurance model for 
outpatient clinical pharmacy services.  
• Publications, outspoken members of the community and high-profile 
individuals can also constitute external support for the program by 
publically and/or financially supporting the creation of the program. 
8. Finances 
• Funding a CDTM program is challenging—likely the most challenging 
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aspect of the principles for implementation guidelines.  A CDTM model 
can be financed through multiple options: internally within a clinic, from 
outside organizations, grants, among others.   
• There are no recommendations for the minimum amount of funding a 
program needs for clinical development and adoption.   
• It is recommended that the program become a line-item budget within 
either a specific medical department’s budget, or receive direct financing 
from the clinic’s managers.  As a line item, the program can be assured 
financing, clinical support, and a higher likelihood of sustainability. 
8.1. Internal Finances 
• Internally, a CDTM model program can receive line-items funding for its 
development and implementation. 
• Clinic departments can identify funds specifically awarded to the program. 
• The program can cite specific aspects of focus areas that are in line with a 
federal or large grant currently in place at the clinic and try and receive 
part of the funding for the development and implementation of the 
program. 
• Estimating Program Expenses: 
o It is important to consider all of the program’s expenses: 1) 
implementation costs (big budget, long-lasting goods), remodeling 
the physical space costs, and necessary supplies, and 2) expected 
operating expenses (labor, office, rent, and overhead). 
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o After recording the estimated total expenses for the program, 
matching the expenses with the value of the program’s service is 
the next challenge. 
• CDTM program business plans should include: a start-up expense budget, 
staffing budget, projected payer mix, a 3-5 year profit and loss statement 
showing volumes, expenses and revenues. 
8.2. External Finances 
• The program can apply for a grant from a large or small institution to 
receive funding to either create, start, and/or maintain the program. 
• The clinic or the program can apply for specific demonstration grants to 
showcase the potential power of the program.  
• The clinic can also ask for community donations to fund the program. 
8.3.  Insurance 
• Since pharmacists do not have provider status, they cannot be reimbursed 
for patient services rendered in the program. 
• Pharmacists can bill for “incident-to” billing in Medicare Part B but not in 
a FQHCs since incident to visits are already part of the all-inclusive 
payment rate in that setting.  This process is described in Figure 13. 
• There are other loopholes that are state and health plan dependent and 
programs need to identify potential areas to potential reimbursement of 
services.  
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• The potential for and degree of reimbursement for pharmacist’s clinical 
services will depend to a significant degree on the insurers and payers in 
the practice setting.  In the case of El Rio, a common range for rate of 
reimbursement for services rendered is 50 percent to 60 percent. 
• Clinicians participating in the program are able to be reimbursed for their 
clinical time through insurance plans and third party payers. 
 
Figure 13. “Incident-to Billing” and the Ambulatory Patient Care Pharmacist47 
 
Source: Kliethermes M. Building a Successful Ambulatory Care Practice. A Complete Guide to 
Pharmacists. Bethesda, Maryland: American Society of Health-System Pharmacists; 2012. 
 
 
                                                        
47 Kliethermes M. Building a Successful Ambulatory Care Practice. A Complete Guide to 
Pharmacists. Bethesda, Maryland: American Society of Health-System Pharmacists; 2012.  
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8.4. Opportunity Costs 
• The amount of staff time and energy to create, adopt, and implement a 
CDTM model program is an opportunity cost for the clinicians, 
administrators, and pharmacists.   
• Opportunity costs are an important consideration if the program 
implementation is a protracted adoption and continues over multiple years. 
 
 
  
  
234
CHAPTER SEVEN 
 
Outpatient Clinical Pharmacy Program Worksheet to Assess the  
Potential Development or Expansion of Pharmacist-Inclusive  
Collaborative Drug Therapy Management (CDTM)  
 
 The following worksheet enables clinics to identify their access to key resources 
and self-assess their perceived barriers when considering whether or not to implement or 
expand an outpatient clinical pharmacy program.  The potential audiences for the 
worksheet are the administrators at a clinic, hospital, or other facility looking to develop 
and adopt a pharmacist-inclusive practice.  The worksheet is a Google Form survey that 
allows the user to answer a series of closed-and-open-ended questions that ultimately 
provide a self-assessment of readiness and willingness for a pharmacist-inclusive 
practice.  The goal of the worksheet is to help clinics read what they perceive their own 
barriers are to implementation.  The worksheet output is a summary table of the user’s 
answers that corresponds to the implementation guidelines for generalizability and 
practice.(135)  The survey can also be printed and administered as a physical worksheet.  
The Implementation Guidelines then delineate more of the recommendations for specific 
actions to consider when implementing a CDTM model program.   
 While it is feasible to add weighted values to each entry based on the perceived 
importance of each area, one should be careful not to project what is most important in 
every setting.  The user must determine the critical areas of importance for their setting 
and add weighted values to the key outputs for program consideration.  In the future, the 
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worksheet could enable an overlay option for users to choose their weighted values per 
area or use the recommended weights for the analysis tool.  The output of the worksheet 
should be a general recommendation of where to best spend time, energy and funds to 
fully develop a collaborative pharmacist-inclusive practice. 
 The worksheet will include a description explaining how to use the tool itself and 
how to interpret the findings.  This document will accompany the worksheet for user 
reference.  An example of the description is below. 
Worksheet Description 
 The worksheet enables clinics to identify their access to key resources and self-
assess their perceived barriers when considering whether or not to implement or expand 
an outpatient clinical pharmacy program.  The worksheet can be used as a directive 
device or to develop a general recommendation of areas to address for future reference.  
The goal of the worksheet is to help you assess and evaluate the benefit and resources 
needs associated with a pharmacist-inclusive collaborative practice. The worksheet will 
ask you a series of questions in eight categories in a survey format.  Most every question 
is close-ended with multiple choice responses.  The worksheet output is a summary of 
your responses and a corresponding set of Implementation Guidelines for generalizability 
and application to your work site.  The summary table created at the end of the 
worksheet, shows projected successes of the current state of your clinic and the potential 
barriers you may encounter. 
 Open the link e-mailed to you, and begin the survey.  A link to the survey is also 
available here.  At the conclusion of the survey, your results will be sent to your e-mail 
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address provided.  Alternatively, you may print the survey and administer the worksheet 
as a physical questionnaire.  Compare the results output against the Implementation 
Guidelines for program creation, adoption, creation and maintenance.  For a more 
accurate summary output, you will need basic descriptive data regarding patient volume, 
clinic budgets and workforce.  Enjoy the worksheet, and we hope it is helpful for you and 
your clinic’s pharmacist-inclusive practice evaluation.  
Worksheet Summary Outline 
1.  People and Human Capital:  Participating clinics need to gather information about 
their community to evaluate factors that may impact the patient demand estimate such 
as changes in the local health care market or organizational emphasis on areas of care 
and government policy shifts in insurance coverage in the service area.  It will be 
easier to make clinic-specific inferences of the People and Human Capital section if 
the data is previously collected. 
1.1. Pharmacists at the Clinic: Total Number of Pharmacists and total Pharmacist 
FTE (Clinical and Dispensing Pharmacists) 
1.2. Primary Care Providers at the Clinic: Physicians, PAs and NPs. 
1.3. Clinical Care Team: Total Number of Medical Assistants, Nutritionists, Social 
Workers, RNs, and Clinical Care Coordinators 
2. Political Environment, Legislation, and Rules Regarding Collaborative Drug Therapy 
Management (CDTM) and Collaborative Practice Agreements (CPAs): Evaluating 
the political and legal environment of the state where a participating clinic is looking 
to implement the implementation guidelines is necessary. 
  
237
2.1. Legality of CDTM (For more information regarding state policy and pharmacist 
scope of practice visit the National Alliance of State Pharmacy Associations, 
NASPA: (http://www.naspa.us/). 
2.2. Creating (CPAs) in clinical settings 
3. Place, Environment, Setting for a CDTM model: A program needs to be housed 
within a physical space and organization. 
3.1. Clinical Program Location (e.g. hospital or clinical setting) 
3.2. Office Space 
3.3. Conference room for education 
3.4. Clinical services/exam rooms 
4. Patients: For program success, identifying the patent demand a patient volume is 
important to evaluate if the CDTM model program will satisfy the community’s 
needs. 
4.1. Patient Demand 
4.2. Patient Referrals 
4.3. Patient Volume 
5. Benchmarking: Each clinic individually needs to create benchmarks for their own 
perceived success.  Data on successes and failures will assist in garnering support 
financially and administratively within a clinic and with external granting institutions. 
5.1. Tracking 30 day re-admission rate to the Emergency Department (ED) 
5.2. Lower A1C levels for patients with diabetes enrolled in the program 
5.3. Clinical Benchmarks Specific to a Clinic’s pre-identified Goals 
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6. Time: A key element to successful program adoption and implementation is time.  
Time is required by those administering the program, and for the clinicians and staff 
involved directly in the program. 
6.1. Project Management and Program Leadership 
6.2. Programmatic Participation of Employees 
6.3. Staff Time for Education 
7. Support: Programmatic support is defined by both financial and non-financial 
support. 
7.1. Clinical Support: Internal 
7.2. Clinical Support: External 
8. Finances: Funding a CDTM program is challenging—likely the most challenging 
aspect of the principles for implementation guidelines.  A CDTM model can be 
financed through multiple options. 
8.1. Internal Finances 
8.2. External Finances 
8.3. Insurance (payer mix, contracting options, shared savings contracts, among 
others)  
8.4. Opportunity Costs 
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Outpatient Clinical Pharmacy Program Worksheet 
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CHAPTER EIGHT 
Teaching Case: La Esperanza Community Health Center:  
The Challenges of Disease Burden and Programmatic Planning 
 
Introduction 
It was August, 8, 2001.  Tony Galeano, Pharmacy Director of the La Esperanza 
Community Health Center in Phoenix, Arizona breathed a sigh of relief as he set down 
the monthly pharmacy reports.  His concern for the increasing number of patients with 
Type II diabetes at La Esperanza led him to compare two groups of patients who had 
uncontrolled and elevated blood sugar levels in a six-month trial program.   
The study consisted of one control group receiving regular clinical care and 
another given the program intervention.  The program intervention placed clinical 
pharmacists as the main interface with the patient, facilitating the patient visit to monitor 
and control the patient’s diabetes.  According to the American College of Clinical 
Pharmacy, a clinical pharmacist provides patient care that optimizes the use of 
medication and promotes health, wellness, and disease prevention.48  Galeano noted that 
the blood sugar levels of the patients enrolled in the intervention group were more 
controlled after participating in the study as compared to the control group. While La 
Esperanza clinic leadership supported this project, Galeano’s program was self-
motivated.  Moreover, Galeano was not convinced his trial program was making a big 
enough impact.  He needed to replicate the outcome of the study and look at other options 
                                                        
48 ACCP - Directory of Residencies, Fellowships, and Graduate Programs [Internet]. [cited 2015 
Feb 19]. Available from: http://www.accp.com/resandfel/index.aspx 
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to treat the patient population to make sure he had thoroughly evaluated the best way to 
treat the high number of diabetic patients in the most effective way possible. 
Galeano was not sure this trial study would ever come to fruition let alone show 
positive clinical results in six months.  As he shuffled through the paperwork, he could 
not pinpoint what aspect of the program had worked most effectively.  Once patients 
were diagnosed with diabetes, they were given the choice to opt into a program where 
they received face-to-face meetings with a clinical pharmacist who treated and educated 
them about their current disease state.  The program was working as Galeano’s statistics 
showed that more patients had more control of their diabetes.  The Emergency 
Department reported lower admissions due to complications with diabetes, however Tony 
did not know why.  After informally speaking with patients to better understand their 
preferences, Tony’s hypothesis was that patients simply enjoyed and preferred talking 
with pharmacists directly about medication management.  Professionally, he felt that he 
had to answer this question. 
A clinic in northwest Phoenix, serving a similar patient population, had created a 
nurse case management program for patients diagnosed with diabetes.  By all accounts 
the northwest Phoenix program was successful and Galeano wondered if the structure of 
his trial program should change in some way to provide increased benefits for La 
Esperanza patients.  Galeano considered the other options for medication management for 
the patient population with diabetes at La Esperanza.  Could there be a nurse case 
manager component to treat these patients at La Esperanza?  Should nurse case managers 
be the primary point of contact for chronic disease care management?  Galeano needed to 
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resolve how to most effectively and efficiently serve his growing population of diabetic 
patients.  What type of outpatient clinical program would best address diabetes care 
management?  Should La Esperanza expand the existing clinical pharmacist program, or 
try a new type of provider like nurse case management to address the patient population 
with diabetes?  It would not be until almost eight years later under the direction of his 
successor, Camila Anzaldua, that the future of the program would be decided. 
Background 
A 1977 graduate of the University of Arizona College of Pharmacy, Galeano 
sought to provide quality practice and service to the Phoenix community and profession.  
He deeply believed in the potential of pharmacy and pharmacists to impact community 
and ambulatory services and felt that equal access to medications and healthcare were 
inalienable rights for all Phoenicians.  After working as a drug-dispensing pharmacist at 
multiple pharmacies in the Phoenix community for over a decade, Galeano became the 
Director of the La Esperanza Community Health Center Pharmacies in January of 1998. 
As Pharmacy Director, Galeano dedicated his time and efforts to providing the 
patients of La Esperanza quality care from the pharmacists on staff and dispensing low or 
no cost medications for those patients who could not afford them.  In 1999 Galeano 
began to work with the Arizona Board of Pharmacy on a new system for remote 
pharmacy services called ScriptPro.  This telepharmacy system provided remote 
pharmacy services to the La Aldea clinical site, one of La Esperanza’s satellite clinics 
outside of Phoenix.  La Aldea mainly served hard-to-reach populations that were either 
uninsured or on Medicaid.  The ScriptPro system used a robot to pre-package tablets and 
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capsules into barcoded containers, which were then sent to the La Aldea clinic for filling 
prescriptions.  The clinic would electronically transmit prescription orders to Health 
Center pharmacists who screened, approved, and released them back to the clinic for 
filling.  Galeano and his team identified how the last step of the process would work.  He 
was deciding whether pharmacy technicians would use scanning stations for prescription 
refills, or simply receive the prefilled containers labeled with instructions for patient use. 
Galeano reveled in questions like: how do we make our patient populations 
healthier and have better access to quality services and low or no cost of medications?  
Over the next few months, Galeano built a team at La Esperanza of likeminded 
pharmacists and pharmacy technicians.  He challenged his staff to be both creative and 
find solutions to daily problems facing their clientele.  He focused on the elderly and on 
young families with linguistic, cultural, economic, and transportation-based barriers that 
hindered their access to health and pharmaceutical care.  Galeano wanted the patients to 
obtain their medications on site at a La Esperanza clinic so that a pharmacist could 
provide counseling services.  He believed that enabling patients to leave the clinic with 
prescriptions in hand would increase prescription pickup compliance and hopefully 
address underlying medical conditions. 
It was from the ScriptPro effort that Galeano realized that pharmacists had more 
to contribute to patient care than just medication dispensation.  Once it was documented 
that there was an increase in medication fulfillment and the patient population had more 
controlled diabetes using ScriptPro, Galeano worked to expand the ScriptPro program for 
a wider patient base.  To lower the cost of medications for the patient population even 
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further, Galeano applied for a low-cost medication grant from Pfizer.  By the end of 
2000, after receiving the grant from Pfizer, La Esperanza’s ScriptPro program became 
one of the largest national recipients of free pharmaceuticals from Pfizer.  Galeano 
estimated that La Esperanza annually received about a quarter of a million dollars in free 
medications from Pfizer, which was only offered to a select few community health 
centers nationally.  After implementing the ScriptPro program at all of the La Esperanza 
clinical sites, the number of prescriptions filled in the La Esperanza pharmacies increased 
over 30 percent from 1998 to 2001.  A total of about 302,000 prescriptions were filled 
using the ScriptPro program and patient meetings with pharmacists increased sixteen 
fold.  Galeano encouraged his staff of pharmacists, medical assistants, and nurses to think 
creatively about potential patient care solutions—including prescribing practices. 
Galeano’s leadership style and superior pharmacy management attracted 
pharmacy students from all over the Phoenix region and beyond.  For experience, the 
University of Arizona College of Pharmacy conducted senior rotations in La Esperanza 
pharmacies.  Pharmacy technicians from Pima Community College, Apollo College and 
Pima Medical Institute also chose to do rotations at La Esperanza where students 
received on-site experience.  This influx of students and trainees bred a culture of 
innovation and learning. 
La Esperanza Health Center 
La Esperanza Community Health Center was founded in the late 1960’s by 
Arizona State University and neighborhood activists.  The clinic founders wanted to 
bring accessible and affordable health care to Phoenicians who were “being overlooked 
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by traditional health care systems.”49  By 2001, La Esperanza consisted of three clinical 
sites and served over 20,000 unique patient visits annually—almost 54 patients per 
day.50,51,52  Over 70 percent of the patient population self-identified as Hispanic or 
Mexican-American.53  La Esperanza provided accessible and affordable health care 
primarily to underserved populations in the greater Phoenix area and southern Arizona. 
Of the patients served at La Esperanza, 76 percent reported living at or below the federal 
poverty level.54  Figure 14 describes the clinic’s organizational make-up. 
 
 
 
 
 
 
 
 
 
 
                                                        
49 About El Rio [Internet]. [cited 2014 Jan 24]. Available from: 
http://www.aphafoundation.org/sites/default/files/ckeditor/files/El Rio - Community Fact 
Sheet(1).pdf 
50 Visits with clinical pharmacists could run between 15-60 minutes depending on the needs of 
the patient. 
51 Leal S, Soto M. Pharmacists disease state management through a collaborative practice model. 
J Health Care Poor Underserved [Internet]. 2005 May [cited 2013 Dec 17];16(2):220–4. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/15937384 
52 Leal S, Soto M. Chronic kidney disease risk reduction in a Hispanic population through 
pharmacist-based disease-state management. Adv Chronic Kidney Dis [Internet]. 2008 Apr [cited 
2013 Dec 17];15(2):162–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18334241 
53 Johnson, William et. al. Evaluation of El Rio Community Health Center ’ s Pharmacy-Based 
Diabetes Disease Management Program Sponsored by and Prepared for Heinz Family 
Philanthropies. 
54Our Story | El Rio COMMUNITY HEALTH CENTER [Internet]. El Rio Community Health 
Center. 2013 [cited 2014 Jun 23]. Available from: http://www.elrio.org/about-us/our-story/ 
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Figure 14. La Esperanza Community Health Center Organizational Chart 
 
 
 
 
Development of the Collaborative Drug Therapy Management (CDTM) Project 
At the core of Galeano’s goals for the patients at La Esperanza and for Phoenix, 
was a desire to address not only the cost of medications, but also the quality of the 
interactions between pharmacists and patients with prescription education and patient 
care.  After his six month study was completed, Galeano knew that he needed to replicate 
his findings in an organized and longitudinal research project.  He had already applied for 
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a Clinical Pharmacy Demonstration Project Grant from the Office of Pharmacy Affairs 
under the U.S. Health Resources and Services Administration (HRSA)’s Healthcare 
Systems Bureau at the U.S. Department of Health 
and Human Services.  The demonstration grant 
from HRSA identified Federally Qualified Health 
Centers to run an outpatient clinical pharmacy 
program within their clinic addressing disease 
state management for one chronic disease. 
The demonstration grant’s specific 
objective was to provide comprehensive 
pharmacy services to the medically underserved 
in Phoenix, Arizona.55  Galeano specified La 
Esperanza’s diabetic patient population in the 
grant application since diabetes was the highest 
burden of chronic disease within the patient 
population at La Esperanza at that time. More 
than one third of La Esperanza’s patient population had diabetes, and almost another third 
were pre-diabetic.  Table 17 describes some of the patient disease profiles as of 2010. 
  
                                                        
55 Johnson, William et. al. Evaluation of El Rio Community Health Center ’ s Pharmacy-Based 
Diabetes Disease Management Program Sponsored by and Prepared for Heinz Family 
Philanthropies. 
What is Diabetes? 
According to the Arizona 
Department of Health Services, 
diabetes mellitus is a group of 
chronic diseases characterized by 
hyperglycemia resulting from 
defects in insulin secretion, insulin 
action, or both. Without insulin, or if 
it is ineffective in the body, glucose 
builds up in the bloodstream leading 
to diabetes.  The concentration of 
blood glucose in the blood stream is 
most often measured in 
milligrams/deciliter (mg/dl) and the 
fasting test reports normal range is 
60-100 mg/dl.  The two preeminent 
risk factors associated with diabetes 
are obesity and physical inactivity. 
Diabetes is largely a preventable and 
manageable chronic disease. People 
with well-managed diabetes have 
better clinical outcomes and reduced 
medical costs. A patient’s A1C level 
(a maker for average blood glucose 
levels) is the primary marker for 
diabetes control.  Citation: Montiel 
M. Arizona Diabetes Burden 
Report: 2011 Arizona Department of 
Health Services. 2011. 
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Table 17. La Esperanza Patient Disease Profiles, 2010 
Disease Total Number of Identified 
Patients 
Total Estimated Number of 
Patients Undiagnosed56 
Diabetes Mellitus, Total 8,629 1,350 
-Pre-Diabetes 3,597 460 
-Diabetes 5,032 890 
Hypertension 15,842 3,500 
Hypercholesterolemia 26,672 12,400 
 
Since 1995, Arizonans were increasingly feeling the effects of diabetes, and the 
patient populations at La Esperanza were no exception.  As of 2010, one in thirteen adults 
living in Arizona had diabetes—nearly 500,000.57 The estimates of the total cost of 
diabetes on Arizona totaled $3.3 billion including $2.3 billion in medical bills and more 
than $1 billion in indirect costs.58  There was an 80 percent increase in people diagnosed 
with diabetes from 1995 to 2010.59  In Arizona, African-Americans, Hispanics, American 
Indians and Asian-Americans are twice as likely to have Type 2 diabetes as non-Hispanic 
Whites.60   
Once Galeano received one of the 17 start-up grants from HRSA, he was off and 
running.  Galeano and his team set-up the HRSA grant in the same way he had organized 
his previous small sized research project at La Esperanza.  For the three year study, he 
added more patients and pharmacists to the study groups and organized the first 
outpatient clinical pharmacy program.  The program had a group of patients with diabetes 
                                                        
56 Figures estimated from 2010 data describing the current patient population seeking services at 
El Rio. 
57 Montiel M. Arizona Diabetes Burden Report: 2011 Arizona Department of Health Services. 
2011. 
58 Ibid. 
59 Ibid. 
60 Philanthropies HF, Information H. Evaluation of El Rio Community Health Center’s 
Pharmacy-Based Diabetes Disease Management Program Sponsored by and Prepared for Heinz 
Family Philanthropies. 
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who were referred to a pharmacist-overseen program.  The program monitored, tested, 
and evaluated A1C levels, foot checks, eye exams, and medication management in the 
patient population.  The program included four pharmacists with 400 diabetic patients 
seeking services.  The patients visited with the pharmacist directly before filling their 
prescriptions at the pharmacy.  Every few weeks, patients had their A1C levels checked 
by the pharmacists in a private exam room in the Internal Medicine Department.  
Operation and Management of the Program 
Patients were referred to La Esperanza’s diabetes management program by their 
physician when they had newly diagnosed or uncontrolled diabetes.  The collaborative 
practice agreements in place at La Esperanza allowed pharmacists to manage the patient’s 
medication therapy within a pre-identified scope.  During the patient visit, pharmacists 
used their understanding of medication therapy, including formulary guidelines and drug 
protocols, to make recommendations and changes in patient‘s therapy regimens.61  The 
pharmacist was responsible for monitoring a patient’s medication therapy and making 
modifications as they were needed.  The pharmacist’s role was to provide continuous 
monitoring, patient education, identification and resolution of adherence and therapy 
related concerns, as well as monitoring for actual or potential adverse drug interactions.62  
As identified during the pharmacy visits, a pharmacist could refer patients to other 
providers in the areas of ophthalmology, podiatry, nutrition or behavioral health.  
After three years, the program had made progress reducing emergency room visits 
                                                        
61 Project IMPACT: Diabetes | APhA Foundation [Internet]. [cited 2015 Mar 23]. Available from: 
http://www.aphafoundation.org/project-impact-diabetes/communities/el-rio-health-center 
62 Ibid. 
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for complications due to diabetes and increasing the number of patients with controlled 
diabetes.  All of the clinical parameters (e.g. blood pressure, A1C levels, and BMI) that 
had been monitored showed statistically significant improvements for diabetic patients 
enrolled in the pharmacist-based program as compared to a control group of diabetic 
patients not enrolled in the program.63, 64 For example, there was a decrease in negative 
drug interactions by 34 percent for patients enrolled in the program.  Data showed that 
hard to manage patients experienced lower and more stable A1C levels.  Most 
importantly, pharmacist providers included diabetes patient education during their office 
visits.  The initial demonstration project was a documented and validated success due in 
part to the providers and patients alike recognizing the program’s potential power and 
embracing it early on into the program.65  
Galeano and his team were ecstatic with the results.  The La Esperanza’s 
administrative team encouraged Galeano to develop a sustainable model program for 
patient continuity for those patients already seeking services through this grant.  Galeano 
ruminated on how he would integrate his findings from his first study and the results 
from the HRSA grant to come up with a more all-encompassing, effective, and 
sustainable program.  How could Galeano harness the effectiveness from ScriptPro, and 
                                                        
63 Leal S, Soto M. Pharmacists disease state management through a collaborative practice model. 
J Health Care Poor Underserved [Internet]. 2005 May [cited 2013 Dec 17];16(2):220–4. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/15937384 
64 Philanthropies HF, Information H. Evaluation of El Rio Community Health Center’s 
Pharmacy-Based Diabetes Disease Management Program Sponsored by and Prepared for Heinz 
Family Philanthropies. 
65 Leal S, Soto M. Pharmacists disease state management through a collaborative practice model. 
J Health Care Poor Underserved [Internet]. 2005 May [cited 2013 Dec 17];16(2):220–4. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/15937384 
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direct patient care to a larger audience?  What other options did he need to consider to 
ensure that he covered his bases?  
In the Beginning: Pharmacy-Based Diabetes Management Program (PBDMP) 
Under the direction of Tony Galeano, the Pharmacy-Based Diabetes Program 
(PBDMP) at La Esperanza officially began in August, 2004.  The HRSA-sponsored 
clinical pharmacy demonstration grant clearly showed the effectiveness of a clinical 
pharmacist working with direct patient consultations.  La Esperanza was now committed 
to hiring a clinical pharmacist and beginning a formal clinical pharmacy program.  The 
program developed slowly, initially working to augment care already provided by 
physicians.  The program expanded over the following six years and the clinical roles of 
the pharmacists were defined over time.  Clinical pharmacy roles became more defined 
regarding the patient encounter and interaction.  Pharmacists began to develop niche 
areas—bilingual pharmacists saw many 
of the Spanish-only speaking patients, 
while other pharmacists specialized in 
Native American populations seeking 
services at La Esperanza.   
The program included direct 
service and interventions for patients 
through disease state management 
including prescribing medications and in-
depth educational consults empowering 
What is Hypercholesterolemia? 
Hypercholesterolemia is the presence of 
high levels of cholesterol in the blood 
stream.  It is typically due to a combination 
of genetic and environmental factors.  
Lifestyle choices including diet, exercise, 
and tobacco smoking strongly influence the 
amount of cholesterol in a patient’s blood.  
Patients diagnosed with 
hypercholesterolemia are recommended to 
make diet modifications, and in specific 
cases, medication is prescribed to lover 
cholesterol levels. Citation: Health NI of. 
Hypercholesterolemia. US National Library 
of Medicine, National Institutes of Health, 
Department of Health & Human Services; 
2015 Mar 16 [cited 2015 Mar 23]; 
Available from: 
http://ghr.nlm.nih.gov/condition/hyperchole
sterolemia  
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patients to proactively manage their health.  This ongoing direct consultation integrated 
treatment of three related diseases: diabetes, hypercholesterolemia and hypertension.  In 
2006, after two years of existence, the program was found to be cost effective and 
clinically effective in treating diabetes (Type 1 and Type 2) and preventing hospital 
admissions.66, 67  
The leadership of La Esperanza noted that most of the decrease in total costs of 
patients was accounted for by a shift from insurance claims for the emergency 
department, inpatient and physician office visits to prescription claims.  In a comparable 
setting, mean costs for insurance claims decreased by $2,704 per patient per year in 2002 
and by $6,502 per patient per year in 2003.68  During the same period, payers realized 
decreases in total direct medical costs that ranged from $1,622 to $3,356 per patient per 
year.69  
The program included increased access to affordable pharmaceuticals, efficient 
program management, and a focus on improved patient outcomes.  Specifically, the 
clinical pharmacists at La Esperanza as well as the medical and administrative team 
determined that a diabetes-focused disease state management clinic would serve the 
                                                        
66 Johnson, William et. al. Evaluation of El Rio Community Health Center ’ s Pharmacy-Based 
Diabetes Disease Management Program Sponsored by and Prepared for Heinz Family 
Philanthropies. 
67 Leal S, Soto M. Pharmacists disease state management through a collaborative practice model. 
J Health Care Poor Underserved [Internet]. 2005 May [cited 2013 Dec 17];16(2):220–4. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/15937384 
68 Cranor CW, Bunting B a, Christensen DB. The Asheville Project: long-term clinical and 
economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash) 
[Internet]. 2003;43(2):173–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12688435 
69 Cranor CW, Bunting B a, Christensen DB. The Asheville Project: long-term clinical and 
economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash) 
[Internet]. 2003;43(2):173–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12688435 
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needs of its members.70  In 2007, the project initially hired one clinical pharmacist to 
begin the outpatient pharmacy program—Camila Anzaldua.  While Anzaldua was a 
recent clinical pharmacy graduate of the University of Arizona School of Pharmacy, she 
was committed to working with underserved Hispanic communities.  As a bilingual 
Mexican-American, Anzaldua connected well with the patient population at La 
Esperanza.   
By 2009, after five years running the PBDMP, Tony Galeano officially stepped 
down and promoted Camila Anzaldua, PharmD, into his role as Pharmacy Director.  
Galeano thought Camila was a perfect fit for the role.  She was passionate about 
medication management and diabetes patient care and took the helm of the program 
seamlessly. 
Further Development and Research on the  
Pharmacy-Based Diabetes Management Program  
In 2009, a team of researchers from 
Arizona State University and La 
Esperanza developed and implemented an 
internal case study analysis of the La 
Esperanza patients who had participated in 
the PBDMP.  The methodology included 
the identification of a few key indicators, 
                                                        
70 Leal S, Soto M. Pharmacists disease state management through a collaborative practice model. 
J Health Care Poor Underserved [Internet]. 2005 May [cited 2013 Dec 17];16(2):220–4. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/15937384 
What is Hypertension? 
Hypertension is a condition where high 
blood pressure forces blood against a 
patient’s artery walls at a high enough rates 
that it may eventually cause health 
problems, such as heart disease.   It is 
estimated that 1 in 3 U.S. adults have high 
blood pressure.   Lifestyle changes are 
recommended to decrease blood pressure, 
and medications are also available to treat 
the condition. Citation: High Blood 
Pressure (Hypertension) Information | 
cdc.gov [Internet]. [cited 2015 Mar 23]. 
Available from: 
http://www.cdc.gov/bloodpressure/ 
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development of an abstraction tool, and then data collection from the program’s data 
base.   
The first deliverable of the project was to evaluate the program’s effectiveness in 
terms of affecting utilization of emergency departments (ED) for diabetes and other 
indicated outcomes.71  After the first phase of data was collected and analyzed, the 
second variable examined by the team was cost effectiveness data of the PBDMP in 
contrast to patients diagnosed with diabetes seeking regular care at La Esperanza. 
The study team found that the La Esperanza measures of the program were 
generally superior by a relatively large amount for test and exams related to diabetes as 
compared to the ED.  The trend data showed substantial improvements in outcome 
measures in La Esperanza performance of the diabetes tests and exams over the study 
period.  This trend was accompanied by a shift from lower rates than the control group 
(regular care at La Esperanza) to higher rates and the maintenance of that superiority in 
all subsequent months of the study.   
The analysis showed average total charges were substantially lower for La 
Esperanza during the PBDMP as compared to the years prior to the program 
implementation.  The team showed that there was substantial evidence to support a 
conclusion that the La Esperanza PBDMP was effective in improving the care and, within 
stated constraints, succeeded in reducing the health care costs for the patient and clinics 
treating the patients.   
                                                        
71 Johnson, William et. al. Evaluation of El Rio Community Health Center ’ s Pharmacy-Based 
Diabetes Disease Management Program Sponsored by and Prepared for Heinz Family 
Philanthropies. 
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The area that Galeano noticed was still lacking for the pharmacists in the program 
was longitudinal care and re-entry into the program.  While most patients were successful 
at lowering biometric markers while enrolled in PBDMP services, some patients cycled 
back into the program if their diabetes was not under control.  Galeano wondered if nurse 
case managers could address this burden of patient re-admission. 
Official Collaborative Drug Therapy Management (CDTM) Recognition 
In the U.S., pharmacists are able to consult and advise patients within a limited scope of 
practice depending on state law.72  Pharmacists are not recognized as healthcare providers 
under the Social Security Administration.73  Some states do offer pharmacists limited 
scopes of prescribing power, a provider status title, and provider reimbursement 
mechanisms.74  In Arizona, pharmacists are providers in title only.  While the PBDMP 
functioned on a small scale at La Esperanza, a comprehensive pharmacist-inclusive team-
based approach to patient care was not yet legal in Arizona.   
Many types of employment and practice agreements currently exist between 
Nurse Practitioners, physicians, and Physician Assistants, however, a Collaborative Drug 
Therapy Management (CDTM) Collaborative Practice Agreement is specific to 
pharmacists.  The CDTM designation is important because it is descriptive of the usual 
scope of practice between the physician and the pharmacist; e.g. drug therapy 
                                                        
72 More information on up-to-date- pharmacist provider status regulations is available from the 
Centers for Disease Control and Prevention.   
73 Services UD of H and H. Collaborative Practice Agreements and Pharmacists’ Patient Care 
Services: A Resource for Pharmacists. US Dept Heal Hum Serv Centers Dis Control Prev 2013. 
2013. 
74 Services UD of H and H. Collaborative Practice Agreements and Pharmacists’ Patient Care 
Services: A Resource for Pharmacists. US Dept Heal Hum Serv Centers Dis Control Prev 
2013. 2013. 
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management.75  The Academy for Managed Care Pharmacy (AMCP) describes CDTM 
models as a formal partnership between a pharmacist and physician or group of 
pharmacists and physicians to allow the pharmacist(s) to manage a patient’s drug therapy 
autonomously.76  
Collaborative Practice Agreements (CPAs) can be arranged between any type of 
licensed health care provider in both inpatient and outpatient settings. CPAs define 
certain patient care functions that each care provider on a team, including pharmacists, 
can provide autonomously under specific situations and conditions.77  Throughout La 
Esperanza, CPAs were in place to create formalized teams of physicians, nurses, and 
pharmacists for more effective patient care. 
Without CDTM in Arizona, pharmacists could not change medications or 
prescribe new medications within the PBDMP.  In January of 2011, the bill SB 1298 
Pharmacists; Drug Therapy Protocols was introduced at the Arizona State Senate.78  The 
state bill described the State Board of Pharmacy’s clinical practice purview for Doctors 
of Pharmacy.  The bill defined the circumstances when a pharmacist could be 
“implementing, monitoring, and modifying drug therapy and use; conditions; definitions” 
in the state of Arizona.79  
                                                        
75 AMCP. Practice Advisory on Collaborative Drug Therapy Management: Academy of Managed 
Care Pharmacy. 2012. p. 1–7.  
76 Ibid. 
77 Lisa Zubkoff. Using a Virtual Breakthrough Series Collaborative to Reduce Postoperative 
Respiratory Failure in 16 Veterans Health Administration Hospitals. Jt Comm J Qual Patient Saf. 
2014;40(1). 
78 Barto S, Carter R, Antenori S, Meyer R. SB 1298 Introduced by the provider and the laboratory 
tests that may be ordered. 2011 
79 Ibid. 
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From January to April, the bill was modified and the pharmacist community of 
Arizona worked to better define pharmacist’s role in Arizona state law.  On April 13, 
2011, the bill was made into law defining pharmacists expanded roles in clinical patient 
care.  Further legislation followed, including Arizona Revised Statute 32-1970 which 
allowed qualified pharmacists in specified health care settings (such as a community 
health center) to implement, monitor, and modify drug therapy as described by written 
protocols in collaboration with physicians.80  
Through these legislative processes and community advocacy, the practice model 
of CDTM was approved for use in Arizona.  The CDTM model, aspects of which were 
already in place at the La Esperanza Health Center, was quickly embraced.  Anzaldua 
knew the passage of CDTM in Arizona was important for the future development and 
flexibility of the PBDMP.  With CDTM, pharmacists and Nurse Practitioners could 
essentially perform the same function, within a specific scope, in a clinical capacity.  
While pharmacists were stronger care providers for medication management due to their 
pharmacology educational background, Nurse Practitioners thrived in offering quality 
and individualized patient care.  The clinic management also noted that Nurse 
Practitioners had a higher degree of flexibility in their training than pharmacists and 
could be assigned to different areas of the clinic as needed.  By 2011, Anzaldua expanded 
the scope of practice for pharmacists and increased the number of CPA agreements for 
both pharmacists and nurses. 
                                                        
80 Philanthropies HF, Information H. Evaluation of El Rio Community Health Center’s 
Pharmacy-Based Diabetes Disease Management Program Sponsored by and Prepared for Heinz 
Family Philanthropies. 
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Current La Esperanza Pharmacy-Based Diabetes Management Program 
The program currently has eight clinical pharmacists (5.6 full-time equivalent 
clinical pharmacists) on staff.  The PBDMP sees about 4,000 to 5,000 unique patient 
visits annually.81  Each pharmacist sees approximately 275 to 350 individual patients per 
year.  From 2001 to 2014, the PBDMP has served over 4,000 patients.82    
There is data to document a decrease in hospital 30-day readmission rates of 
patients participating in the La Esperanza PBDMP.83  To date, there are clinical 
pharmacists based in 16 of the 17 clinical sites of La Esperanza.  While there is not 
clinical pharmacist coverage every day of the work week at each clinical site, usually 
four out of five days a week, there is a clinical pharmacist on-hand at each clinic.   
Recently, more data was collected on comorbid hypercholesterolemia in diabetic 
patients treated in the PBDMP.  A quick chart review on the NEXGEN system showed 
that hypercholesterolemia and cardiovascular disease were common among patients 
seeking services from the PBDMP.  Anzaldua wondered to herself…just how common?  
Table 17 represents the patient population seeking services at La Esperanza as of 2010.  
 
Different Levels of Readiness and Buy-in from Stakeholders 
By 2014, La Esperanza was considered one of the largest non-profit community 
health centers in the United States.  Due to the work of Galeano, Anzaldua, and their 
                                                        
81 Goldberg J. Program Director, El Rio, Key Informant Interview. Tucson, Arizona; p. 18. 
82 Ibid. 
83 Philanthropies HF, Information H. Evaluation of El Rio Community Health Center’s 
Pharmacy-Based Diabetes Disease Management Program Sponsored by and Prepared for Heinz 
Family Philanthropies. 
  
271
teams, La Esperanza had become a national model for pharmacy-based outpatient health 
care delivery.84  However, Anzaldua wanted more—she wanted to make her mark on the 
world of clinical pharmacy and expand services to include other allied health 
professionals to treat diabetes in El Rio’s patient population. 
While the efforts of Galeano and Anzaldua all directly addressed the high burden 
of diabetes among the patient population at La Esperanza, diabetes is still one of the 
largest burdens of chronic disease in the U.S. In 2011, 8.1 percent of adults in Arizona 
were diagnosed with diabetes, consistent with the 8.3 percent of percent of adults in the 
greater Phoenix area.85 According to the Arizona Department of State Health Services, 
there has been an 80 percent increase in people diagnosed with diabetes from 1995 to 
2012.86  Research has shown that since one third of the U.S. population with diabetes is 
undiagnosed, it is estimated that there are nearly 600,000 adults with diabetes in 
Arizona.87  
In 2014, the number of patients with uncontrolled diabetes enrolled in the 
program was the highest recorded in the history of La Esperanza.  Anzaldua was not sure 
if patients were coming to the PBDMP explicitly for the diabetes management 
programming, or if the incidence of diabetes was increasing within the La Esperanza 
patient population.  Anzaldua knew she needed to do more for the current patient 
                                                        
84 Johnson, William et. al. Evaluation of El Rio Community Health Center ’ s Pharmacy-Based 
Diabetes Disease Management Program Sponsored by and Prepared for Heinz Family 
Philanthropies. 
85 Centers for Disease Control and Prevention; Diabetes Statistics, Arizona, 2012 [Internet]. [cited 
2015 Mar 23]. Available from: http://gis.cdc.gov/grasp/diabetes/DiabetesAtlas.html 
86 Project IMPACT: Diabetes | APhA Foundation [Internet]. [cited 2015 Mar 23]. Available from: 
http://www.aphafoundation.org/project-impact-diabetes/communities/el-rio-health-center 
87 Ibid. 
  
272
population with medication management.  She also knew that there were multiple other 
clinical care options within medication management (utilizing pharmacists and nurses) 
that she could choose from to address chronic disease care management.  How could she 
address this growing population of diabetes patients? 
Anzaldua was not sure how to approach this potential program expansion.  
Anzaldua looked to her fellow Directors at La Esperanza for guidance.  Would expanding 
the scope of the PBDMP would increase the breadth of care for potential comorbidities of 
La Esperanza’s diabetic patients or dilute the program and undermine its current success?  
Additionally, the Registered Nurse Care Coordinators (RNCC)s at La Esperanza had 
recently presented Anzaldua with a proposal to build on the success of their current nurse 
case manager program.  Anzaldua found herself at a decision point—should she expand 
the PBDMP to include cardiovascular disease, hypercholesterolemia, hypertension or 
another chronic condition comorbid with diabetes, or look to incorporate nurse care 
coordinators to work with the diabetic population at La Esperanza? 
Anzaldua spoke with Hector Bonilla, the Chief Clinical Officer of La Esperanza, 
and Clarice Smith, the Chief Operations Officer.  She sought assistance to help identify 
the potential benefits between a nurse case manager program and an expansion of the 
scope of the PBDMP. 
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Nurse Case Managers and Diabetes Care 
Anzaldua knew that nurse case management was widely used at La Esperanza to 
provide high quality care with efficient utilization of medical resources.  Nurse case 
managers served as patient connectors for 
specialty services at La Esperanza.  They 
assisted in patient transitions of care and 
helped with ‘warm’ hand-offs between 
clinicians.  Anzaldua knew that there was 
a role for nurses in outpatient clinical 
pharmacy—she just had to define their 
purview. 
After consulting with the Chief Operating Officer, Clarice Smith, who herself is a 
registered nurse, Anzaldua decided to learn more about the essence of nurse patient-
centered, multidisciplinary approach of case management.  She identified the elements of 
patient navigation of the nurse’s roles that were highly effective in patient coordination.  
Through a literature review and key informant interviews of successful nurse case 
management programs, Anzaldua learned that to perform holistic care, nurse case 
managers place great importance on individualized care.  They develop partnership and 
trust with patients, facilitate communication between patients and care providers, and 
empower patients with knowledge of disease care.   
Anzaldua knew that nurses had less of a background in pharmacotherapies than 
pharmacists and similar to pharmacists, had prescription power limited to a pre-
What is a Nurse Case Manager? 
A nurse case manager is responsible for 
organizing and coordinating resources and 
services in response to individual healthcare 
needs.  Case management is directed toward 
a targeted or selected client or family 
population such as transplant, head-injured, 
or diabetic patients.  The goals of nurse case 
management are to foster patient self-
managed care, and maximize the efficient 
and cost-effective use if health resources for 
the health care setting and patent. Citation: 
Case Management Society of America.  
Chapter [Internet]. [cited 2015 Mar 24]. 
Available from: 
http://www.cmsa.org/chapter/tabid/63/defaul
t.aspx   
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established formulary.  However, she was sure they had a high potential for effectiveness 
with the diabetes management patients due to their heightened sensitivities of patient 
awareness.  Not all pharmacists complete a clinical residency; however, all nurses must 
be certified on their clinical skills to be able to practice clinically. 
Anzaldua found that in comparable clinical settings, nurse case managers had 
shown a measurable difference in increasing positive patient outcomes as compared to a 
control group.88  Studies have shown the benefit of nurse case management through 
patient empowerment that promotes adjustment to new chronic illness diagnoses.89 The 
data from nurse case managers in a diabetes self-management program showed that after 
the intervention, there were a lower number of hospitalizations, better recovery, and 
better quality of life for the patient population in the intervention group as compared to 
the control.90 Table 18 describes many of these benefits. 
  
                                                        
88 Goldberg J. Program Director, El Rio, Key Informant Interview. Tucson, Arizona; p. 18. 
89 Chen Y-C, Chang Y-J, Tsou Y-C, Chen M-C, Pai Y-C. Effectiveness of nurse case 
management compared with usual care in cancer patients at a single medical center in Taiwan: a 
quasi-experimental study. BMC Health Serv Res [Internet]. BMC Health Services Research; 
2013;13(1):202. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3673875&tool=pmcentrez&rendertyp
e=abstract 
90 Ibid. 
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Table 18. Benefits of Nurse Case Management91 
• Planning with all stakeholders to maximize healthcare responses, quality, and cost-effective 
outcomes 
• Facilitating communication and coordination among stakeholders, involving the patient in 
the decision-making process in order to minimize service fragmentation 
• Empowering the patient to problem solve by exploring care options and alternative plans, 
when necessary, to achieve desired outcome 
• Encouraging the appropriate use of healthcare services and striving to improve the quality of 
care and maintain cost-effectiveness on a case-by-case basis 
• Assisting the client in safe transitions of care to the next most appropriate level 
 
Other studies showed that patients with poor social support received greater 
benefit from nurse case management as compared to any other provider. Case 
management programs have demonstrated positive outcomes through various 
methodologies and settings including: diversity in target groups, intervention settings, 
outcome measures, and disease profiles.92  Rigorous methods and unequivocal outcome 
measures are required to validate the effects of nurse case management and collaborative 
pharmacist models. 
One of the studies supported positive effects of nurse case management in 
timeliness and frequency of treatment regimen.93  Utilizing nurse case managers reduced 
unplanned readmission due to complications, improved patients’ self-reliance, and further 
enhanced treatment continuity of patients.  Importantly, nurse case managers were shown 
                                                        
91 Leonard, Margaret, et al., Nursing Case Management Review and Resource Manual, 4th 
Edition, 2012 Dec [cited 2015 June 11].  Available from: 
http://www.nursecredentialing.org/documents/certification/reviewmanuals/nursecasemgmtsample
chap.aspx. 
92 Chen Y-C, Chang Y-J, Tsou Y-C, Chen M-C, Pai Y-C. Effectiveness of nurse case 
management compared with usual care in cancer patients at a single medical center in Taiwan: a 
quasi-experimental study. BMC Health Serv Res [Internet]. BMC Health Services Research; 
2013;13(1):202. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3673875&tool=pmcentrez&rendertyp
e=abstract 
93 Ibid. 
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to be effective in treating multiple chronic disease profiles during one patient visit, 
including diabetes, hypercholesterolemia, and hypertension. 
Moreover, Anzaldua was fascinated by the cost benefit analyses of the nurse case 
management studies.  The initial results of a diabetes management program showed 
greater reduced costs per patient per year using a nurse case manager model than a 
pharmacist-inclusive model.  Of the studies researched, they showed that mean costs for 
insurance claims decreased by $10,312 per patient per year in 2010 and by $19,691 per 
patient per year in 2011.  During the same period in a comparable setting, payers realized 
decreases in total direct medical costs that ranged from $3,752 to $6,853 per patient per 
year.  These findings support the significant cost effectiveness and increased flexibility of 
nurse case manager care as compared to a pharmacist-inclusive practice.   
 
Task-Shifting and Management 
As Anzaldua contemplated the benefits of nurse case management at La 
Esperanza, she realized that flexibility was integral for the management of her staff.  Due 
to their educational background, Anzaldua and the senior leadership felt that nurses and 
Nurse Practitioners were able to task-shift around the clinic at more seamlessly than 
pharmacists.  Nurses were able to work in the PBDMP, float to cardiovascular clinics or 
other internal medicine departments with minimal transition and workflow disruption.  
However, clinical pharmacists were only able to task shift into two key areas—a drug-
dispensing pharmacy and an outpatient clinic.    
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Another factor Anzaldua needed to weigh was salary differences between 
pharmacists and nurses or Nurse Practitioners.  In Phoenix, an experienced pharmacist 
practicing in a drug-dispensing pharmacy earned $126,460 annually.94  In contrast, a 
registered nurse in Arizona earned $55,000 annually, which was 18 percent lower than 
national averages.95  Nurse Practitioners in Arizona earned an average of $72,000 
annually.96  Anzaldua realized that each care provider brought a specific set of strengths 
to a team, regardless of salary.  She needed to define her clinical needs, stay within a set 
budget, and ensure that the programmatic decision she made were in line with other 
senior leadership. 
External Pressures and Organizational Challenges 
Like many Federally Qualified Health Centers, a key challenge for La Esperanza 
was self-sufficiency for long-term sustainability.  In 2011, the federal government cut the 
appropriation for health centers by 27 percent (from $2.2 billion to $1.6 billion).97  Due to 
the appropriation cut, a substantial amount of the FY 2011 Patient Protection and 
Affordable Care Act (ACA) was diverted to maintain existing health center operations.98  
The diversion of ACA funds meant that HRSA was no longer allowed to fund “new 
access points” or “expanded services” grant applications.99  This cut represented the first 
federal health center budget reduction since 1982.  Anzaldua and La Esperanza 
                                                        
94 Salary.com (http://www1.salary.com/AZ/Pharmacist-salary.html) 
95 Salary.com (http://www1.salary.com/AZ/Phoenix/Staff-Nurse-RN-salary.html) 
96 Salary.com (http://www1.salary.com/AZ/Nurse-Practitioner-salary.html) 
97 Goldman, L. E., Chu, P. W., Tran, H., & Stafford, R. S. (2012). Federally Qualified Health 
Centers and, 1–8. 
98 Ibid. 
99 Ibid. 
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management worried that a HRSA grant would not fund the creation of a new access 
point for care utilizing nurse case managers and pharmacists.  Adding to current services 
was still an option, but Anzaldua wondered how she could work around this potential 
challenge.  
This reduction in potential HRSA funding for expanded services worried 
Anzaldua and La Esperanza senior leadership.  In addition to these fiscal challenges, La 
Esperanza continued to serve as an important public safety net for undocumented and 
uninsured families.  The ACA’s Medicaid expansion also excludes undocumented 
immigrants regardless of income level.  Since La Esperanza did not ask patients for 
citizenship status upon receipt or enrollment of care services, the leadership worried that 
they could lose funding if it were perceived that federal dollars were being spent on 
undocumented immigrants.    
La Esperanza was also facing growing challenges of increased need in rural and 
hard-to-reach communities.  Patients were traveling farther distances to reach a clinic site 
and patient no-shows were rising in low income patient clientele.  Many patients 
requested clinical services closer to their home communities near Native American 
reservations and farming communities outside of the greater Phoenix area.  Many of these 
communities did not have a health center, pharmacy, or physician within a 50-mile 
radius, and patients were putting off medical visits with potentially dangerous 
complications.  While the telemedicine program at La Esperanza was strong, clinical 
pharmacists had never been included as part of a potential long distance care team. 
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The leadership at La Esperanza was committed to address the issues of federal 
reimbursement of services and the distances patients traveled to visit a clinician. 
 
Recommendations for Action: Criteria for Decision 
Anzaldua knew that she had to create criteria for the Administrators to evaluate 
the two potential programs—include nurse case management in the patient population 
utilizing the PBDMP or expand the scope of comorbid chronic disease care management 
with pharmacists in the PBDMP.  Anzaldua had to present clear data about both program 
options to Clarice Smith and Hector Bonilla so they could make a clinic-wide decision.  
She knew that criteria profoundly influence decision making and they needed to be 
relevant, kept to the minimum necessary for a sound decision, and be able to relate a 
significant amount of the available evidence to the options.100   
As Anzaldua began to draw up the strategic plan for 2015-2016, she immediately 
thought of financial stability. Which program model is the most financially sustainable 
and provides continued positive clinical outcomes in the future?  She wanted to make 
sure that the practitioners at La Esperanza were being used to the top of their education 
level as well.  She wondered which model utilizes the skills of the health care team to the 
fullest potential.  Positive patient outcomes were clear from employing both nurse case 
managers as well as pharmacists, but what would be the patient outcomes that would 
matter most to La Esperanza in the coming years?  Which program would be able to 
deliver those outcomes?  Lastly, Anzaldua thought about program impact in the El 
                                                        
100 Ellet W. The Case Study Handbook: How to Read, Discuss, and Write Persuasively About 
Cases. Boston, MA: Harvard Business School Press; 2007. 
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Esperanza community.  Which program provided the greatest good for the greatest 
number?  She wondered which program affected the largest number of people in a 
positive and impactful way.  The choice would come down to these key concepts, 
organized by specific criterion. 
Anzaldua knew that she could widen the scope of the questions or make the 
criteria more specific to one of the programs or another, but she felt that the four basic 
criteria were the best solution for how to evaluate the potential programs. 
 
Conclusion 
Anzaldua knew that the PBDMP needed modifications to address the growing 
number of diabetic patients.  As 2014 drew to a close, Anzaldua and her top managers 
were preparing for their second meeting with La Esperanza administration.  The meeting 
was instituted the year before as a forum for discussing major problem areas and 
developing a commitment to division objectives for the coming year.  Now it was time to 
look ahead to 2015, and Anzaldua had to make the case for both programs.  Would 
Smith, Bonilla and the rest of La Esperanza’s administration endorse a nurse case 
management model, focus on an outpatient clinical pharmacy model, or suggest that the 
pharmacists expand their scope of chronic disease care management?  She knew the 
Administrators could choose either program, and she was aware of the benefits and 
potential downfalls of both.  As the door closed behind her, Anzaldua’s thoughts drifted 
to memories of Tony Galeano and his passion and commitment to serving the needs of 
the community. 
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APPENDIX A 
Key Informant Interview Template 
 
-Explain dissertation topic 
 -goals 
 -outputs: 1) interventional guidelines, 2) data tool and 3) management case study 
-Interview Itself 
 -what you will do with the interviews 
 -keeping them short and to the point 
-Consent 
 -recording 
 
Interviewee Name: 
1. When you arrived at XX how was chronic disease management addressed? 
-what are these goals based on? 
-what are the benchmarks? 
 
2. What programs does XX believe address chronic disease care management 
well?  
 
3. What programs are currently in place at XX that address chronic disease 
management? 
 
4. How and why was a (CDTM model) specifically chosen to address chronic 
disease care management? 
 
5. When did the (CDTM model) begin at XX? 
 
6. What was the ecology of Tucson/ XX when the program began?  Why do you 
think it started?  Was it about charismatic leadership?  What was it? 
 
7. Did the Tucson ACO support these goals?  How?  Why or why not? 
 
8. What are the steps to implementation of the CDTM model? 
 
9. How do patients get referred to the program? 
 
10. Do you have pharmacists on staff? Why? Why not? 
 
11. Do you have care coordinators on staff? Why? Why not? 
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12. What happens to patients once they are in the program?  How does the 
program work? 
 
13. What is the patient volume that uses the CDTM model now? 
 
14. Based on clinical 30 day re-admission data, patient feedback, and satisfaction 
surveys, what were the successes and failures of the program within the first 
few years of implementation? 
 
15. What are the future plans for the program?  Any changes? 
 
16. What changes in population data have you seen that could be/are attributable 
to the CDTM model?   
-Care coordinators?   
-How can we show their effectiveness? 
-How do we know it is the care coordinators? 
 
17. Have you seen evidence that pharmacist provider status affects chronic 
disease care management? 
 
18. According to Arizona statewide data (data that is not from XX), did the CDTM 
model affect health on a community level? 
 
19. What are the barriers or road blocks to a successful CDTM model? 
 
20.  Are there others you think I should speak with? Why? 
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APPENDIX B 
Code Book Definitions  
Payment 
1) Clinic support 
a) Internal monetary support from the clinic.  Budgeted funds for the program or 
funds transferred from a different department all fall under this category.  Clinical 
support is also understood as time and staff donated/dedicated to the program’s 
success. 
2) Outside support 
a) External monetary support from a third party payer excluding insurance 
companies.  This definition includes hospitals, reimbursements, government 
funds, and grants.  Any support for the program that comes from outside the clinic 
is considered outside support.  Outside support is also understood as time and 
staff.  
3) Insurance 
a) Insurance is the monetary transaction and payments related to patient or clinical 
services.  This definition includes the insurance payments given or received by 
clinics and hospitals.  Insurance billing and related definitions around lack of 
insurance, or an existence of insurance are also defined in this node.  
4) Total Costs 
a) Total costs relates to the actual reference of total costs in the interview transcript.  
When a total is mentioned or sum amount of anything—payment, reimbursement, 
expenditures, etc., it is identified in this category. 
5) Payment Successes 
a) Payment success is a term used to code for any type of model or modality that is 
perceives as a billing, cost, or payment ‘win’ at the clinic.  When a payment is 
made more effective, or a provider is able to be reimbursement—it is a payment 
success. 
6) Payment Failures 
a) Payment failure is a disconnection, barrier, failure or inefficient way for a 
payment to be made or received.  It is defined by a comment or discussion or 
failures within a payment mechanism.  
 
Teamwork 
1) CDTM 
a) Collaborative Drug Therapy Management (CDTM) is literally defined by the 
mention of a CDTM model.  CDTM can also be defined when medication 
management models in pharmacist-inclusive practices are present. 
2) CPA 
a) A Collaborative Practice Agreement (CPA) can be coded when the definition is 
literally defined and when a model of collaborative practice is discussed.  A team-
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based care model that emphasizes collaborative practice is also included in this 
definition. 
3) Team-based care 
a) Team-based care is defined as care given in a team-based approach that does not 
fall under the guidelines of a specific CPA or CDTM.  This definition is also 
inclusive of generalized teamwork within a clinical setting. 
4) Teamwork Successes 
a) Teamwork successes are examples of teamwork executed well.  A program, 
patient, or situation that is enhanced by teamwork falls under this category. 
5) Teamwork Failures 
a) Teamwork failures are examples of teamwork not executed well.  A program, 
patient, or situation that is not enhanced or is diminished by teamwork failures or 
general teamwork barriers falls under this category. 
 
Pharmacists 
1) Education 
a) Education of pharmacists is defined by the literal mention of what pharmacists are 
taught to do/complete during their training.  Education is the knowledge base of 
pharmacists.  Education can also be understood as continuing education for 
current pharmacists. 
2) Scope of Work 
a) The scope of work for pharmacists is the work purview for pharmacists in clinical 
practice and in drug dispensing pharmacy.  Scope of work relates to the tasks 
pharmacists are assigned to complete and what their day-to-day work practices 
entail with a CDTM, CPA, or just teamwork—it is all inclusive. 
3) Provider Status 
a) Provider status relates to both the existence and absence of provider status for 
pharmacists.  Provider status refers to the Social Security Administration (SSA)’s 
definition of a clinician.  Pharmacists do not have a clinical status according to the 
SSA and therefore do not have provider status.  Barriers to or successes related to 
provider status are both categorized in this same node.  
4) Pharmacists Successes 
a) Pharmacist’s successes are defined by major ‘wins’ or efficiencies either created 
by or for pharmacists to work for effectively in the clinical setting.   
5) Pharmacist Failures 
a) Pharmacist’s failures are defined by major ‘losses’ or inefficiencies either created 
by or for pharmacists that do not allow pharmacists to work effectively and 
efficiently in the clinical setting.   
 
El Rio 
1) History 
a) El Rio history relates to the history of the clinic’s development, creation, or past 
clinical or patient practices.  It encompasses the past—writ large—at El Rio.  Past 
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leaders, supporters, barriers, programs, etc. are all categorized under this 
definition. 
2) Present 
a) Present refers to the current practices at El Rio.  The definition also includes 
current employees, programs, and practices in place.  This definition includes all 
programmatic support and information about the present at El Rio except for the 
Pharmacy-Based Diabetes Management Program. 
3) Future 
a) Future defined El Rio’s plans for the future in programming, staffing, and goal 
setting.  Items or aspects of current programs or situations that an interviewee 
wants to change for the future are also defined under this node. 
4) El Rio Strengths 
a) El Rio strengths define the literal strengths of El Rio.  This definition includes 
only aspects of El Rio from items that are currently in place.  Strengths can be 
understood as people, programs, attitudes, behaviors, etc.  Past strengths and 
future goals are not identified under this definition. 
5) El Rio Failures 
a) El Rio failures define the literal failures or barriers of El Rio.  This definition 
includes only aspects of El Rio from items that are currently in place.  Failures or 
barriers can be understood as people, programs, attitudes, behaviors, etc.  Past 
strengths and future goals are not identified under this definition. 
 
Process 
1) Efficiencies 
a) Efficiencies are programs, decisions, changes in work flow, etc. that improve 
efficiency.  This definition refers to any efficiency in place now or set in place in 
the past to increase efficiency.   
2) Quality Improvement 
a) Quality improvement refers to goals or programs in place to improve quality.  The 
definition can be for programs defined as ‘QI’ projects or improvements that were 
directly aimed at quality improvement.  This definition refers to any efficiency in 
place now or set in place in the past to increase efficiency.   
3) Current State 
a) Current state is the current status of the Pharmacy-Based Diabetes Management 
program.  The definition includes how the program functions on a day-to-day 
basis. 
4) Process strengths 
a) Process strengths refer to the strengths, successes and supports of the Pharmacy-
Based Diabetes Management Program. 
5) Process weaknesses 
a) Process weaknesses refer to the barriers, weaknesses and lack of supports for the 
Pharmacy-Based Diabetes Management Program. 
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Successes (Same definitions as above, just re-collated for data analysis) 
1) Payment 
a) Payment Success is a term used to code for any type of model or modality that is 
perceives as a billing, cost, or payment ‘win’ at the clinic.  When a payment is 
made more effective, or a provider is able to be reimbursement—it is a payment 
success. 
2) Teamwork 
a) Teamwork successes are examples of teamwork executed well.  A program, 
patient, or situation that is enhanced by teamwork falls under this category. 
3) Pharmacists 
a) Pharmacist’s successes are defined by major ‘wins’ or efficiencies either created 
by or for pharmacists to work for effectively in the clinical setting.   
4) El Rio 
a) El Rio strengths define the literal strengths and successes of El Rio.  This 
definition includes only aspects of El Rio from items that are currently in place.  
Strengths can be understood as people, programs, attitudes, behaviors, etc.  Past 
strengths and future goals are not identified under this definition. 
5) Process 
a) Process successes refer to the strengths, successes and supports of the Pharmacy-
Based Diabetes Management Program. 
 
Failures 
1) Payment 
a) Payment failure is a disconnection, barrier, failure or inefficient way for a 
payment to be made or received.  It is defined by a comment or discussion or 
failures within a payment mechanism.  
2) Teamwork 
a) Teamwork failures are examples of teamwork not executed well.  A program, 
patient, or situation that is not enhanced or is diminished by teamwork failures or 
general teamwork barriers falls under this category. 
3) Pharmacists 
a) Pharmacist’s failures are defined by major ‘losses’ or inefficiencies either created 
by or for pharmacists that do not allow pharmacists to work effectively and 
efficiently in the clinical setting.   
4) El Rio 
a) El Rio failures define the literal failures or barriers of El Rio.  This definition 
includes only aspects of El Rio from items that are currently in place.  Failures or 
barriers can be understood as people, programs, attitudes, behaviors, etc.  Past 
strengths and future goals are not identified under this definition. 
5) Process 
a) Process weaknesses refer to the barriers, weaknesses and lack of supports for the 
Pharmacy-Based Diabetes Management Program. 
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Assertions/Generalizations 
 Assertions and generalizations refer to a ‘crowning’ comment, or a key phrase that is 
repeated.  If a sweeping generalization is made about an area of study, type of 
practitioner or the program, it is categorized under this definition. 
 
Sustainability of Model 
 Sustainability of the model refers to any aspect of description that directly hints at 
plans, changes, or current practices supporting the sustainability of the current model 
or program. 
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APPENDIX C 
Process Maps 
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Pharmacist Groups 1-3 
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Group 2 
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Group 3 
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Clinical Group 
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APPENDIX D 
Root Cause Analysis Diagrams (Fishbone Diagrams)  
 
Administrative Group 
 
RCA: Successes 
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RCA: Barriers 
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Pharmacist Group 
 
RCA: Successes 
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RCA: Barriers 
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Clinical Group 
 
RCA: Successes 
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RCA: Barriers 
 
 
  
  
299
APPENDIX E 
Key Informant Interview Word Tree Diagrams 
 
Word Tree Diagram: Barriers 
 
 
 
  
Word Tree for Barriers in All Transcripts 
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Word Tree Diagram: Success/Successful 
 
 
 
  
Word Tree for Success/Successful in All Transcripts 
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